rivastigmine has been researched along with Acute Confusional Senile Dementia in 724 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 28 (3.87) | 18.2507 |
| 2000's | 321 (44.34) | 29.6817 |
| 2010's | 271 (37.43) | 24.3611 |
| 2020's | 104 (14.36) | 2.80 |
| Authors | Studies |
|---|---|
| Chorev, M; Finberg, J; Finkelstein, N; Friedman, R; Goldenberg, W; Goren, T; Gross, A; Herzig, Y; Huang, W; Krais, B; Lavian, G; Lerner, D; Miskolczi, I; Molnar, S; Rantal, F; Razin, M; Sterling, J; Tamas, T; Toth, G; Weinstock, M; Youdim, MB; Zagyva, A; Zekany, A | 1 |
| Amari, G; Bartolucci, C; Bolzoni, PT; Delcanale, M; Ghidini, E; Lamba, D; Racchi, M; Siotto, M; Villetti, G | 1 |
| Decker, M; Lehmann, J; Rommelspacher, H; Schott, Y | 1 |
| Andrisano, V; Banzi, R; Bartolini, M; Bergamini, C; Bolognesi, ML; Cattaneo, A; Cavalli, A; Fato, R; Hrelia, P; Lenaz, G; Melchiorre, C; Minarini, A; Recanatini, M; Rosini, M; Tarozzi, A; Tumiatti, V | 1 |
| Bolognesi, ML; Cavalli, A; Melchiorre, C; Minarini, A; Recanatini, M; Rosini, M; Tumiatti, V | 1 |
| Fridkin, M; Youdim, MB; Zheng, H | 1 |
| Blériot, Y; Goulart, M; Justino, J; Marcelo, F; Rauter, AP; Silva, FV; Sinaÿ, P | 1 |
| Al-Rashid, ZF; Hsung, RP | 1 |
| Gu, LQ; Huang, ZS; Li, YP; Luo, W; Tan, JH | 1 |
| Boido, V; Carotti, A; Catto, M; Giangreco, I; Nicolotti, O; Novelli, F; Pisani, L; Sparatore, A; Sparatore, F; Tasso, B; Tonelli, M | 1 |
| Andrisano, V; Bartolini, M; Bolognesi, ML; Hrelia, P; Matera, R; Melchiorre, C; Milelli, A; Rosini, M; Simoni, E; Tarozzi, A | 1 |
| Chander, S; Nath, C; Roy, KK; Saxena, AK; Tota, S; Tripathi, T | 1 |
| Finkin-Groner, E; Ginsburg, I; Lerman, L; Nudelman, A; Shalom, H; Weill, T; Weinstock, M; Yanovsky, I; Zaikin, A; Zeeli, S | 1 |
| Carotti, A; Catto, M; Cellamare, S; Leonetti, F; Nicolotti, O; Pesce, P; Pisani, L; Stefanachi, A | 1 |
| Hong, C; Li, Y; Luo, W; Su, LP; Su, YB; Tian, RG; Wang, CJ; Wang, YQ; Yue, JJ | 1 |
| Arán, VJ; Campillo, NE; Fernández-Ruiz, J; García-Arencibia, M; Girón, R; Gómez-Cañas, M; González-Naranjo, P; Martín, MI; Páez, JA; Pérez, C; Pérez-Macias, N; Sánchez-Robles, E | 1 |
| Adam, BL; Gao, J; Terry, AV | 1 |
| Hu, Y; Li, Y; Peng, P; Sheng, R; Tang, L | 1 |
| Deng, Y; Li, Y; Liu, Q; Qiang, X; Sang, Z; Tan, Z; Xiao, G | 1 |
| Ang, W; Deng, Y; Li, Y; Liu, Q; Luo, Y; Qiang, X; Sang, Z; Shi, Y; Tan, Z; Yuan, W | 1 |
| Deng, Y; Li, Y; Qiang, XM; Sang, ZP; Wu, B; Zhang, H; Zhao, MG | 1 |
| Bajda, M; Czarnecka, K; Girek, M; Gumieniczek, A; Jończyk, J; Malawska, B; Mikiciuk-Olasik, E; Olszewska, P; Sikora, J; Skibiński, R; Szymański, P | 1 |
| Amooru, GD; Ampasala, DR; Darla, MM; Devineni, SR; Eadlapalli, S; Kotapati, KV; Palaka, BK; Penumala, M; Shaik, JB; Vadde, R | 1 |
| Liu, SX; Sun, ZQ; Tu, LX; Zhuo, FJ | 1 |
| Cao, Z; Deng, Y; Li, Y; Luo, L; Qiang, X; Tan, Z; Xiao, G; Yang, X | 1 |
| Hoda, N; Jameel, E; Jayaram, B; Kumar, J; Maqbool, M; Meena, P; Mobashir, M; Shandilya, A; Singh, A; Tiwari, M | 1 |
| Aitken, L; Benek, O; Dohnal, V; Dolezal, R; Guest, P; Gunn-Moore, F; Hroch, L; Janockova, J; Kuca, K; Musil, K; Musilek, K; Smith, TK; Soukup, O | 1 |
| Akbarzadeh, T; Edraki, N; Foroumadi, A; Karimpor-Razkenari, E; Khanavi, M; Mahdavi, M; Moghadam, FH; Najafi, Z; Sabourian, R; Saeedi, M; Shafiee, A; Sharifzadeh, M; Tehrani, MB | 1 |
| Andrisano, V; Bartolini, M; Belluti, F; Bisi, A; Di Marzo, V; Gobbi, S; Ligresti, A; Montanari, S; Mor, M; Rampa, A; Rivara, S; Scalvini, L | 1 |
| Brazzolotto, X; Chan, S; De la Mora, E; Deora, GS; Dighe, SN; Nachon, F; Parat, MO; Ross, BP | 1 |
| Chen, J; Chen, Q; Chen, Z; Chu, J; Digiacomo, M; Gu, Q; Han, Y; Macchia, M; Nesi, G; Pi, R; Rapposelli, S; Sestito, S; Tu, Y; Wang, S; Yang, X | 1 |
| Chen, H; Shang, J; Sun, X; Tan, W; Tian, Y; Wang, H; Wang, L; Wang, Y | 1 |
| Akbarzadeh, T; Asatouri, R; Karimpour-Razkenari, E; Khanavi, M; Mahdavi, M; Moghadam, FH; Najafi, Z; Saeedi, M; Sharifzadeh, M; Vafadarnejad, F | 1 |
| Akbarzadeh, T; Edraki, N; Karimpour-Razkenari, E; Khanavi, M; Mahdavi, M; Moghadam, FH; Saeedi, M; Safavi, M | 1 |
| Cao, Z; Deng, Y; Li, Y; Luo, L; Qiang, X; Sang, Z; Su, F; Xiao, G; Xu, R; Yang, X; Zheng, Y | 1 |
| Azzouz, R; Bohn, P; Gembus, V; Levacher, V; Papamicaël, C; Peauger, L; Sopková-de Oliveira Santos, J; Ţînţaş, ML | 1 |
| Andrisano, V; Apperley, KYP; Bartolini, M; Baschieri, A; Basso, M; Chen, HH; De Simone, A; Guardigni, M; Keillor, JW; Kobrlova, T; Milelli, A; Montanari, S; Soukup, O; Valgimigli, L | 1 |
| Chen, Q; Digiacomo, M; Nesi, G; Pi, R; Rapposelli, S; Sestito, S; Wang, S; Yang, X | 1 |
| Brazzolotto, X; Colletier, JP; Coquelle, N; Gobec, S; Jukič, M; Knez, D; Kos, J; Mravljak, J; Nachon, F; Pišlar, A; Sova, M; Žakelj, S | 1 |
| Cao, Z; Deng, Y; Li, Y; Liu, H; Qiang, X; Song, Q; Tan, Z; Tian, C; Yang, Z | 1 |
| Kumar, A; Mishra, P; Panda, G | 1 |
| Abu-Serie, MM; AlFadly, ED; Bakkar, NZ; Bartolini, M; Belal, ASF; El-Yazbi, AF; Elkazaz, S; Elzahhar, PA; Ghareeb, DA; Iriepa, I; Janockova, J; Kobeissy, F; Moraleda, I; Rafeh, RW; Saudi, MNS; Shaltout, H; Soukup, O; Tramarin, A | 1 |
| Krishnamurthy, S; Prajapati, SK; Seth, A; Sharma, P; Shrivastava, SK; Srivastava, P; Tiwari, V; Tripathi, A; Tripathi, MK; Tripathi, PN | 1 |
| Chen, C; Fu, J; Hu, M; Li, X; Shao, S; Shi, G; Wang, D; Wu, S; Zhang, D; Zhang, T; Zhou, Y | 1 |
| Liu, W; Sang, Z; Shi, J; Tan, Z; Wang, K | 1 |
| Liu, W; Sang, Z; Shi, J; Tan, Z; Wang, K; Zhang, P | 1 |
| Alsulami, H; Chen, X; Jiang, X; Qin, HL; Tang, W; Wang, Z; Xu, Y; Zhang, Z | 1 |
| Choubey, PK; Krishnamurthy, S; Prajapati, SK; Seth, A; Sharma, P; Shrivastava, SK; Tripathi, A; Tripathi, MK; Tripathi, PN | 1 |
| Calderone, V; Citi, V; Martelli, A; Pruccoli, L; Rapposelli, S; Runfola, M; Saccomanni, G; Sestito, S; Tarozzi, A | 1 |
| Decker, M; Endres, E; Gunesch, S; Hoffmann, M; Maurice, T; Scheiner, M; Sotriffer, C; Stiller, C | 1 |
| Chen, YP; Guo, HY; Luo, W; Lv, JW; Ma, J; Song, ZY; Wang, CJ; Wang, T; Zhang, ZY | 1 |
| do Carmo Carreiras, M; Ismaili, L; Marco-Contelles, J | 1 |
| Cheng, X; Liu, W; Ma, Q; Sang, Z; Shi, J; Tan, Z; Wang, K; Wei, R; Yu, L; Zhao, Y; Zhu, G | 1 |
| Cheng, X; Liu, W; Qiao, Z; Sang, Z; Shi, J; Tan, Z; Wang, K; Wang, Y; Wu, A; Zhao, Y; Zhu, G | 1 |
| Bai, P; Chen, Z; Lan, Y; Liu, W; Qiao, Z; Sang, Z; Shi, J; Tan, Z; Wang, C; Wang, K; Wang, Y; Wu, A; Zhao, Y; Zhu, G | 1 |
| Farias, AB; Henriques, RR; Junior, MAAL; Nogueira, TLDC; Quimas, JVF; Romeiro, NC; Santos, DC; Silva, LLD; Souza, ALF | 1 |
| Brogi, S; Gabr, MT | 1 |
| Choubey, PK; Sharma, P; Shrivastava, SK; Tripathi, A | 1 |
| Boulouard, M; Claeysen, S; Corvaisier, S; Dallemagne, P; Davis, A; Freret, T; Hatat, B; Lalut, J; Lecoutey, C; Rochais, C; Since, M; Sopková-de Oliveira Santos, J; Toublet, FX | 1 |
| Andrys, R; Capek, J; Handl, J; Hrabinova, M; Janockova, J; Kobrlova, T; Korabecny, J; Marco-Contelles, JL; Mezeiova, E; Micankova, P; Muckova, L; Nepovimova, E; Pejchal, J; Rousar, T; Simunkova, M; Soukup, O; Valko, M | 1 |
| Cao, Z; Cong, S; Deng, Y; Liu, Z; Song, Q; Tan, Z; Yu, G | 1 |
| Kutluana, EG; Oztekin, A; Zilbeyaz, K | 1 |
| Chowdhury, SR; Fu, L; Gu, J; Hu, Y; Jiang, F; Lam, C; Lei, S; Lu, D; Tavallaie, MS; Wang, J | 1 |
| Jiang, X; Liu, XH; Shi, J; Tang, W; Wang, S; Wu, C; Xu, Y; Zha, L; Zhang, J; Zhang, Z; Zuo, J | 1 |
| Deng, Y; Liu, X; Liu, Z; Shi, Y; Song, Q; Tan, Z; Yu, G; Zhang, H; Zhong, F | 1 |
| He, Y; Liu, W; Mi, J; Sang, Z; Wu, A; Yang, J; Zhou, Y; Zhu, G | 1 |
| Bayomi, SM; El-Subbagh, HI; Ghaly, MA; Saad, KM; Waly, OM | 1 |
| Chan, L; Chang, CC; Chen, CI; Chen, TB; Chen, TF; Chou, HH; Hu, CJ; Yang, A; Yang, YW | 1 |
| Natarajan, R; Raji, V; Sivaraman, B; Velmurugan, BA | 1 |
| Hoe, HS; Jeong, HR; Kim, J; Lee, H; Lee, HJ; Lee, S; Park, JH; Park, SK; Seol, E | 1 |
| Ajtay, A; Balázs, N; Bereczki, D; Kovács, T; Oberfrank, F | 1 |
| Moss, DE; Perez, RG | 1 |
| Ai, Y; Cheng, Y; Fan, F; Liu, H; Liu, Q; Shi, X | 1 |
| Cui, Y; Ren, G; Shi, X; Xu, Z | 1 |
| Barr, PG; Rajkumar, AP; Storr, NJ; Watts, KE | 1 |
| Lee, JH | 1 |
| Mehranfar, F; Saeedi, M | 1 |
| Cucos, CA; Dobre, M; Dragnea, EM; Manda, G; Milanesi, E | 1 |
| Bak, SH; Byeon, GH; Byun, J; Choi, HS; Chun, IK; Heo, J; Hong, Y; Jang, JW; Jeong, CW; Kasani, PH; Kim, JA; Kim, JH; Kim, JK; Kim, KL; Kim, S; Kim, WJ; Kim, Y; Kwon, SO; Lee, DY; Lee, EJ; Lee, K; Lee, SA; Moon, KW; Nam, SJ; Park, JI; Park, SW; Park, YJ; Rhee, HY | 1 |
| Bellahnid, Y; Cunha, S; Forbes, B; Silva, AC; Sousa Lobo, JM; Swedrowska, M; Xu, Z | 1 |
| Carvalho, AF; Chen, TY; Chen, YW; Cheng, YS; Hsu, CW; Li, DJ; Liang, CS; Lin, PY; Matsuoka, YJ; Shiue, YL; Stubbs, B; Su, KP; Sun, CK; Tseng, PT; Tu, YK; Wu, YC; Yang, CP; Yeh, PY; Zeng, BY | 1 |
| Bos, JHJ; de Vos, S; Hak, E; Hutten, DR | 1 |
| Ashoor, HM; Clarke, M; Hemmelgarn, BR; Holroyd-Leduc, J; Mavridis, D; Rios, P; Seitidis, G; Stewart, L; Straus, SE; Tricco, AC; Tudur-Smith, C; Veroniki, AA | 1 |
| Larkin, HD | 1 |
| Akash, MSH; Akbar, M; Chaudhary, Z; Panichayupakaranant, P; Rehman, K; Shabbir, A; Shah, MA | 1 |
| Markowicz-Piasecka, M; Podsiedlik, M; Sikora, J | 1 |
| Bloemberg, JS; de Lange, ECM; Elassaiss-Schaap, J; Saleh, MAA | 1 |
| Hughes, C; Lim, WY; Loy, C; McGuinness, B; Parsons, C; Passmore, P; Ward, SA | 1 |
| Abrahim-Vieira, BA; De Mesquita, JF; Gonçalves, LM; Pereira, GRC | 1 |
| Aameri, R; Ghorbani, H; Korani, B; Reza Bazrafshan, H; Zahra Gharib, F | 1 |
| Aparasu, RR; Chatterjee, S; Chen, H; Johnson, ML; Masurkar, PP; Sherer, JT | 1 |
| Andrzejewski, K; Conde, SV; Jampolska, M; Kaczyńska, K; Mojzych, I | 1 |
| Bai, P; Ban, Y; Hu, J; Mi, J; Sang, Z; Tan, Z; Tang, L; Wang, C; Wang, J; Wang, K; Wu, A; Xu, R; Zhang, J; Zhu, G | 1 |
| Majidazar, R; Naseri, A; Rezazadeh-Gavgani, E; Sadigh-Eteghad, S | 1 |
| Abdelhady, GT; Abu-El-Rub, E; Al-Soudi, HS; Alzu'bi, A; Khasawneh, RR | 1 |
| Alhajri, AM; Alshamari, AK; Elharrif, MG; Hassan, AA; Hassan, NA; Khattab, RR; Sattam, M | 1 |
| Bu, K; Cheng, F; Han, W; Morris, R; Patel, D; Umeukeje, G; Zhu, T | 1 |
| De la Torre, R; Iniesta, M; Koch, C; Morte, A; Schug, B; Schurad, B; Vaqué, A | 1 |
| Ayaz, M; Islam, ZU; Nawaz, A; Naz, F; Sadiq, A; Ullah, F | 1 |
| Andersen, K; Grøntved, S; Lolk, A; Nielsen, RE; Valentin, JB | 1 |
| Eriksson, LA; Gholami, A; Minai-Tehrani, D | 1 |
| Bharathi J, J; Chintha, N; Jupudi, S; Justin, A; Palathoti, N | 1 |
| Fujimoto, S; Imai, G; Matsuzono, K; Mita, Y | 1 |
| Abraham, R; Benade, V; Gagginapally, SR; Ganuga, N; Grandhi, VR; Jayarajan, P; Medapati, R; Mohammed, AR; Nirogi, R; Palacharla, VRC; Petlu, S; Ravella, SR; Srirangavaram, M; Subramanian, R; Thentu, JB | 1 |
| Borges, F; Brunetti, L; Cardoso, SM; Chavarria, D; Chaves, S; Guedes, B; Madrid, Y; Piemontese, L; Santos, MA; Vicente-Zurdo, D | 1 |
| Achten, E; Beun, S; Clement, P; Moyaert, P | 1 |
| Yamada, M | 1 |
| Bures, J; Knoblochova, V; Kohoutova, D; Kvetina, J; Radochova, V; Rejchrt, S; Soukup, O; Tacheci, I; Tsianou, CC; Valis, M; Zdarova Karasova, J | 1 |
| Kathuria, H; Monohar Pandey, M; Subhash Hinge, N | 1 |
| Begemann, MJH; d'Angremont, E; Sommer, IEC; van Laar, T | 1 |
| He, Y; Liu, W; Ma, Q; Mi, J; Sang, Z; Tan, Z; Teng, X; Wei, R; Yang, J; Zhou, Y | 1 |
| Baddeley, TC; Harrington, CR; Klein, J; Kondak, C; Leith, M; Riedel, G; Santos, RX; Wischik, CM | 1 |
| Boada, M; Carnero-Pardo, C; Fortea, J; García-Ribas, G; Martínez-Lage, P; Olazarán, J; Sánchez-Juan, P; Viñuela, F | 1 |
| Algharably, EEA; Bermpohl, F; Bittner, N; Brandl, EJ; Funk, CSM; Kreutz, R; Riemer, TG; Schmidt, A | 1 |
| Hamidi, M; Hosseini, MJ; Kaboli, Z; Manjili, HK; Rostamizadeh, K; Sadighian, S | 1 |
| Ahmed, M; Anwaar, S; Bhatti, MZ; Dilshad, E; Haq, IU; Ijaz, MU; Ismail, H; Khalid, D; Saleem, S; Waseem, D | 1 |
| Ahirwar, K; Khairnar, P; Shukla, R; Singh, A | 1 |
| Alcaro, S; Borges, F; Chavarria, D; Gaspar, A; Mesiti, F | 1 |
| Fleet, JL; Garg, AX; McArthur, E; Montero-Odasso, M; Patel, A; Weir, MA | 1 |
| Asadipour, A; Eskandari, K; Pourshojaei, Y | 1 |
| Ahmed, M; Aleya, L; Ashraf, GM; Barreto, GE; Begum, MM; Kabir, MT; Mathew, B; Rahman, MS; Thangapandiyan, S; Uddin, MS | 1 |
| Mehrabadi, S; Moradbeygi, K; Motevaseli, E; Sadr, SS | 1 |
| Fan, D; Feng, T; Ji, Y; Jia, J; Kuang, W; Li, Y; Liang, Z; Ning, Y; Peng, D; Wei, W; Xiao, S; Ye, Q | 1 |
| Sharma, P; Shrivastava, SK; Tripathi, MK | 1 |
| Çinar, N; Şahiner, TAH | 1 |
| Chen, SD; Guo, QH; Ji, Y; Jia, JP; Luo, BY; Ning, YP; Peng, DT; Wang, YP; Wei, WW; Xiao, J; Xiao, SF; Xiao, WZ; Xu, RL; Yang, YH; Yuan, Q; Zhang, JJ; Zhang, W | 1 |
| Banerjee, A; Lipp, L; Sharma, D; Singh, J | 1 |
| Ahmad, F; Alajmi, MF; Anwar, S; Hassan, MI; Hussain, A; Islam, A; Mohammad, T; Shamsi, A | 1 |
| Chakkamparambil, B; Friedman, L; Grossberg, GT; Haake, A; Nguyen, K | 1 |
| Honjo, Y; Ide, K; Takechi, H | 1 |
| Greig, NH; Karnati, HK; Lahiri, DK; Maloney, B; Nelson, PT; Ray, B; Sambamurti, K | 1 |
| Cranston, A; Harrington, CR; Klein, J; Kondak, C; Lauer, D; Magbagbeolu, M; Melis, V; Niewiadomska, G; Riedel, G; Santos, RX; Schwab, K; Steczkowska, M; Theuring, F; Wischik, CM; Wydrych, M; Zadrozny, M | 1 |
| Aguilar, LF; Jemiola-Rzeminska, M; Strzalka, K; Suwalsky, M; Zambrano, P | 1 |
| Madadi, S; Saidijam, M; Soleimani, M; Yavari, B | 1 |
| Barthold, D; Drabo, EF; Ferido, P; Gray, SL; Joyce, G; Marcum, ZA; Zissimopoulos, J | 1 |
| Bülbül, EÖ; Karantas, ID; Mutlu, G; Okur, ME; Okur, NÜ; Siafaka, PI | 1 |
| Ali, N; Arora, M; Ghai, R; Grover, P; Kapoor, G; Nagarajan, K | 1 |
| Alsabbagh, MW; Huang, Y | 1 |
| Mathew, B | 1 |
| Elango, DS; Espay, AJ; Gomez-Mancilla, B; Mahajan, A; Marsili, L; Masellis, M; Pathan, R; Pezous, N; Pilotto, A; Sturchio, A | 1 |
| Amenta, F; Ben, DD; Buccioni, M; Lambertucci, C; Marucci, G; Volpini, R | 1 |
| Bhanuprakash, K; Chitumalla, RK; Karthikraj, R; Nagaveni, V; Prabhakar, S; Vairamani, M | 1 |
| Chakkamparambil, B; Grossberg, GT; Hoffman, H; Nguyen, K | 1 |
| Chmielewska, K; Dzierzbicka, K; Inkielewicz-Stepniak, I; Kowalski, S; Przybyłowska, M | 1 |
| Han, E; Kalisch Ellett, L; Lee, HJ; Lee, J; Roughead, EE | 1 |
| Castagna, A; Fabbo, A; Lacava, R; Manzo, C; Ruberto, C; Ruotolo, G | 1 |
| Bayat, S; Ghahvechi Akbari, M; Rezaei Rad, F; Zamani, M | 1 |
| Hattori, N; Hayashi, A; Saiko, A; Shimura, H; Urabe, T | 1 |
| Delgado-Lara, DLC; Gabriel Ortiz, G; Mireles-Ramírez, MA; Mora-Navarro, MA; Pacheco-Moisés, FP; Rincón-Sánchez, AR; Torres-Mendoza, BM; Velázquez-Brizuela, IE | 1 |
| Chua, EV; Kandiah, N; Lim, LLH; Ng, A; Ng, KP; Silva, E; Wang, JS; Yatawara, C; Zailan, FZ | 1 |
| Gupta, P; Mishra, A; Pal, A; Singh, A; Singh, S; Tiwari, S | 1 |
| Abdel-Daim, MM; Akhtar, MF; Albadrani, GM; Arya, A; Chahal, R; El-Seedi, HR; Kamel, M; Kaushik, D; Khalifa, SMA; Mittal, V; Rahman, MH; Rao, R; Saleem, A | 1 |
| Barot, T; Kulkarni, P; Rawtani, D | 1 |
| Halminen, O; Hörhammer, I; Linna, M; Mehtälä, J; Mikkola, T; Vesikansa, A; Virta, LJ; Ylisaukko-Oja, T | 1 |
| Allarà, M; Bartolini, M; Belluti, F; Bisi, A; Gobbi, S; Kostrzewa, M; Ligresti, A; Montanari, S; Naldi, M; Rampa, A; Rivara, S; Scalvini, L | 1 |
| Arumugam, K; Bojja, SL; Kumar, N; Rao, CM; Rompicherla, SKL | 1 |
| Afzal, O; Al-Abbasi, FA; Almalki, WH; Alrobaian, M; Alshehri, S; Altamimi, ASA; Beg, S; Gao, Y; Ibrahim, IAA; Katouah, HA; Kazmi, I; Panda, SK; Rahman, M; Soni, K | 1 |
| Duvvuri, K; Karan, R; Modali, S; Pathan, RK; Reinhardt, F; Scarmeas, N; Veldandi, UK | 1 |
| Bu, K; Cheng, F; Morris, R; Umeukeje, G | 1 |
| Avila, A; Lawler, E | 1 |
| Ampil, E; Christopher, S; Kandiah, N; Karanam, AK; Looi, I; Pai, MC; Park, KW; Senanarong, V | 1 |
| Fujita, Y; Kamijo, Y; Kishino, T; Suzuki, Y; Usui, K; Yoshizawa, T | 1 |
| Chen, TH; Chou, MC; Hsu, CL; Lai, CL; Wu, SJ; Yang, YH | 1 |
| Cacciafesta, M; Ettorre, E; Servello, A | 1 |
| Bradley, J; Chan, P; Herrmann, N; Lanctôt, K; Mohammad, D | 1 |
| Ali, MR; Boutajangout, A; Mezei, M; Møller, SG; Sadoqi, M | 1 |
| Chang, CT; Chen, YH; Chiang, JH; Lai, CY; Lin, JG; Sun, MF; Wu, MY; Yen, HR | 1 |
| Huang, YD; Luo, HB; Wu, D; Wu, XN; Wu, Y; Yu, YF; Zhang, C; Zhou, Q | 1 |
| Choi, SH; Chung, EJ; Han, HJ; Kang, H; Kim, BC; Kim, EJ; Kim, KK; Kim, S; Ku, BD; Kwon, JC; Kwon, OD; Lee, HW; Lee, JH; Park, KH; Park, KW; Park, MY; Park, SW; Seo, SW; Shim, YS; Yang, DW; Yi, HA; Yoon, B | 1 |
| Godyń, J; Malawska, B; Panek, D; Pasieka, A; Wichur, T | 1 |
| Kaushik, V; Mikobi, E; Raji, MA; Smith, ST | 1 |
| Chao, PC; Li, JC; Yeh, CB; Yeh, TC | 1 |
| Abdel-Megied, AM; Aboul-Enein, HY; Hanafi, RS | 1 |
| Chang, SY; Dong, L; Feng, M; Guo, X; Hügel, H; Hyde, AJ; Lu, C; May, BH; Xue, CC; Zhang, AL | 1 |
| Khunt, D; Misra, M; Padh, H; Shah, B | 1 |
| Beckers, N; Dietlein, M; Fink, GR; Kracht, L; Kukolja, J; Neumaier, B; Onur, OA; Richter, N; Tittgemeyer, M | 1 |
| Atri, A; Ballard, C; Boneva, N; Cummings, JL; Frölich, L; Molinuevo, JL; Raket, LL; Tariot, PN; Windfeld, K | 1 |
| Alonge, O; Cifonelli, E; Iqbal, FM | 1 |
| Cho, AH; Kim, JS; Lim, EY; Yang, DW | 1 |
| Gkioka, M; Kazmierski, J; Messini-Zachou, C; Tsolaki, M | 1 |
| Cao, TT; Chen, JT; Feng, TL; Ma, ZY; Tian, YF; Yang, CL | 1 |
| Caltagirone, C; Colombo, D; Ori, A; Padovani, A; Simoni, L; Sorbi, S; Spalletta, G; Zagni, E | 1 |
| Amieva, H; Andrieu, S; Delabrousse-Mayoux, JP; Dubois, B; Jeandel, C; Krolak-Salmon, P; Perret-Liaudet, A; Sellal, F; Vandel, P | 1 |
| Hang, L; Jia, R; Li, J; Liang, J; Wang, Y; Wu, R; Xu, Y; Zhang, H | 1 |
| Baranowska-Bosiacka, I; Chlubek, D; Goschorska, M; Gutowska, I; Metryka, E; Piotrowska, K; Safranow, K | 1 |
| Chou, PS; Huang, LC; Jhang, KM; Wang, WF; Yang, YH | 1 |
| Bonnet, U; Knierim, U; Stuehler, L; Taha, S | 1 |
| Bando, N; Hirano, T; Ishikawa, I; Matsumoto, Y; Mori, I; Mori, T; Nakamura, Y; Park, H; Tanaka, M; Tsuno, N | 1 |
| Chang, CC; Lai, TJ; Li, CH; Liu, CK; Peng, GS | 1 |
| Chan, TY; Chan, WC; Chiu, J; Kng, CPL; Kong, HL; Lam, LCW; Lau, KH; Law, CB; Lin, KL; Ma, SL; Poon, TK; Tam, CCW; Tang, JHY; Tang, NLS; Wat, KHY | 1 |
| Borah, A; Dutta, A; Gothwal, A; Gupta, U; Jain, SK; Singh, H | 1 |
| Jacob, L; Kosik, J; Kostev, K; Kurylo, P | 1 |
| Eap, CB; Noetzli, M | 1 |
| Adorni, F; Caltagirone, C; Di Santo, SG; Musicco, M; Prinelli, F | 1 |
| Johnell, K; Sonde, L | 1 |
| Fujii, M; Kajiwara, M; Kiyokawa, E; Sasaki, H; Satoh, S; Toukairin, Y | 1 |
| Dejthevaporn, C; Kulkantrakorn, K; Laptikultham, S; Pongpakdee, S; Rangseekajee, P; Rodprasert, K; Setthawatcharawanich, S; Tanyakitpisal, P; Thinkhamrop, B; Towanabut, S | 1 |
| Anand, KS; Dhikav, V | 1 |
| Gard, PR; Isaac, M; Klugman, A; Richardson, C; Tabet, N | 1 |
| Black, S; Cohen, S; Colizza, D; de Takacsy, F; Gauthier, S; Robillard, A; Sampalis, J; Schecter, R | 1 |
| Londos, E; Minthon, L; Paulsson, E; Wattmo, C | 1 |
| Hernández, B; Reñé, R; Ricart, J | 1 |
| Chang, HA; Chao, CY; Hsu, YC; Hwang, SY; Tzeng, NS | 1 |
| Hattori, H | 1 |
| Peters, KR | 1 |
| Bahrammi, MA; Naghibis, SN; Nasab, NM; Nikpour, MR; Rahim, F | 1 |
| Farlow, MR; Grossberg, GT; Meng, X; Sadowsky, CH; Somogyi, M | 1 |
| Farlow, M; Ferris, SH | 1 |
| Bellelli, G; Cummings, J; Frölich, L; Grossberg, G; Krahnke, T; Molinuevo, JL; Strohmaier, C | 1 |
| Schmutz, JL; Trechot, P | 1 |
| Broggio, E; Corbo, RM; Gambina, G; Scacchi, R | 1 |
| Fukunaga, K; Moriguchi, S; Narahashi, T; Sakagami, H; Sasaki, Y; Tagashira, H; Yeh, JZ | 1 |
| Cumbo, E; Ligori, LD | 1 |
| Shimohama, S | 2 |
| Misra, M; Padh, H; Shah, BM; Shishoo, CJ | 1 |
| Mullangi, R; Ponnayyan Sulochana, S; Sharma, K; Sukumaran, SK | 1 |
| Alva, G; Grossberg, G; Isaacson, R; Meng, X; Sadowsky, C; Somogyi, M | 1 |
| Attar, M; Caltagirone, C; Colombo, D; Cravello, L; Padovani, A; Sorbi, S; Spalletta, G | 1 |
| Adler, G; Articus, K; Mueller, B | 1 |
| Hartikainen, S; Koponen, M; Taipale, H; Tanskanen, A; Tiihonen, J; Tolppanen, AM | 1 |
| Castagna, A; Cotroneo, AM; De Palo, G; Fabbo, A; Forgione, L; Gareri, P; Giacummo, A; Lacava, R; Marino, S; Putignano, D; Putignano, S; Simone, M; Zurlo, A | 1 |
| Jiang, T; Meng, XF; Tan, CC; Tan, L; Tan, MS; Wang, C; Wang, HF; Yu, JT; Zhu, XC | 1 |
| Citrome, L | 1 |
| Riepe, MW | 1 |
| Pagar, KP; Sardar, SM; Vavia, PR | 1 |
| Shoji, M | 1 |
| Bonnì, S; Bozzali, M; Caltagirone, C; Di Lorenzo, F; Giacobbe, V; Koch, G; Martorana, A | 1 |
| Isik, AT; Soysal, P; Yay, A | 1 |
| Aguiar, P; Feres, A; Gomes, I; Melo, A; Monteiro, L | 1 |
| Frampton, JE | 1 |
| Utsumi, K | 1 |
| Amanatkar, HR; Grossberg, GT | 1 |
| Bartha, R; Borrie, MJ; Penner, J; Wells, JL; Woolmore-Goodwin, SM | 1 |
| Cascavilla, L; D'Onofrio, G; Fontana, A; Gravina, C; Greco, A; Paroni, G; Pellegrini, F; Pilotto, A; Seripa, D; Urbano, M | 1 |
| Cho, SJ; Choi, SH; Han, HJ; Kim, JE; Kim, SG; Kwon, JC; Moon, SY; Park, JM; Park, KC; Park, KH; Park, KW; Seo, SW | 1 |
| Cagnin, A; Cester, A; Costa, B; Ermani, M; Gabelli, C; Gambina, G | 1 |
| Addante, F; Cascavilla, L; Ciccone, F; D'Onofrio, G; Elia, AC; Greco, A; Nuzzaci, C; Panza, F; Paris, F; Picoco, M; Pilotto, A; Sancarlo, D | 1 |
| Farlow, MR; Grossberg, GT; Meng, X; Velting, DM | 1 |
| Batistela, MS; Bono, GF; Dias, PF; Furtado-Alle, L; Josviak, ND; Nascimento, GA; Piovezan, MR; Simão-Silva, DP; Souza, RK; Souza, RL | 1 |
| Carmichael, PH; Egberts, T; Kröger, E; Souverein, P; Van Marum, R | 1 |
| Farlow, MR; Islam, MZ; Meng, X; Sadowsky, CH; Velting, DM | 1 |
| Alva, G; Cummings, JL; Galvin, JE; Meng, X; Velting, DM | 1 |
| Birks, JS; Grimley Evans, J | 1 |
| Chaves, R; Knox, S; Mulick Cassidy, A; Müller, B; Osae-Larbi, J; Riepe, M; Weinman, J | 1 |
| Chamberlin, KW; Ehret, MJ | 1 |
| Bogerts, B; Bommhardt, U; Busse, M; Busse, S; Dobrowolny, H; Glorius, S; Greiner-Bohl, S; Hartig, R; Mawrin, C; Steiner, J | 1 |
| Mohammadi, M; Tavasoli, A; Zamani, H; Zamani, M | 1 |
| Liu, Y; Ren, L; Su, J | 1 |
| Gröhn, H; Hänninen, T; Jauhiainen, AM; Miettinen, PS; Niskanen, E; Pihlajamäki, M; Soininen, H; Tarkka, IM; Vanninen, R | 2 |
| Diaz, MCB; Rosales, RL | 1 |
| Berkers, M; Carmichael, PH; Egberts, T; Kröger, E; Laroche, ML; Mouls, M; Souverein, P; van Marum, R; Wilchesky, M | 1 |
| Ehlis, AC; Fallgatter, AJ; Haeussinger, FB; Hagen, K; Metzger, FG | 1 |
| Ferris, S; Isaacson, RS; Meng, X; Velting, DM | 1 |
| Abe, K; Deguchi, K; Hishikawa, N; Kono, S; Matsuzono, K; Nakano, Y; Ohta, Y; Sato, K; Yamashita, T | 2 |
| Alter, J; Bogerts, B; Busse, M; Busse, S; Dobrowolny, H; Hartig, R; Mawrin, C; Steiner, J | 1 |
| Aref, H; Bassil, N; diTommaso, S; Kandiah, N; Lee, JH; Pai, MC; Srinivasan, AV; Yuksel, O | 1 |
| Abagyan, R; Ali, TB; Chen, WY; Reilly, BM; Schleret, TR | 1 |
| Lewis, SJ; Szeto, JY | 1 |
| Kobayashi, H; Nakagawa, R; Ohnishi, T; Yoshizawa, K | 1 |
| Caetano, R; da Costa, RD; da Silva, RM; Maia, Ade A; Osorio-de-Castro, CG; Ramos, Mde C | 1 |
| Kaddoumi, A; Keller, JN; Mohamed, LA | 1 |
| Confaloni, A; Tata, AM; Tosto, G | 1 |
| Minthon, L; Wallin, ÅK; Wattmo, C | 2 |
| Deardorff, WJ; Grossberg, GT; Nieto, RA | 1 |
| Callegari, F; He, L; Hong, Z; Shang, L; Strohmaier, C; Wang, N; Wang, YP; Weisskopf, M; Zhang, ZX; Zhao, G; Zhao, ZX | 1 |
| Caporaso, R; Minarini, A; Rosini, M; Simoni, E | 1 |
| Choi, SH; Han, HJ; Kim, EJ; Lee, JH; Na, DL; Na, HR; Park, KW; Shim, YS; Yoon, SJ | 1 |
| Matsuda, T | 1 |
| Deardorff, WJ; Grossberg, GT | 1 |
| Bando, N; Nakamura, Y | 1 |
| Chou, MC; Ho, BL; Kao, YH; Yang, YH | 1 |
| Castagna, A; Cotroneo, AM; Gareri, P; Ruotolo, G | 1 |
| Fišar, Z; Hroudová, J; Singh, N | 1 |
| Hartikainen, S; Lampela, P; Lavikainen, P; Taipale, H; Tanskanen, A; Tiihonen, J; Tolppanen, AM | 1 |
| Hisatsune, T; Matsuda, T | 1 |
| Cho, SJ; Kim, BC; Lee, JH; Lee, KJ; Park, M | 1 |
| Fujioka, S; Futagami, K; Kamimura, H; Ouma, S; Shibaguchi, H; Terasawa, M; Tsuboi, Y; Yasutaka, Y | 1 |
| Abe, K; Darwish, M; Hishikawa, N; Ohta, Y; Sato, K; Takemoto, M; Yamashita, T | 1 |
| Bassett, K; Carney, G; Dormuth, CR; Fisher, A | 1 |
| Wightman, EL | 1 |
| Abe, K; Fukui, Y; Hishikawa, N; Ichinose, J; Morihara, R; Nakano, Y; Ohta, Y; Sato, K; Yamashita, T | 1 |
| Boustani, MA; Callahan, CM; Campbell, NL; Fowler, N; Gao, S; Hendrie, HC; Li, L; Perkins, AJ; Skaar, TC | 1 |
| Grossberg, GT | 2 |
| Cuffel, B; Del Valle, M; Mark, TL; McRae, T; Mucha, L; Shaohung, S | 1 |
| Gartlehner, G; Hansen, RA; Jonas, DE; Moore, CG; Morgan, LC; Webb, AP | 1 |
| Andreasen, N; Eriksson, S; Minthon, L; Wallin, AK; Wattmo, C | 1 |
| Corbo, RM; Gambina, G; Moretto, G; Scacchi, R | 1 |
| Ruis, J | 1 |
| Feldman, HH; Hsiung, GY | 1 |
| Fedorova, IaB; Gavrilova, SI; Kalyn, IaB; Kolykhalov, IV; Selezneva, ND | 1 |
| Guay, DR | 1 |
| Machado, JC; Winblad, B | 1 |
| Salmon, E | 1 |
| Appenroth, D; Decker, M; Fleck, C; Lehmann, J | 1 |
| Krulder, JW; Rietveld, T; Van der Cammen, TJ; Van Harskamp, F; Van Rhee Temme, W; Visch Brink, EG | 1 |
| Bennett, C; Carpenter, PK; Mohan, M | 1 |
| Chen, SH; Hsieh, YH; Lin, PC; Yang, YH; Yeh, HH | 1 |
| Darreh-Shori, T; Eagle, G; Lane, R; Mousavi, M; Nordberg, A; Peskind, E; Soininen, H | 1 |
| Blais, L; Forget, A; Kergoat, MJ; Kettani, FZ; Leroux, JC; Perreault, S | 1 |
| Hasselbalch, SG; Kampmann, JP | 1 |
| Alf, C; Bancher, C; Benke, T; Berek, K; Dal-Bianco, P; Führwürth, G; Imarhiagbe, D; Jagsch, C; Lechner, A; Rainer, M; Reisecker, F; Rotaru, J; Schmidt, R; Uranüs, M; Walter, A; Winkler, A; Wuschitz, A | 1 |
| Crutchfield, D | 1 |
| Birks, J; Grimley Evans, J; Holt, FE; Iakovidou, V; Tsolaki, M | 1 |
| Farlow, M; Kurz, A; Lefèvre, G | 1 |
| Smith, DA | 1 |
| Lane, R; Venneri, A | 1 |
| Bullock, R; Hatoum, HT; Lane, R; Lin, SJ; Thomas, SK | 1 |
| Morgan, S; Rodda, J; Walker, Z | 1 |
| Binder, C; Camacho, F; Dalziel, W; Herrmann, N; Smyth, S | 1 |
| Darreh-Shori, T; Ferris, S; Lane, R; Nordberg, A; Soininen, H | 1 |
| Bhatnagar, V; Brannan, S; Koumaras, B; Meng, X; Olin, JT; Reyes, P | 1 |
| Litvinenko, IV; Sakharovskaia, AA | 1 |
| Farlow, M; Feldman, HH; Ferris, S; Lane, R; Sfikas, N; Winblad, B | 1 |
| Dominguez, J; Gauthier, S; Homma, A; Ikeda, M; O'Connor, D; Suh, GH; Wimo, A; Yang, BM | 1 |
| Alfonso, V; González-Adalid, M; Jiménez Caballero, PE; Sevilla, C | 1 |
| Felberbaum, M; Hoffman, RS; Manini, AF; Mercurio-Zappala, M; Russell-Haders, AL | 1 |
| Cantor, MD; Farwell, W; Hernandez, RK; Lawler, EV | 1 |
| Chiu, PY; Dai, DE; Hsu, HP; Huang, YC; Kuo, HC; Lee, C; Lin, JJ; Liu, YC; Tsai, CP | 1 |
| Carmignani, G; Cei, M; Chiavistelli, P; Luschi, R; Mumoli, N | 1 |
| Aggelides, X; Kalogeromitros, D; Koti, I; Koulouris, S; Makris, M | 1 |
| Kelly, S; Lockhart, IA; Mitchell, SA | 1 |
| Leifer, BP | 1 |
| Bailey, JA; Lahiri, DK | 1 |
| Alva, G; Farlow, MR; Meng, X; Olin, JT | 1 |
| Cummings, JL; Farlow, MR; Meng, X; Olin, JT; Tekin, S | 1 |
| Darreh-Shori, T; Jelic, V | 1 |
| Bouchard, RW; Goodman, I; Perez, JA; Sadowsky, C; Tekin, S | 1 |
| Bagnoli, S; Bellavista, E; Benussi, L; Binetti, G; Chiamenti, AM; Crepaldi, G; Cruciani, G; Di Iorio, A; Feraco, E; Franceschi, C; Gabelli, C; Ghidoni, R; Gianni, W; Ginestroni, A; Grimaldi, LM; Marchegiani, F; Minicuci, N; Mishto, M; Nacmias, B; Olivieri, F; Paganelli, R; Santoro, A; Scarpino, O; Scognamiglio, M; Siviero, P; Sorbi, S | 1 |
| Farlow, MR; Meng, X; Olin, JT; Sadowsky, CH | 1 |
| Grossberg, GT; Olin, JT; Sadowsky, C | 1 |
| Aarsland, D; Cummings, J; Dronamraju, N; Emre, M; Lane, R; Tekin, S | 1 |
| Calciano, MA; Einstein, R; Snyder, PJ; Zhou, W | 1 |
| Dalziel, W; Gauthier, S; Juby, A; Réhel, B; Schecter, R | 1 |
| Formiga, F; Fort, I; Regalado, P; Robles, MJ; Rodriguez, D | 1 |
| Granero, AL; Lucchetti, G | 1 |
| Bernabei, R; Blesa, R; Bullock, R; Cunha, L; Daniëls, H; Dziadulewicz, E; Emre, M; Förstl, H; Frölich, L; Gabryelewicz, T; Levin, O; Lindesay, J; Martínez-Lage, P; Monsch, A; Tsolaki, M; van Laar, T | 1 |
| Cummings, JL; Farlow, MR; Meng, X; Olin, JT | 1 |
| Gadzhanova, S; Mackson, J; Roughead, L | 1 |
| Schenck, CH; Yeh, PY; Yeh, SB | 1 |
| Larner, AJ | 1 |
| Bastiat, G; Dumont, Y; Fuhrmann, G; Furtos, A; Leroux, JC; Motulsky, A; Plourde, F; Quirion, R | 1 |
| Cummings, JL; Farlow, MR; Ferris, SH; Meng, X; Olin, JT | 1 |
| Londos, E; Minthon, L; Wallin, AK; Wattmo, C | 1 |
| Mimica, N; Presecki, P | 1 |
| Borah, B; Sacco, P; Zarotsky, V | 1 |
| Dautzenberg, L; Dautzenberg, PL; Thissen, A; Wouters, CJ | 1 |
| Criado-Alvarez, JJ; Romo Barrientos, C | 1 |
| Egberts, T; Kröger, E; Souverein, P; van Marum, R | 1 |
| Farlow, MR; Gauthier, S; Grossberg, G; Meng, X; Olin, JT | 1 |
| Akehurst, R; Brandtmüller, A; Brennan, A; Nagy, B; Sullivan, SD; Thomas, SK | 1 |
| Osborn, GG; Saunders, AV | 1 |
| Appelt, DM; Balin, BJ; Galluzzi, KE | 1 |
| Duh, MS; Kahler, KH; Lefebvre, P; Mody-Patel, N; Scharre, DW; Vekeman, F | 1 |
| Desmarais, JE; Gauthier, S; Massoud, F | 1 |
| Grossberg, GT; Meng, X; Olin, J; Schmitt, FA; Tekin, S | 1 |
| Burian, R | 1 |
| Mets, T; Van Puyvelde, K | 1 |
| Almagro, CA; Blesa González, R; Boada Rovira, M; Gil-Saladié, D; Gobartt Vázquez, AL; Martínez Parra, C | 1 |
| Değim, Z; Eşsiz, D; Mutlu, NB; Nacar, A; Yilmaz, Ş | 1 |
| Grossberg, G; Meng, X; Olin, JT | 1 |
| Grossberg, GT; Meng, X; Olin, JT; Somogyi, M | 1 |
| Alva, G; Grossberg, GT; Meng, X; Olin, JT; Schmitt, FA | 1 |
| Kinnair, D; Machili, C; Prettyman, R; Van Diepen, E | 1 |
| Gavrilova, SI; Gerasimov, NP; Kolykhalov, IV; Rassadina, GA | 1 |
| Bohlken, J; Selke, GW; van den Bussche, H | 1 |
| Hüll, M; Voigt-Radloff, S | 1 |
| Berrut, G; Bourdeix, I; Carcaillon, L; Dartigues, JF; Gillette, S; Pere, JJ; Sellal, F | 1 |
| Choi, SH; Han, HJ; Kim, EJ; Lee, JH; Na, DL; Park, KW; Shim, YS | 1 |
| Adam, DN; Greenspoon, J; Herrmann, N | 1 |
| Barbujani, G; Chianella, C; Fuselli, S; Gragnaniello, D; Maisano Delser, P; Sette, E; Tola, MR; Visentini, MF | 1 |
| Articus, K; Baier, M; Kühn, F; Kurz, A; Preuss, UW; Tracik, F | 1 |
| Dhillon, S | 2 |
| Bozoglu, E; Doruk, H; Karadurmus, N; Karaman, M; Kurt, O; Naharci, IM | 1 |
| Barone, E; Butterfield, DA; Mancuso, C; Preziosi, P; Siciliano, R | 1 |
| Yanagisawa, K | 1 |
| Jagiella, J; Klimkowicz-Mrowiec, A; Marona, M; Slowik, A; Spisak, K; Szczudlik, A; Wolkow, P | 1 |
| Okochi, M; Takeda, M; Tanaka, T | 1 |
| Duan, G; Shen, C; Yang, B; Yu, Y; Zhou, T | 1 |
| Cambieri, C; Ceccanti, M; D'Antonio, F; de Lena, C; Gilio, F; Inghilleri, M; Trebbastoni, A | 1 |
| Meng, X; Somogyi, M; Weintraub, D | 1 |
| Caraci, F; Drago, F; Fedotova, J; Leggio, GM; Salomone, S | 1 |
| Farlow, MR; Grossberg, GT; Meng, X; Olin, J; Somogyi, M | 1 |
| Natali, B; Taffet, GE; Wagle, KC | 1 |
| Atri, A | 1 |
| Chatani, Y; Fujii, A; Shinagawa, R; Shirahase, T; Suzuki, K; Toriyama, K | 1 |
| Arranz, FJ; Molinuevo, JL | 1 |
| Bozoglu, E; Eker, D; Isik, AT | 1 |
| Aisen, PS; Cummings, J; Schneider, LS | 1 |
| Isaac, M; Klugman, A; Naughton, DP; Petroczi, A; Shah, I; Tabet, N | 1 |
| Dawid-Milner, MS; Gormaz, I; Martin, I; Mendez, L; Ojea, T; Perez, A; Rojas, F; Sanchez-Siles, JM; Tamimi, F; Tamimi, I | 1 |
| Brown, ME; Fahnestock, M; Francis, BM; Hajderi, E; McLaurin, J; Michalski, B; Mount, HT; Yang, J | 1 |
| Anderson, R; Bond, M; Davis, S; Hoyle, M; Hyde, C; Jeffreys, M; Miners, A; Moxham, T; Peters, J; Rogers, G; Thokala, P; Wailoo, A | 1 |
| Cytryn, E; Segers, K; Surquin, M | 1 |
| Nakamura, Y | 1 |
| Ateskan, U; Bozoglu, E; Isik, AT; Soysal, P; Yay, A | 1 |
| Tseng, WS; Tzeng, NS | 1 |
| Chen, CH; Chen, SH; Chou, MC; Liu, CK; Wu, SJ; Yang, YH | 1 |
| Monji, A | 1 |
| Bakchine, S; Bellelli, G; Black, SE; Caputo, A; Cummings, J; Downs, P; Froelich, L; Kressig, RW; Molinuevo, JL; Strohmaier, C | 1 |
| Muthu, MS; Samanta, MK; Vinothapooshan, G; Wilson, B | 1 |
| Hassan, H; Hussein, A; Mahdy, K; Nassar, Y; Shaker, O; Wafay, H | 1 |
| Pregelj, P | 1 |
| Bonnì, S; Caltagirone, C; Koch, G; Lo Gerfo, E; Lupo, F; Martorana, A; Perri, R | 1 |
| Cho, SJ; Choi, MS; Choi, SH; Han, HJ; Heo, JH; Kim, BC; Kim, KK; Lee, JY; Na, HR; Park, HY; Park, KW; Ryu, SH; Shin, JH; Yi, HA; Yoon, SJ | 1 |
| Aikawa, T; Arai, H; Ebihara, T; Furukawa, K; Kosaka, Y; Ohrui, T; Okinaga, S; Suzuki, M; Tomita, N; Une, K; Uwano, C | 1 |
| Sagar, R; Sonali, N; Subbiah, V; Tripathi, M; Velpandian, T | 1 |
| Berkers, M; Carmichael, PH; Egberts, T; Kröger, E; Souverein, P; van Marum, R | 1 |
| Adams, C; Haque, MS; Prasher, VP; Sachdeva, N | 1 |
| Arranz, FJ; Boada, M | 1 |
| Elmeshad, AN; Ismail, MF; Salem, NA | 1 |
| Chen, SH; Lin, SJ; Lu, CY; Wang, YR; Yang, YH | 1 |
| Cutler, NR; Enz, A; Giacobini, E; Spiegel, R; Veroff, AE | 1 |
| Demers, L; Momoli, F; Moride, Y; Oremus, M; Perrault, A; Shukla, V; Wolfson, C | 1 |
| Farlow, MR | 3 |
| Jann, MW; Shirley, KL; Small, GW | 1 |
| Darcourt, J; Ebmeier, K; Koulibaly, M; Mariani, G; Migneco, O; Nobili, F; Pupi, A; Robert, PH; Rodriguez, G; Vitali, P | 1 |
| Daniele, A; Di Lazzaro, V; Marra, C; Masullo, C; Oliviero, A; Pilato, F; Profice, P; Rothwell, JC; Saturno, E; Tonali, PA | 1 |
| Ott, BR | 1 |
| Anand, R; Danyluk, J; Doraiswamy, PM; Hartman, RD; Krishnan, KR; Sohn, H; Veach, J | 1 |
| Anand, R; Grossberg, G; Hartman, R; Potki, SG; Veach, J | 1 |
| Almkvist, O; Darreh-Shori, T; Garlind, A; Guan, ZZ; Hellström-Lindahl, E; Nordberg, A; Soreq, H; Strandberg, B; Svensson, AL | 1 |
| Kim, JM; Shin, IS; Yoon, JS | 1 |
| Howard, R; Sauer, J | 1 |
| Castro, A; Martinez, A | 1 |
| Barberger-Gateau, P; Bourdeix, I; Dartigues, JF; Goulley, F; Péré, JJ | 1 |
| Bryant, J; Clegg, A; De Broe, S; Gerard, K; McIntyre, L; Nicholson, T; Waugh, N | 2 |
| Henn, FA; Lederbogen, F; Sartorius, A; Zink, M | 1 |
| Barkhof, F; Rombouts, SA; Scheltens, P; Van Meel, CS | 1 |
| McRae, TD; Schwam, EM | 1 |
| Järvenpää, T; Kaasinen, V; Kurki, T; Någren, K; Oikonen, V; Rinne, JO; Roivainen, A; Yu, M | 1 |
| Blesa, R; Cardellach, F; Casademont, J; Miró, O; Rodriguez-Santiago, B; Viedma, P | 1 |
| Kamei, H; Nabeshima, T; Noda, Y | 1 |
| Andrews, C; Erkinjuntti, T; Lane, R; Skoog, I | 2 |
| André, G; Pere, JJ; Rigaud, AS; Touchon, J; Vellas, B | 1 |
| Amici, S; Andreasen, N; Antognelli, C; Blennow, K; Davidsson, P; Gallai, V; Lanari, A; Minthon, L; Parnetti, L; Pottel, H; Romani, C | 1 |
| Almkvist, O; Blennow, K; Hellström-Lindahl, E; Nordberg, A; Stefanova, E | 1 |
| Berghmans, RL; Huizing, AR; Verhey, FR; Widdershoven, GA | 2 |
| Adler, G; Berger, FM; Calabrese, P; Frölich, L; Gertz, HJ; Hampel, H; Haupt, M; Jendroska, K; Kohler, J; Mielke, R; Paulus, HJ; Pilartz, H; Riepe, MW; Zedlick, D | 1 |
| Farlow, M | 1 |
| Retz, W; Retz-Junginger, P; Rösler, M; Supprian, T; Wobrock, T | 1 |
| Thacker, PD | 1 |
| Gabelli, C | 1 |
| Akkawi, N; Bordonali, T; Borroni, B; Di Luca, M; Padovani, A; Pettenati, C | 1 |
| Barnaby, L; Gibson, RC | 1 |
| Farlow, M; Koumaras, B; Mirski, D; Potkin, S; Veach, J | 1 |
| Bianchetti, A; Rozzini, R; Trabucchi, M | 1 |
| Gill, MA; Nazarians, A; Williams, BR | 1 |
| Alagiakrishnan, K; Robertson, D; Sclater, A | 1 |
| Doody, RS | 1 |
| Butler, R; Prabhakaran, P; Warner, J | 1 |
| Rakonczay, Z | 1 |
| Fuchsberger, T; Hampel, H; Möller, HJ | 1 |
| Baezner, H; Daffertshofer, M | 1 |
| Bochynska, A; Jakubowska, T; Jarosz, H; Jedrzejczak, T; Lojkowska, W; Minc, S; Ryglewicz, D | 1 |
| André, G; Loria-Kanza, Y; Pere, JJ; Rigaud, AS; Touchon, J; Vellas, B | 1 |
| Alhainen, K | 1 |
| Adler, G; Brassen, S | 2 |
| Kaufer, DI | 1 |
| Bullock, R; Emre, M; Farlow, MR; Gauthier, S; Grossberg, GT; Potkin, SG | 1 |
| Auriacombe, S; Pere, JJ | 1 |
| Adler, G; Brassen, S; Chwalek, K; Dieter, B; Teufel, M | 1 |
| Haen, E; Ibach, B | 1 |
| Alisky, JM | 1 |
| Amaya, K; Casciano, J; Casciano, R; Chang, S; Cheng, I; Cuccia, AJ; Marin, D; Puder, KL; Snyder, EH | 1 |
| Darreh-Shori, T; Flores-Flores, C; Guan, ZZ; Hellström-Lindahl, E; Nordberg, A; Soreq, H | 1 |
| Daniele, A; Di Lazzaro, V; Dileone, M; Gainotti, G; Ghirlanda, S; Marra, C; Oliviero, A; Pilato, F; Saturno, E; Tonali, PA | 1 |
| Burns, A; Quarg, P; Spiegel, R | 1 |
| Almkvist, O; Darreh-Shori, T; Nordberg, A; Spiegel, R; Stefanova, E | 1 |
| Feldman, H; Ferris, S; Hermann, N; Lane, R; Mancione, L; Mesenbrink, P; Scarpini, E; Scheltens, P; Tekin, S | 1 |
| Arcona, S; Mirski, D; Powers, C; Rabinowicz, AL; Shin, H; Suh, DC; Thomas, SK | 1 |
| Rioux, S | 1 |
| Liang, YQ; Tang, XC | 1 |
| Bardelli, F; Bencini, F; Biagini, CA; Caleri, V; Cantini, C; Cavallini, MC; Marini, M; Masotti, G; Mecacci, R; Mossello, E; Razzi, E; Sarcone, E; Tilli, S; Tonon, E | 1 |
| Prasher, VP | 1 |
| Feldman, H; Portet, F; Reynish, E; Vellas, B; Voisin, T | 1 |
| Birks, J; Evans, JG; Wilcock, G | 1 |
| Kurz, A; Van Baelen, B | 1 |
| van Dyck, CH | 1 |
| Farlow, M; He, Y; Kudaravalli, S; Lane, R | 1 |
| Herrmann, N; Lanctôt, KL; Thompson, S | 1 |
| Finkel, SI | 1 |
| Andin, J; Enz, A; Gentsch, C; Marcusson, J | 1 |
| Erdoğan, F; Ersoy, AO; Karaman, Y; Köseoğlu, E; Turan, T | 1 |
| Aupperle, PM; Chen, M; Koumaras, B; Mirski, D; Rabinowicz, A | 1 |
| Edwards, K; Gorman, C; Therriault O'connor, J | 1 |
| Aguglia, E; Maso, E; Onor, ML; Saina, M | 1 |
| Charles, HC; Farlow, MR; He, Y; Lane, R; Tekin, S; Xu, J | 1 |
| Arcona, S; Beusterien, KM; Gause, D; Kimel, M; Mirski, D; Thomas, SK | 1 |
| Cruz-Jentoft, AJ; del Ser, T; Fernández-Bullido, Y; Frank, A; Galiano, M; García de la Rocha, ML; González-Salvador, MT; Muñiz, R; Navarro, E; Olazarán, J; Peña-Casanova, J; Reisberg, B; Serra, JA; Serrano, P; Sevilla, C | 1 |
| Pelgrim, E; Scheltens, P; Verhey, FR; Visser, PJ | 1 |
| Arya, P; Butler, R; Warner, J | 2 |
| Abramowski, D; De Deyn, PP; Staufenbiel, M; Van Dam, D | 1 |
| Farlow, MR; Lilly, ML | 1 |
| Garre-Olmo, J; Gelada-Batlle, E; Hernández-Ferràndiz, M; Isern-Vila, A; López-Pousa, S; Lozano-Gallego, M; Majó-Llopart, J; Morante-Muñoz, V; Pericot-Nierga, I; Turon-Estrada, A; Vilalta-Franch, M | 1 |
| Ballard, C; Bannister, C; Douglas, S; Elvish, R; Everratt, A; Jacoby, R; Juszczak, E; Lee, L; Maddison, C; Margallo-Lana, M; O'Brien, J; Sadler, S; Swann, A; Thomas, A | 1 |
| Kmietowicz, Z | 1 |
| Lee, WC; Mauskopf, JA; Paramore, C; Snyder, EH | 1 |
| Gauthier, S | 1 |
| Adams, C; Fung, N; Prasher, VP | 1 |
| Kaufer, D; Mendiondo, MS; Quarg, P; Small, GW; Spiegel, R | 1 |
| Ellis, JM | 1 |
| Gavrilova, SI; Kalyn, IaB; Kolykhalov, IV; Korovaĭtseva, GI; Selezneva, ND; Zharikov, GA | 1 |
| Caffari, B; Maggini, M; Martini, N; Raschetti, R; Sorrentino, GC; Vanacore, N | 1 |
| Román, GC | 1 |
| Bullock, R; Dengiz, A | 1 |
| Borkowska, A; Rybakowski, JK; Ziolkowska-Kochan, M | 1 |
| Di Lazzaro, V; Dileone, M; Gainotti, G; Ghirlanda, S; Marra, C; Oliviero, A; Pilato, F; Ranieri, F; Saturno, E; Tonali, P | 1 |
| Aisen, PS | 1 |
| Almkvist, O; Forsberg, A; Långström, B; Nilsson, A; Nordberg, A; Stefanova, E; Wall, A | 1 |
| Arcona, S; Suh, DC; Thomas, SK; Valiyeva, E; Vo, L | 1 |
| Schölzel-Dorenbos, CJ | 2 |
| Beck-Bornholdt, HP; Kaduszkiewicz, H; van den Bussche, H; Zimmermann, T | 1 |
| Bergman, H; Bullock, R; Gambina, G; He, Y; Lane, R; Nagel, J; Rapatz, G; Touchon, J | 1 |
| Farlow, MR; Krause, A; Quarg, P; Small, GW | 1 |
| Arcona, S; Lingala, V; Mithal, A; Singh, G; Thomas, SK | 1 |
| Desai, AK; Grossberg, GT | 1 |
| O'Neill, MF | 1 |
| Lane, R; Vincent, S | 1 |
| Lublin, HK; Olsen, CE; Poulsen, HD | 1 |
| Eskander, MF; Geula, C; Khelghati, B; Leung, EY; Nagykery, NG | 1 |
| de Silva, HA; Gunatilake, SB; Pathmeswaran, A | 1 |
| Chen, M; Cummings, JL; Koumaras, B; Mirski, D | 1 |
| Cummings, JL | 2 |
| Jelic, V; Kivipelto, M; Winblad, B | 1 |
| Bartorelli, L; Bottini, G; Cammarata, S; Fasanaro, AM; Giraldi, C; Saccardo, M; Trequattrini, A | 1 |
| Appels, BA; Beijnen, JH; de Boer, A; Frankfort, SV; Koks, CH; Tulner, LR; van Campen, JP | 2 |
| Clegg, A; Green, C; Kirby, J; Loveman, E; Payne, E; Picot, J; Takeda, A | 2 |
| Alvarez, AM; Andrade, FC; Avila, R; Bottino, CM; Bustamante, SE; Câmargo, CH; Carvalho, IA; Hototian, SR; Saffi, F; Zukauskas, PR | 2 |
| Davis, B; Sadik, K | 1 |
| Bergman, H; Bullock, R; Lane, R; Nagel, J; Rapatz, G; Touchon, J | 1 |
| Auriacombe, S; Becker, H; Bourdeix, I; Dantoine, T; Pere, JJ; Sarazin, M | 1 |
| Beusterien, KM; Musher, J; Narayanan, S; Strunk, B; Thomas, SK | 1 |
| Kloszewska, I; Sobow, T | 1 |
| Birks, J | 1 |
| Abdullah, L; Crowell, TA; Mullan, M; Paramadevan, J | 1 |
| Muhlack, S; Müller, T; Przuntek, H | 1 |
| Hara, J; Hoffman, D; Rodriquez, A; Saha, U; Shankle, WR; Sneddon, R | 1 |
| Kuo, SC; Lin, SJ; Yang, YH | 1 |
| Ownby, RL | 1 |
| Bergman, H; Bullock, R; Gambina, G; He, Y; Lane, R; Nagel, J; Touchon, J | 1 |
| Butler, R; Warner, J; Wuntakal, B | 1 |
| Cummings, JL; Ringman, JM | 1 |
| Hughes, TL; Iraqi, A | 1 |
| Nourhashémi, F | 1 |
| Gilbert, S; Kergoat, MJ; Kerneis, S; Legrain, S; Vantelon, C; Wolmark, Y | 1 |
| Beck, C; Blank, K; Colenda, CC; Doraiswamy, MP; Kalunian, DA; Lyketsos, CG; Yaffe, K | 1 |
| Dybicz, SB; Erwin, WG; Keohane, DJ; McRae, T; Shah, SN | 1 |
| Ancoli-Israel, S; Cooke, JR; Corey-Bloom, J; Fiorentino, L; Harrison, T; Liu, L; Loredo, JS; Marler, M | 1 |
| Blennow, K; de Leon, MJ; Zetterberg, H | 1 |
| Verhey, FR | 1 |
| Díaz, M; Fayed, N; Modrego, PJ; Pina, MA | 1 |
| Johannsen, P | 1 |
| Bergman, H; Blesa, R; Bullock, R; Gambina, G; He, Y; Lane, R; Meyer, J; Nagel, J; Rapatz, G | 1 |
| Gauthier, S; Juby, A; Morelli, L; Rehel, B; Schecter, R | 1 |
| Appels, BA; Beijnen, JH; de Boer, A; Frankfort, SV; Koks, CH; Schmand, BA; Tulner, LR; van Campen, JP | 1 |
| Gavrilova, SI | 1 |
| Krueger, PM; Shah, SK | 1 |
| Akbaş, A; Bullock, R; Venkatesh, K | 1 |
| Almkvist, O; Darreh-Shori, T; Kadir, A; Långström, B; Nordberg, A; Wall, A | 1 |
| Campanozzi, MD; Casali, E; Martini, E; Neri, M; Neviani, F | 1 |
| Ashani, Y; Groner, E; Herzig, Y; Schorer-Apelbaum, D; Sterling, J; Weinstock, M | 1 |
| Gruber, J; Hollenack, K; O'Shea, T; Stefanacci, R; Tangalos, EG; Zarowitz, BJ | 1 |
| Feldman, HH; Lane, R | 1 |
| Adler, G; Gunay, I; Ibach, B; Riepe, MW; Tracik, F; Weinkauf, B | 1 |
| Clare, C; Dean, C; El-Okl, M; Hensford, C; Holmes, C; Moghul, S; Wilkinson, D | 1 |
| Andreasen, N; Cummings, J; Grossberg, G; Lane, R; Nagel, J; Onofrj, M; Sadowsky, C; Winblad, B; Zechner, S | 1 |
| Beusterien, KM; Blesa, R; Fillit, H; Kawata, AK; Lane, R; Thomas, SK; Wimo, A; Winblad, B | 1 |
| Aerssens, J; Alvidrez, J; Anand, R; Faison, WE; Farrer, LA; Jarvik, L; Manly, J; McRae, T; Mintzer, JE; Murphy, GM; Olin, JT; Regier, D; Sano, M; Schultz, SK | 1 |
| Starr, JM | 1 |
| Gauthier, S; Juby, A; Rehel, B; Schecter, R | 1 |
| Burns, A; Charles, HC; Cummings, J; del Ser, T; Farlow, M; Feldman, HH; Ferris, S; Fox, NC; He, Y; Herrmann, N; Inzitari, D; Lane, R; Mancione, L; Orgogozo, JM; Potkin, S; Sauer, H; Scarpini, E; Scheltens, P; Sfikas, N; Tekin, S; Winblad, B | 1 |
| Egert, S; Förstl, H; Wagenpfeil, S | 1 |
| Appel-Dingemanse, S; Enz, A; Ereshefsky, L; Huang, HL; Jhee, SS; Lefèvre, G; Leibowitz, MT; Maton, S; Pommier, F; Schmidli, H; Sedek, G | 1 |
| Anderson, KE; Bell, K; Brickman, AM; Flynn, J; Marder, KS; Moeller, JR; Sackeim, H; Scarmeas, N; Stern, Y; Van Heertum, R | 1 |
| Basun, H; Cederholm, T; Eriksdotter-Jönhagen, M; Faxén-Irving, G; Freund-Levi, Y; Garlind, A; Grut, M; Palmblad, J; Vedin, I; Wahlund, LO | 1 |
| Bonham, J; Connelly, PJ; Cousland, G; Prentice, NP | 1 |
| Wesnes, K | 1 |
| Appel-Dingemanse, S; Cummings, J; Lefèvre, G; Small, G | 1 |
| Farlow, M; Frölich, L; Grossberg, G; Lane, R; Nagel, J; Winblad, B; Zechner, S | 1 |
| Ballard, C; Blesa, R; Lane, R; Orgogozo, JM; Thomas, SK | 1 |
| Cummings, JL; Emre, M; Lane, RM | 1 |
| Baker, AS; Brandt, J; Lyketsos, CG; Mayer, LS; McNabney, M; Onyike, CU; Rosenblatt, A; Samus, QM | 1 |
| Caffarra, P; Copelli, S; Dieci, F; Messa, G; Nonis, E; Venneri, A; Vezzadini, G | 1 |
| Flirski, M; Kloszewska, I; Liberski, P; Sobow, T | 1 |
| Anghelescu, I; Heuser, I | 1 |
| Abraham, I; Deblander, A; Jacquy, J; MacDonald, K; Mets, T; Sloesen, A; Vandewoude, M | 1 |
| Green, C | 1 |
| Borhani Haghighi, A; Haghshenas, H; Mosavinasab, M; Mowla, A | 1 |
| Neno, R | 1 |
| Keating, GM; Yang, LP | 1 |
| Lang, CJ | 1 |
| Bajda, M; Malawska, B; Musiał, A | 1 |
| Cummings, J; Winblad, B | 1 |
| Amzal, B; Appel-Dingemanse, S; Huang, HL; Lefèvre, G; Mercier, F; Schmidli, H | 1 |
| Carnahan, RM; Kennedy, WK; Kutscher, EC; Pavlis, CJ; Schlenker, E; Van Gerpen, S | 1 |
| Aguglia, E; Onor, ML; Trevisiol, M | 1 |
| Bogetto, F; Marino, F; Montemagni, C; Perrone, D; Rocca, P | 1 |
| Landmark, K; Reikvam, A | 1 |
| Kumar, KP; Paramakrishnan, N; Samanta, MK; Santhi, K; Suresh, B; Wilson, B | 1 |
| Downey, D | 1 |
| Burr, O; Kaps, M; Paulsen, S; Rosengarten, B | 1 |
| Lonie, J; Starr, JM | 1 |
| Avila, R; Bottino, CM; Carvalho, IA; Miotto, EC | 1 |
| Faber, PL; Gianotti, LR; Kochi, K; Künig, G; Lehmann, D; Pascual-Marqui, RD; Schreiter-Gasser, U | 1 |
| Athalye, S; Lefèvre, G; Picard, F; Pommier, F; Sedek, G; Shua-Haim, J; Smith, J | 1 |
| Ayhan, SS; Kayrak, M; Koc, F; Ulgen, MS; Yazici, M | 1 |
| Amstutz, R; Boddeke, H; Enz, A; Gmelin, G; Malanowski, J | 1 |
| Anand, R; Cutler, NR; Hartman, RD; Irwin, P; Sramek, JJ; Wardle, TS | 1 |
| Palacios, JM | 1 |
| Schneider, LS | 2 |
| Honma, A | 1 |
| Cutler, NR; Enz, A; Hourani, J; Jhee, SS; Mancione, L; Polinsky, RJ; Sramek, JJ; Zolnouni, P | 1 |
| Noble, S; Spencer, CM | 1 |
| Lacomblez, L | 1 |
| Derquesné, C | 1 |
| Jansen, RW; Olde Rikkert, MG | 1 |
| Agid, Y; Anand, R; Cicin-Sain, A; Dal-Bianco, P; Gauthier, S; Gharabawi, M; Hartman, R; Rösler, M; Stähelin, HB | 1 |
| Bayer, T | 1 |
| Berger, A | 1 |
| Anand, R; Forette, F; Gharabawi, G | 1 |
| Dom, R; Lemière, J; Van Gool, D | 1 |
| Bentham, P; Gray, R; Raftery, J; Sellwood, E | 1 |
| de Haan, RJ; Vermeulen, M | 1 |
| Harvey, RJ; Rossor, MN; Selai, CE; Trimble, MR | 1 |
| Elferink, AJ; Storosum, JG; van Zwieten-Boot, BJ | 1 |
| Hébert, M | 1 |
| Ebert, MH; Enz, A; Johnson, B; Kennedy, JS; Laplanche, R; Loosen, P; Mancione, LC; Parris, WC; Polinsky, RJ; Schmidt, D | 1 |
| McMillan, H | 1 |
| Burns, A; Page, S; Russell, E | 1 |
| Jann, MW | 1 |
| Sim, A | 1 |
| Bullock, R; Howard, R; Jones, R; Passmore, P; Wilkinson, D | 1 |
| Kosasa, T; Kuriya, Y; Matsui, K; Yamanishi, Y | 1 |
| Anand, R; Grossberg, GT; Messina, JC; Stahelin, HB; Veach, J | 1 |
| Birks, J; Iakovidou, V; Tsolaki, M | 2 |
| Anand, R; Hartman, R; Kumar, V; Messina, J; Veach, J | 1 |
| Gnanasakthy, A; Hauber, AB; Mauskopf, JA | 1 |
| Baik, J; Han, IW; Koo, MS; Kwak, YT | 1 |
| Bala, MV; Gnanasakthy, A; Hauber, AB; Mauskopf, JA; Richter, A; Snyder, EH | 1 |
| Babic, T; Banfic, L; Barisic, N; Jelincic, Z; Papa, J; Zurak, N | 1 |
| Stahl, SM | 2 |
| Anand, R; Farlow, M; Hartman, R; Messina, J; Veach, J | 1 |
| Grace, JB; McKeith, IG; Walker, MP | 1 |
| Fisher, A | 1 |
| Bailey, PA; Baladi, JF; Black, S; Bouchard, RW; Farcnik, KD; Gauthier, S; Kertesz, A; Mohr, E; Robillard, A | 1 |
| Giacobini, E | 1 |
| Grutzendler, J; Morris, JC | 1 |
| Hjelmstad, GO; Linkins, KW; Lloyd, JR; Strausbaugh, HJ | 1 |
| Hogan, DB; Patterson, C | 1 |
| Anand, R; Farlow, MR; Hake, A; Hartman, R; Messina, J; Veach, J | 1 |
| Kosasa, T; Kuriya, Y; Ogura, H; Yamanishi, Y | 1 |
| Lemstra, AW; Richard, E; van Gool, WA; Walstra, GJ | 1 |
| Goa, KL; Lamb, HM | 1 |
| Desai, A; Grossberg, G | 1 |
| Hake, AM | 1 |
| Cagiano, R; Cassano, T; Cuomo, V; Kendrick, KM; Pietra, C; Steardo, L; Tattoli, M; Trabace, L | 1 |
| Lampley-Dallas, VT | 1 |
| Gavrilova, SI; Zharikov, GA | 1 |
| Deleu, D | 1 |
| Slagle, MA | 1 |
| Smith, DJ; Yukhnevich, S | 1 |
| Cutler, NR; Gobburu, JV; Jhee, SS; Lesko, L; Sramek, JJ; Tammara, V; Yuan, R | 1 |
| Amici, S; Antognelli, C; Gallai, V; Lanari, A; Parnetti, L; Romani, R | 1 |
| Alva, G; Anand, R; Carreon, D; Fallon, JH; Fleming, K; Hartman, R; Keator, D; Messina, J; Potkin, SG; Wu, JC | 1 |
| Winblad, B | 1 |
| Sternon, J; Ventura, M | 1 |
| Camarda, R; Lopez, G; Mannino, M; Monastero, R | 1 |
| Caffarra, P; Godani, M; Majer, S; Paolello, P | 1 |
| Gasser, T; Schreiter Gasser, U | 1 |
| Richard, E; van Campen, J; van Gool, WA; Vissers, E; Walstra, GJ | 1 |
| Ballard, CG | 1 |
| Gasser, T; Gasser, US | 1 |
| Borioni, A; Del Giudice, MR; Ferretti, R; Gatta, F; Lorenzini, P; Meneguz, A; Mustazza, C; Volpe, MT | 1 |
| Barcikowska, M; Bilikiewicz, A; Bilińska, M; Gabryelewicz, T; Ochudło, S; Opala, G; Paradowski, B; Parnowski, T; Pfeffer, A; Podemski, R; Puzyński, S; Sołtys, K; Łapin, J | 1 |
| Lechner, A; Petrovic, K; Schmidt, R | 1 |
| Bullock, R; Connolly, C | 1 |
| Forbes, KE; Gemmell, HG; Murray, AD; Pestell, SJ; Shanks, MF; Staff, RT; Venneri, A | 1 |
| Cutler, NR; Hossain, M; Jhee, SS; McDonald, C; Pommier, F; Sedek, G; Shiovitz, T | 1 |
| Allain, H; Bentue-Ferrer, D; Lecavorzin, P; Polard, E; Reymann, JM; Tribut, O | 1 |
| Andreae, D; Grohmann, R; Heinze, M | 1 |
| Dourish, J; Walsh, E | 1 |
| Klein, C; Rabey, JM; Werber, AE | 1 |
| Anand, R; Graham, S; Hartman, R; Morganroth, J | 1 |
| Bullock, R | 1 |
| Cherry, D; Cummings, JL; Frank, JC; Hewett, L; Kemp, B; Kohatsu, ND; Mittman, B | 1 |
| Auriacombe, S; Loria-Kanza, Y; Pere, JJ; Vellas, B | 1 |
| Robert, P | 1 |
| Blount, PJ; McDeavitt, JT; Nguyen, CD | 1 |
| Boddeke, H; Enz, A; Gray, J; Spiegel, R | 1 |
187 review(s) available for rivastigmine and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
Multi-target-directed ligands to combat neurodegenerative diseases.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Binding Sites; Calcium Channel Blockers; Chelating Agents; Cholinesterase Inhibitors; Humans; Huntington Disease; Ligands; Multiple Sclerosis; Neurodegenerative Diseases; Neurofibrillary Tangles; Neurotransmitter Agents; Parkinson Disease; Plaque, Amyloid | 2008 |
Anti-cholinesterase hybrids as multi-target-directed ligands against Alzheimer's disease (1998-2018).
Topics: Alzheimer Disease; Animals; Cholinesterase Inhibitors; Cholinesterases; Drug Design; Humans; Ligands; Neuroprotective Agents | 2019 |
Propargylamine-derived multi-target directed ligands for Alzheimer's disease therapy.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Cholinesterases; Humans; Ligands; Monoamine Oxidase; Neuroprotective Agents; Oxidative Stress; Pargyline; Propylamines | 2020 |
Acetylcholinesterase Enzyme Inhibitor Molecules with Therapeutic Potential for Alzheimer's Disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Humans; Rivastigmine | 2022 |
Anti-Neurodegenerative Benefits of Acetylcholinesterase Inhibitors in Alzheimer's Disease: Nexus of Cholinergic and Nerve Growth Factor Dysfunction.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Cholinesterase Inhibitors; Humans; Nerve Growth Factor; Rivastigmine | 2021 |
The Efficacy and Safety of Alzheimer's Disease Therapies: An Updated Umbrella Review.
Topics: Activities of Daily Living; Alzheimer Disease; Amino Acids; Cholinesterase Inhibitors; Cognition; Donepezil; Galantamine; Ginkgo biloba; Humans; Nootropic Agents; Patient Safety; Plant Extracts; Rivastigmine | 2022 |
Comparative Efficacy and Acceptability of Cholinesterase Inhibitors and Memantine Based on Dosage in Patients with Vascular Cognitive Impairment: A Network Meta-analysis.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognitive Dysfunction; Donepezil; Galantamine; Humans; Indans; Memantine; Network Meta-Analysis; Nootropic Agents; Randomized Controlled Trials as Topic; Rivastigmine | 2022 |
Systematic review of pharmacological interventions for people with Lewy body dementia.
Topics: Alzheimer Disease; Dementia; Humans; Lewy Body Disease; Parkinson Disease; Rivastigmine | 2023 |
Challenges and Approaches of Drugs Such as Memantine, Donepezil, Rivastigmine, and Aducanumab in the Treatment, Control and Management of Alzheimer's Disease.
Topics: Alzheimer Disease; Animals; Antibodies, Monoclonal, Humanized; Donepezil; Indans; Memantine; Patents as Topic; Piperidines; Rivastigmine | 2022 |
The Dose and Duration-dependent Association between Melatonin Treatment and Overall Cognition in Alzheimer's Dementia: A Network Meta- Analysis of Randomized Placebo-Controlled Trials.
Topics: Alzheimer Disease; Cognition; Humans; Melatonin; Network Meta-Analysis; Randomized Controlled Trials as Topic; Rivastigmine | 2022 |
Comparative safety and efficacy of cognitive enhancers for Alzheimer's dementia: a systematic review with individual patient data network meta-analysis.
Topics: Adult; Alzheimer Disease; Donepezil; Galantamine; Humans; Memantine; Network Meta-Analysis; Nootropic Agents; Rivastigmine | 2022 |
Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia.
Topics: Activities of Daily Living; Alzheimer Disease; Cholinesterase Inhibitors; Dementia; Donepezil; Humans; Memantine; Parkinson Disease; Quality of Life; Rivastigmine | 2021 |
Pharmacotherapy of Alzheimer's disease: an overview of systematic reviews.
Topics: Alzheimer Disease; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Cholinesterase Inhibitors; Donepezil; Galantamine; Glycogen Synthase Kinase 3; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Indans; Lithium; Melatonin; Memantine; Neurodegenerative Diseases; Rivastigmine; Systematic Reviews as Topic | 2022 |
Advances on Therapeutic Strategies for Alzheimer's Disease: From Medicinal Plant to Nanotechnology.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Humans; Indans; Nanotechnology; Piperidines; Plants, Medicinal; Rivastigmine | 2022 |
Effect of Acetylcholinesterase Inhibitors on Cerebral Perfusion and Cognition: A Systematic Review.
Topics: Acetylcholinesterase; Alzheimer Disease; Cerebrovascular Circulation; Cholinesterase Inhibitors; Cognition; Dementia; Galantamine; Humans; Indans; Parkinson Disease; Perfusion; Phenylcarbamates; Piperidines; Rivastigmine | 2023 |
[Anti-Dementia Drugs (Anti-Alzheimer's Disease Drugs)].
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Memantine; Receptors, N-Methyl-D-Aspartate; Rivastigmine | 2023 |
Cholinesterase Inhibitors for Treatment of Psychotic Symptoms in Alzheimer Disease and Parkinson Disease: A Meta-analysis.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Female; Hallucinations; Humans; Male; Parkinson Disease; Randomized Controlled Trials as Topic; Rivastigmine | 2023 |
Psychiatric Adverse Events of Acetylcholinesterase Inhibitors in Alzheimer's Disease and Parkinson's Dementia: Systematic Review and Meta-Analysis.
Topics: Acetylcholinesterase; Alzheimer Disease; Anorexia; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Parkinson Disease; Phenylcarbamates; Randomized Controlled Trials as Topic; Rivastigmine; Sleep Initiation and Maintenance Disorders | 2023 |
The chemistry toolbox of multitarget-directed ligands for Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Chemistry Techniques, Synthetic; Donepezil; Dopamine Agents; Drug Design; Drug Discovery; Humans; Indans; Memantine; Molecular Targeted Therapy; Neuroprotective Agents; Nootropic Agents; Rivastigmine; Tacrine | 2019 |
Highly Significant Scaffolds to Design and Synthesis Cholinesterase Inhibitors as Anti-Alzheimer Agents.
Topics: Acetylcholinesterase; Alkaloids; Alzheimer Disease; Butyrylcholinesterase; Cholinesterase Inhibitors; Donepezil; Drug Design; Humans; Rivastigmine; Tacrine | 2019 |
Cholinesterase Inhibitors for Alzheimer's Disease: Multitargeting Strategy Based on Anti-Alzheimer's Drugs Repositioning.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Drug Repositioning; Galantamine; Humans; Rivastigmine; Tacrine | 2019 |
An update on the utility and safety of cholinesterase inhibitors for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Rivastigmine | 2020 |
Transdermal Drug Delivery Systems and their Potential in Alzheimer's Disease Management.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Drug Delivery Systems; Humans; Memantine; Rivastigmine | 2020 |
Current Strategies and Novel Drug Approaches for Alzheimer Disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Brain; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Mice; Phytotherapy; Plant Preparations; Rats; Rivastigmine | 2020 |
Comparative risk of cardiac arrhythmias associated with acetylcholinesterase inhibitors used in treatment of dementias - A narrative review.
Topics: Alzheimer Disease; Animals; Arrhythmias, Cardiac; Cholinesterase Inhibitors; Dementia; Donepezil; Galantamine; Humans; Rivastigmine | 2020 |
Privileged Pharmacophore of FDA Approved Drugs in Combination with Chalcone Framework: A New Hope for Alzheimer's Treatment.
Topics: Acetylcholinesterase; Alzheimer Disease; Chalcones; Drug Approval; Drug Design; Enzyme Inhibitors; Flurbiprofen; Humans; Monoamine Oxidase; Neuroprotective Agents; Rivastigmine; Structure-Activity Relationship; United States; United States Food and Drug Administration | 2020 |
Efficacy of acetylcholinesterase inhibitors in Alzheimer's disease.
Topics: Alzheimer Disease; Antioxidants; Cholinesterase Inhibitors; Donepezil; Drug Therapy, Combination; Excitatory Amino Acid Antagonists; Galantamine; Humans; Receptors, N-Methyl-D-Aspartate; Rivastigmine | 2021 |
Acetylcholinesterase Inhibitory Potential of Various Sesquiterpene Analogues for Alzheimer's Disease Therapy.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Cholinesterase Inhibitors; Galantamine; Humans; Rivastigmine; Sesquiterpenes | 2021 |
Alzheimer Disease: Monotherapy vs. Combination Therapy.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Dopamine Agents; Drug Therapy, Combination; Galantamine; Humans; Indans; Memantine; Piperidines; Rivastigmine | 2017 |
Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson's disease dementia.
Topics: Acetylcholinesterase; Activities of Daily Living; Alzheimer Disease; Behavioral Symptoms; Butyrylcholinesterase; Cholinesterase Inhibitors; Cognition; Dementia; Dementia, Vascular; Humans; Parkinson Disease; Rivastigmine | 2017 |
Acetylcholinesterase inhibitors for treating dementia symptoms - a safety evaluation.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Dementia; Donepezil; Drug Interactions; Galantamine; Humans; Indans; Piperidines; Rivastigmine; Severity of Illness Index | 2017 |
Advances toward multifunctional cholinesterase and β-amyloid aggregation inhibitors.
Topics: Alkaloids; Alzheimer Disease; Amyloid beta-Peptides; Cholinesterase Inhibitors; Cholinesterases; Donepezil; Humans; Indans; Inhibitory Concentration 50; Piperidines; Rivastigmine; Tacrine | 2017 |
Acetylcholinesterase Inhibitors: Beneficial Effects on Comorbidities in Patients With Alzheimer's Disease.
Topics: Alzheimer Disease; Cardiovascular Diseases; Cholinesterase Inhibitors; Comorbidity; Donepezil; Galantamine; Polypharmacy; Rivastigmine | 2018 |
Comparisons between traditional medicines and pharmacotherapies for Alzheimer disease: A systematic review and meta-analysis of cognitive outcomes.
Topics: Alzheimer Disease; Asia, Eastern; Cholinesterase Inhibitors; Cognition; Donepezil; Galantamine; Humans; Indans; Medicine, Traditional; Memantine; Nootropic Agents; Piperidines; Plant Extracts; Rivastigmine | 2018 |
Collapse in the elderly: rivastigmine-induced heart block and a literature review of the pharmacology of acetylcholinesterase inhibitors used in Alzheimer's disease.
Topics: Accidental Falls; Aged, 80 and over; Alzheimer Disease; Bradycardia; Cholinesterase Inhibitors; Female; Femoral Neck Fractures; Heart Block; Hemiarthroplasty; Humans; Pacemaker, Artificial; Rivastigmine; Treatment Outcome | 2018 |
Identification of the optimal cognitive drugs among Alzheimer's disease: a Bayesian meta-analytic review.
Topics: Alzheimer Disease; Antiparkinson Agents; Bayes Theorem; Cholinesterase Inhibitors; Cognition; Donepezil; Galantamine; Humans; Memantine; Neuroprotective Agents; Nootropic Agents; Rivastigmine | 2018 |
Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer's disease.
Topics: Aging; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Excitatory Amino Acid Antagonists; Galantamine; Humans; Indans; Memantine; Pharmacogenetics; Phenylcarbamates; Piperidines; Receptors, N-Methyl-D-Aspartate; Rivastigmine | 2013 |
A meta-analysis of the efficacy of donepezil, rivastigmine, galantamine, and memantine in relation to severity of Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Behavior; Cholinesterase Inhibitors; Cognition; Data Interpretation, Statistical; Disability Evaluation; Disease Progression; Donepezil; Female; Galantamine; Humans; Indans; Male; Memantine; Middle Aged; Neuroprotective Agents; Neuropsychological Tests; Phenylcarbamates; Piperidines; Randomized Controlled Trials as Topic; Rivastigmine; Treatment Outcome | 2013 |
[Effectiveness and limitation of newly approved drugs for Alzheimer's disease].
Topics: Alzheimer Disease; Clinical Trials as Topic; Galantamine; Humans; Japan; Memantine; Phenylcarbamates; Quality of Life; Rivastigmine | 2013 |
Language impairment in Alzheimer's disease and benefits of acetylcholinesterase inhibitors.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Communication Disorders; Donepezil; Galantamine; Humans; Indans; Outcome Assessment, Health Care; Phenylcarbamates; Piperidines; Rivastigmine | 2013 |
Drugs for cognitive loss and dementia.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Cholinesterase Inhibitors; Cognition Disorders; Dementia; Donepezil; Excitatory Amino Acid Antagonists; Galantamine; Humans; Indans; Memantine; Phenylcarbamates; Piperidines; Randomized Controlled Trials as Topic; Receptors, N-Methyl-D-Aspartate; Rivastigmine | 2013 |
[Development of therapies for Alzheimer's disease based on cholinergic hypothesis-status quo and future directions].
Topics: Alzheimer Disease; Amyloid beta-Peptides; Cholinergic Neurons; Cholinesterase Inhibitors; Donepezil; Drug Discovery; Galantamine; Humans; Indans; Molecular Targeted Therapy; Neuroprostanes; Phenylcarbamates; Piperidines; Rivastigmine | 2013 |
Review of the validated HPLC and LC-MS/MS methods for determination of drugs used in clinical practice for Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Chromatography, High Pressure Liquid; Donepezil; Galantamine; Humans; Indans; Neuroprotective Agents; Nootropic Agents; Phenylcarbamates; Piperidines; Rivastigmine; Tandem Mass Spectrometry | 2014 |
Efficacy and safety of donepezil, galantamine, rivastigmine, and memantine for the treatment of Alzheimer's disease: a systematic review and meta-analysis.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Indans; Memantine; Nootropic Agents; Phenylcarbamates; Piperidines; Randomized Controlled Trials as Topic; Rivastigmine | 2014 |
[Programs for continuing medical education: a session; 3. Dementia: diagnosis and therapy].
Topics: Alzheimer Disease; Amyloid beta-Peptides; Biomarkers; Cholinesterase Inhibitors; Cognitive Dysfunction; Dementia; Disease Progression; Donepezil; Education, Medical, Continuing; Galantamine; Humans; Indans; Lewy Body Disease; Nootropic Agents; Peptide Fragments; Phenylcarbamates; Piperidines; Positron-Emission Tomography; Reference Standards; Rivastigmine; tau Proteins; Tomography, Emission-Computed, Single-Photon | 2014 |
Rivastigmine transdermal patch 13.3 mg/24 h: a review of its use in the management of mild to moderate Alzheimer's dementia.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Humans; Neuroprotective Agents; Phenylcarbamates; Randomized Controlled Trials as Topic; Rivastigmine; Severity of Illness Index; Transdermal Patch; Treatment Outcome | 2014 |
[Progress of dementia medicine: Special reference to Alzheimer's disease].
Topics: Alzheimer Disease; Amyloid beta-Peptides; Biomarkers; Brain; Cholinesterase Inhibitors; Donepezil; Drug Discovery; Galantamine; Humans; Indans; Magnetic Resonance Imaging; Memantine; Neurofibrillary Tangles; Nootropic Agents; Phenylcarbamates; Piperidines; Receptors, N-Methyl-D-Aspartate; Rivastigmine; Tomography, Emission-Computed, Single-Photon | 2014 |
Transdermal rivastigmine in the treatment of Alzheimer's disease: current and future directions.
Topics: Administration, Cutaneous; Alzheimer Disease; Cholinesterase Inhibitors; Humans; Phenylcarbamates; Rivastigmine; Transdermal Patch; Treatment Outcome | 2014 |
Rivastigmine for Alzheimer's disease.
Topics: Alzheimer Disease; Caregivers; Cholinesterase Inhibitors; Cognition Disorders; Drug Administration Schedule; Humans; Phenylcarbamates; Randomized Controlled Trials as Topic; Rivastigmine; Severity of Illness Index | 2015 |
Current Practices in the Treatment of Alzheimer Disease: Where is the Evidence After the Phase III Trials?
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials, Phase III as Topic; Donepezil; Galantamine; Humans; Indans; Memantine; Nootropic Agents; Piperidines; Rivastigmine; Treatment Outcome | 2015 |
Long-term effectiveness of rivastigmine patch or capsule for mild-to-severe Alzheimer's disease: a meta-analysis.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Humans; Rivastigmine; Treatment Outcome | 2015 |
Current Treatment Options for Alzheimer's Disease and Parkinson's Disease Dementia.
Topics: Alzheimer Disease; Animals; Antiparkinson Agents; Cholinesterase Inhibitors; Cognitive Behavioral Therapy; Dementia; Donepezil; Excitatory Amino Acid Antagonists; Exercise Therapy; Galantamine; Humans; Indans; Memantine; Parkinson Disease; Piperidines; Rivastigmine; Sleep Wake Disorders; Treatment Outcome | 2016 |
The comparative efficacy and safety of cholinesterase inhibitors in patients with mild-to-moderate Alzheimer's disease: a Bayesian network meta-analysis.
Topics: Aged; Alzheimer Disease; Bayes Theorem; Cholinesterase Inhibitors; Cognition; Donepezil; Female; Galantamine; Humans; Indans; Male; Middle Aged; Network Meta-Analysis; Piperidines; Randomized Controlled Trials as Topic; Rivastigmine | 2016 |
Promising Therapies for Alzheimer's Disease.
Topics: Allosteric Regulation; Alzheimer Disease; Animals; Donepezil; Humans; Indans; Ligands; Neuroprotective Agents; Piperidines; Receptors, Cholinergic; Rivastigmine | 2016 |
Multitarget strategies in Alzheimer's disease: benefits and challenges on the road to therapeutics.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Cholinesterase Inhibitors; Donepezil; Drug Discovery; Galantamine; Humans; Indans; Molecular Targeted Therapy; Piperidines; Rivastigmine; Structure-Activity Relationship | 2016 |
Psychopharmacological Studies in Mice.
Topics: Alzheimer Disease; Animals; Cholinesterase Inhibitors; Disease Models, Animal; Donepezil; Dopamine; Drug Discovery; Environment; Female; Galantamine; Indans; Male; Mental Disorders; Mice; Molecular Targeted Therapy; Motivation; Piperidines; Psychopharmacology; Rats; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT1D; Receptors, Dopamine D2; Research; Rivastigmine | 2016 |
Pharmacotherapeutic strategies in the treatment of severe Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Donepezil; Humans; Indans; Memantine; Piperidines; Receptors, N-Methyl-D-Aspartate; Rivastigmine; Transdermal Patch | 2016 |
Potential benefits of phytochemicals against Alzheimer's disease.
Topics: Alkaloids; Alzheimer Disease; Animals; Cholinesterase Inhibitors; Disease Models, Animal; Galantamine; Ginkgo biloba; Humans; Melissa; Panax; Phytochemicals; Plant Extracts; Resveratrol; Rivastigmine; Salvia officinalis; Stilbenes; Terpenes | 2017 |
Impact of rivastigmine on caregiver burden associated with Alzheimer's disease in both informal care and nursing home settings.
Topics: Administration, Cutaneous; Alzheimer Disease; Caregivers; Cholinesterase Inhibitors; Cognition; Cost of Illness; Drug Costs; Health Care Costs; Homes for the Aged; Humans; Nursing Homes; Phenylcarbamates; Rivastigmine; Severity of Illness Index; Time Factors; Treatment Outcome | 2008 |
Efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer's disease: a systematic review and meta-analysis.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Indans; Phenylcarbamates; Piperidines; Rivastigmine; Treatment Outcome | 2008 |
Pharmacological treatment in moderate-to-severe Alzheimer's disease.
Topics: Alzheimer Disease; Donepezil; Double-Blind Method; Humans; Indans; Memantine; Phenylcarbamates; Piperidines; Placebos; Randomized Controlled Trials as Topic; Rivastigmine; Selegiline; Severity of Illness Index; Vitamin E | 2008 |
Rivastigmine transdermal patch: role in the management of Alzheimer's disease.
Topics: Administration, Cutaneous; Alzheimer Disease; Cholinesterase Inhibitors; Humans; Phenylcarbamates; Practice Guidelines as Topic; Rivastigmine | 2008 |
Use of rivastigmine transdermal patch in the treatment of Alzheimer's disease.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Drug Delivery Systems; Female; Humans; Male; Phenylcarbamates; Rivastigmine; Skin Absorption | 2008 |
Rivastigmine for dementia in people with Down syndrome.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Down Syndrome; Humans; Phenylcarbamates; Rivastigmine | 2009 |
Discontinuing Alzheimer's disease drug therapy: why, when, and how.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Drug Approval; Drug Monitoring; Excitatory Amino Acid Antagonists; Galantamine; Humans; Indans; Memantine; Neuroprotective Agents; Nursing Homes; Patient Selection; Phenylcarbamates; Piperidines; Prevalence; Receptors, N-Methyl-D-Aspartate; Rivastigmine; Severity of Illness Index; Treatment Failure; United States; Withholding Treatment | 2008 |
Rivastigmine for Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Humans; Phenylcarbamates; Randomized Controlled Trials as Topic; Rivastigmine; Severity of Illness Index | 2009 |
Pharmacokinetics of a novel transdermal rivastigmine patch for the treatment of Alzheimer's disease: a review.
Topics: Administration, Cutaneous; Alzheimer Disease; Biological Availability; Cholinesterase Inhibitors; Humans; Phenylcarbamates; Rivastigmine; Treatment Outcome | 2009 |
Treatment of Alzheimer's disease in the long-term-care setting.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Dopamine Agents; Galantamine; Humans; Indans; Long-Term Care; Memantine; Phenylcarbamates; Piperidines; Rivastigmine | 2009 |
Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Evidence-Based Medicine; Galantamine; Humans; Indans; Mental Disorders; Nootropic Agents; Phenylcarbamates; Piperidines; Randomized Controlled Trials as Topic; Rivastigmine; Treatment Outcome | 2009 |
Safety and tolerability of donepezil, rivastigmine and galantamine for patients with Alzheimer's disease: systematic review of the 'real-world' evidence.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Evidence-Based Medicine; Galantamine; Humans; Indans; Phenylcarbamates; Piperidines; Randomized Controlled Trials as Topic; Rivastigmine | 2009 |
Safety and tolerability of transdermal and oral rivastigmine in Alzheimer's disease and Parkinson's disease dementia.
Topics: Administration, Cutaneous; Administration, Oral; Alzheimer Disease; Cholinesterase Inhibitors; Dementia; Dermatitis, Irritant; Humans; Nausea; Parkinson Disease; Phenylcarbamates; Randomized Controlled Trials as Topic; Rivastigmine; Treatment Outcome; Vomiting | 2010 |
Switching from oral cholinesterase inhibitors to the rivastigmine transdermal patch.
Topics: Administration, Cutaneous; Administration, Oral; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Databases, Factual; Donepezil; Female; Humans; Indans; Male; Phenylcarbamates; Piperidines; Randomized Controlled Trials as Topic; Retrospective Studies; Rivastigmine | 2010 |
Safety and tolerability of rivastigmine transdermal patch compared with rivastigmine capsules in patients switched from donepezil: data from three clinical trials.
Topics: Administration, Cutaneous; Administration, Oral; Aged; Alzheimer Disease; Blood Pressure; Capsules; Cholinesterase Inhibitors; Donepezil; Female; Humans; Indans; Male; Phenylcarbamates; Piperidines; Pulse; Randomized Controlled Trials as Topic; Respiration; Rivastigmine | 2010 |
Rivastigmine transdermal system for the treatment of mild to moderate Alzheimer's disease.
Topics: Administration, Cutaneous; Alzheimer Disease; Humans; Neuroprotective Agents; Phenylcarbamates; Practice Guidelines as Topic; Rivastigmine; Treatment Outcome | 2010 |
Drug profile: transdermal rivastigmine patch in the treatment of Alzheimer disease.
Topics: Administration, Cutaneous; Alzheimer Disease; Animals; Antipsychotic Agents; Humans; Phenylcarbamates; Rivastigmine | 2010 |
Current treatments for patients with Alzheimer disease.
Topics: Aggression; Alzheimer Disease; Behavior Therapy; Cholinesterase Inhibitors; Depression; Excitatory Amino Acid Antagonists; Galantamine; Health Status; Humans; Memantine; Neuroprotective Agents; Parasympathomimetics; Phenylcarbamates; Psychomotor Agitation; Psychotherapy; Psychotic Disorders; Rivastigmine; Time Factors; United States; United States Food and Drug Administration | 2010 |
Modern care for patients with Alzheimer disease: rationale for early intervention.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Cholinesterase Inhibitors; Cognition; Donepezil; Excitatory Amino Acid Antagonists; Humans; Immunosuppressive Agents; Indans; Memantine; Neuroprotective Agents; Phenylcarbamates; Piperidines; Psychological Tests; Rivastigmine; Severity of Illness Index; Tacrolimus | 2010 |
Switching cholinesterase inhibitors in older adults with dementia.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Indans; Phenylcarbamates; Piperidines; Practice Guidelines as Topic; Rivastigmine; Treatment Outcome | 2011 |
Reviews: Effects of transdermal rivastigmine on ADAS-cog items in mild-to-moderate Alzheimer's disease.
Topics: Administration, Cutaneous; Aged; Alzheimer Disease; Cognition; Controlled Clinical Trials as Topic; Humans; Neuroprotective Agents; Phenylcarbamates; Rivastigmine; Severity of Illness Index | 2010 |
[Daily functioning in dementia: pharmacological and non-pharmacological interventions demonstrate small effects on heterogeneous scales].
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Angiotensin-Converting Enzyme Inhibitors; Caregivers; Donepezil; Galantamine; Geriatric Assessment; Ginkgo biloba; Humans; Indans; Institutionalization; Memantine; Nootropic Agents; Phenylcarbamates; Phytotherapy; Piperidines; Plant Extracts; Randomized Controlled Trials as Topic; Rivastigmine | 2011 |
Transdermal rivastigmine: management of cutaneous adverse events and review of the literature.
Topics: Administration, Cutaneous; Alzheimer Disease; Cholinesterase Inhibitors; Dermatitis, Allergic Contact; Dermatitis, Contact; Humans; Medication Adherence; Phenylcarbamates; Rivastigmine; Transdermal Patch | 2011 |
Rivastigmine transdermal patch: a review of its use in the management of dementia of the Alzheimer's type.
Topics: Administration, Cutaneous; Alzheimer Disease; Cholinesterase Inhibitors; Humans; Medication Adherence; Phenylcarbamates; Rivastigmine; Transdermal Patch | 2011 |
Pharmacologists and Alzheimer disease therapy: to boldly go where no scientist has gone before.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Brain; Cholinesterase Inhibitors; Cognition; Donepezil; Galantamine; Humans; Indans; Memantine; Neurons; Oxidative Stress; Phenylcarbamates; Piperidines; Receptors, N-Methyl-D-Aspartate; Receptors, Serotonin; Rivastigmine | 2011 |
[Newly approved drugs for Alzheimer disease: effectiveness and limitation].
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Galantamine; Humans; Memantine; Phenylcarbamates; Receptors, N-Methyl-D-Aspartate; Rivastigmine; Treatment Outcome | 2011 |
New drugs for Alzheimer's disease in Japan.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Drug Discovery; Excitatory Amino Acid Antagonists; Galantamine; Humans; Indans; Japan; Memantine; Phenylcarbamates; Piperidines; Rivastigmine; Tacrine | 2011 |
New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs.
Topics: Alzheimer Disease; Clinical Trials as Topic; Donepezil; Drug Discovery; Excitatory Amino Acid Antagonists; Galantamine; Humans; Indans; Memantine; Neuroprotective Agents; Phenylcarbamates; Piperidines; Plaque, Amyloid; Rivastigmine; tau Proteins | 2012 |
Spotlight on rivastigmine transdermal patch: in dementia of the Alzheimer's type.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Humans; Phenylcarbamates; Rivastigmine; Transdermal Patch | 2011 |
Effective pharmacological management of Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Dementia; Disease Progression; Donepezil; Galantamine; Humans; Indans; Memantine; Nootropic Agents; Phenylcarbamates; Piperidines; Rivastigmine; Tacrine; Time Factors; Treatment Outcome | 2011 |
[Pharmacological profile and clinical results of the rivastigmine patch as a new therapeutic agent for Alzheimer's disease].
Topics: Aged; Alzheimer Disease; Animals; Cholinesterase Inhibitors; Humans; Phenylcarbamates; Rats; Rivastigmine; Transdermal Patch | 2012 |
Symptomatic and nonamyloid/tau based pharmacologic treatment for Alzheimer disease.
Topics: Alkaloids; Alzheimer Disease; Amino Acids; Animals; Cholinesterase Inhibitors; Dietary Supplements; Disease Progression; Docosahexaenoic Acids; Donepezil; Drug Approval; Galantamine; Ginkgo biloba; Half-Life; History, 20th Century; Humans; Indans; Memantine; Nootropic Agents; Phenylcarbamates; Phytotherapy; Piperidines; Psychotropic Drugs; Receptors, AMPA; Receptors, N-Methyl-D-Aspartate; Rivastigmine; Sesquiterpenes; Vitamin B Complex; Vitamin E | 2012 |
The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model.
Topics: Adult; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cost-Benefit Analysis; Donepezil; Dopamine Agents; Female; Galantamine; Humans; Indans; Male; Memantine; Middle Aged; Models, Economic; Phenylcarbamates; Piperidines; Rivastigmine; Technology Assessment, Biomedical | 2012 |
[Rivastigmine].
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Humans; Phenylcarbamates; Rivastigmine | 2011 |
Donepezil and rivastigmine in the treatment of Alzheimer's disease: a best-evidence synthesis of the published data on their efficacy and cost-effectiveness.
Topics: Aged; Alzheimer Disease; Canada; Carbamates; Cholinesterase Inhibitors; Cost-Benefit Analysis; Donepezil; Humans; Indans; Middle Aged; Multicenter Studies as Topic; Phenylcarbamates; Piperidines; Randomized Controlled Trials as Topic; Rivastigmine; Treatment Outcome | 2002 |
Do cholinesterase inhibitors slow progression of Alzheimer's disease?
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Disease Progression; Humans; Nootropic Agents; Phenylcarbamates; Rivastigmine | 2002 |
Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors.
Topics: Aging; Alzheimer Disease; Biological Availability; Carbamates; Cholinesterase Inhibitors; Donepezil; Drug Interactions; Half-Life; Humans; Indans; Intestinal Absorption; Liver; Phenylcarbamates; Piperidines; Protein Binding; Rivastigmine; Tacrine; Tissue Distribution | 2002 |
Medical treatment of Alzheimer's disease: past, present, and future.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; Donepezil; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Forecasting; Galantamine; Humans; Indans; Male; Phenylcarbamates; Piperidines; Prognosis; Rivastigmine; Severity of Illness Index; Tacrine; Treatment Outcome | 2002 |
Peripheral and dual binding site acetylcholinesterase inhibitors: implications in treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Aged; Alzheimer Disease; Binding Sites; Carbamates; Cholinesterase Inhibitors; Donepezil; Drug Design; Humans; Indans; Molecular Conformation; Molecular Structure; Phenylcarbamates; Piperidines; Rivastigmine; Structure-Activity Relationship; Tacrine | 2001 |
Clinical and cost-effectiveness of donepezil, rivastigmine, and galantamine for Alzheimer's disease. A systematic review.
Topics: Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Cost of Illness; Cost-Benefit Analysis; Donepezil; Galantamine; Humans; Indans; Phenylcarbamates; Piperidines; Quality of Life; Randomized Controlled Trials as Topic; Rivastigmine; Treatment Outcome | 2002 |
[Anti-dementia drugs for Alzheimer disease in present and future].
Topics: Acetylcholine; Alzheimer Disease; Amyloid beta-Peptides; Carbamates; Cholinesterase Inhibitors; Donepezil; Drug Design; Galantamine; Humans; Indans; Memantine; Phenylcarbamates; Piperidines; Rivastigmine; Tacrine; tau Proteins | 2002 |
A clinical overview of cholinesterase inhibitors in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; Donepezil; Dose-Response Relationship, Drug; Galantamine; Humans; Indans; Neuropsychological Tests; Phenylcarbamates; Piperidines; Rivastigmine; Treatment Outcome | 2002 |
Rivastigmine: an update on therapeutic efficacy in Alzheimer's disease and other conditions.
Topics: Activities of Daily Living; Alzheimer Disease; Carbamates; Cognition; Disease Progression; Economics, Pharmaceutical; Humans; Mental Disorders; Meta-Analysis as Topic; Neuroprotective Agents; Phenylcarbamates; Risk Factors; Rivastigmine; Treatment Outcome | 2003 |
A review of rivastigmine: a reversible cholinesterase inhibitor.
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition; Drug Interactions; Humans; Phenylcarbamates; Rivastigmine | 2003 |
Current treatments for Alzheimer's disease: cholinesterase inhibitors.
Topics: Alzheimer Disease; Behavioral Symptoms; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition Disorders; Donepezil; Galantamine; Humans; Indans; Multicenter Studies as Topic; Phenylcarbamates; Piperidines; Rivastigmine; Treatment Outcome | 2003 |
Dementia.
Topics: Alzheimer Disease; Anticonvulsants; Antipsychotic Agents; Carbamates; Donepezil; Galantamine; Ginkgo biloba; Humans; Indans; Nootropic Agents; Phenylcarbamates; Phosphatidylcholines; Physostigmine; Phytotherapy; Piperidines; Rivastigmine; Tacrine; Vitamin E | 2003 |
[Current therapy of patients with dementia].
Topics: Activities of Daily Living; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Controlled Clinical Trials as Topic; Dementia; Dementia, Vascular; Donepezil; Dopamine Agents; Female; Galantamine; Ginkgo biloba; Humans; Indans; Male; Memantine; Meta-Analysis as Topic; Multicenter Studies as Topic; Neuroprotective Agents; Nootropic Agents; Phenylcarbamates; Phytotherapy; Piperidines; Placebos; Plant Preparations; Prospective Studies; Rivastigmine; Tacrine; Time Factors | 2003 |
[Subcortical vascular encephalopathy].
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amantadine; Brain; Carbamates; Clinical Trials as Topic; Dementia, Vascular; Diagnosis, Differential; Donepezil; Dopamine Agents; Gait; Humans; Indans; Magnetic Resonance Imaging; Neuroprotective Agents; Nootropic Agents; Phenylcarbamates; Pilot Projects; Piperidines; Placebos; Prognosis; Risk Factors; Rivastigmine; Time Factors; Tomography, X-Ray Computed; Walking | 2003 |
Update on rivastigmine.
Topics: Alzheimer Disease; Animals; Carbamates; Cholinesterase Inhibitors; Humans; Phenylcarbamates; Rivastigmine | 2003 |
[Mechanisms of action of Alzheimer medications].
Topics: Alzheimer Disease; Animals; Carbamates; Cholinesterase Inhibitors; Cognition; Donepezil; Excitatory Amino Acid Antagonists; Galantamine; Humans; Indans; Memantine; Phenylcarbamates; Piperidines; Receptors, N-Methyl-D-Aspartate; Receptors, Nicotinic; Rivastigmine | 2003 |
Strategies for continued successful treatment of Alzheimer's disease: switching cholinesterase inhibitors.
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; Donepezil; Female; Humans; Indans; Male; Nootropic Agents; Phenylcarbamates; Piperidines; Practice Guidelines as Topic; Rivastigmine; Treatment Failure; Treatment Outcome | 2003 |
Acetylcholinesterase inhibition in Alzheimer's Disease.
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; Donepezil; Galantamine; Humans; Indans; Phenylcarbamates; Piperidines; Rivastigmine; Tacrine | 2004 |
Review of donepezil, rivastigmine, galantamine and memantine for the treatment of dementia in Alzheimer's disease in adults with Down syndrome: implications for the intellectual disability population.
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Donepezil; Down Syndrome; Galantamine; Humans; Indans; Memantine; Nootropic Agents; Phenylcarbamates; Piperidines; Rivastigmine | 2004 |
What are the treatment options for patients with severe Alzheimer's disease?
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; Galantamine; Humans; Memantine; Phenylcarbamates; Receptors, N-Methyl-D-Aspartate; Rivastigmine; Severity of Illness Index; Treatment Outcome | 2004 |
Evidence-based pharmacotherapy of Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Carbamates; Cholinergic Agents; Cholinesterase Inhibitors; Cost-Benefit Analysis; Donepezil; Evidence-Based Medicine; Galantamine; Humans; Indans; Phenylcarbamates; Piperidines; Randomized Controlled Trials as Topic; Research Design; Rivastigmine | 2004 |
Ginkgo biloba compared with cholinesterase inhibitors in the treatment of dementia: a review based on meta-analyses by the cochrane collaboration.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Galantamine; Ginkgo biloba; Humans; Indans; Multicenter Studies as Topic; Neuropsychological Tests; Nootropic Agents; Phenylcarbamates; Piperidines; Plant Extracts; Randomized Controlled Trials as Topic; Rivastigmine; Treatment Outcome | 2004 |
The benefits and risks associated with cholinesterase inhibitor therapy in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Animals; Basal Ganglia Diseases; Bradycardia; Central Nervous System Diseases; Cholinesterase Inhibitors; Clinical Trials as Topic; Comorbidity; Donepezil; Double-Blind Method; Drug Evaluation; Drug Interactions; Female; Galantamine; Gastrointestinal Diseases; Humans; Indans; Institutionalization; Longitudinal Studies; Male; Memantine; Meta-Analysis as Topic; Mice; Middle Aged; Nootropic Agents; Phenylcarbamates; Piperidines; Randomized Controlled Trials as Topic; Rivastigmine; Single-Blind Method; Sleep Wake Disorders; Treatment Outcome | 2004 |
Effects of rivastigmine on behavioral and psychological symptoms of dementia in Alzheimer's disease.
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; Humans; Mental Disorders; Meta-Analysis as Topic; Neuroprotective Agents; Phenylcarbamates; Rivastigmine; Severity of Illness Index; Treatment Outcome | 2004 |
Dementia.
Topics: Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Cognition; Dementia; Donepezil; Galantamine; Ginkgo biloba; Haloperidol; Humans; Indans; Memantine; Olanzapine; Phenylcarbamates; Physostigmine; Phytotherapy; Piperidines; Risperidone; Rivastigmine; Selegiline; Tacrine; Vitamin E | 2004 |
Cognitive performance in Alzheimer's disease patients receiving rivastigmine for up to 5 years.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials, Phase III as Topic; Cognition Disorders; Double-Blind Method; Female; Humans; Male; Multicenter Studies as Topic; Phenylcarbamates; Randomized Controlled Trials as Topic; Rivastigmine; Time Factors; Treatment Outcome | 2005 |
Cholinesterase inhibitors in the treatment of dementia.
Topics: Acetylcholine; Acetylcholinesterase; Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cost of Illness; Dementia; Donepezil; Galantamine; Humans; Indans; Phenylcarbamates; Piperidines; Randomized Controlled Trials as Topic; Rivastigmine; Severity of Illness Index | 2005 |
Dementia.
Topics: Alzheimer Disease; Dementia; Donepezil; Galantamine; Ginkgo biloba; Humans; Indans; Memantine; Nootropic Agents; Phenylcarbamates; Physostigmine; Phytotherapy; Piperidines; Rivastigmine; Tacrine | 2004 |
Rivastigmine for subcortical vascular dementia.
Topics: Alzheimer Disease; Animals; Cholinesterase Inhibitors; Dementia, Vascular; Humans; Phenylcarbamates; Rivastigmine | 2005 |
Cognitive performance in patients with Alzheimer's disease receiving cholinesterase inhibitors for up to 5 years.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Donepezil; Galantamine; Humans; Indans; Long-Term Care; Phenylcarbamates; Piperidines; Rivastigmine | 2005 |
Pharmacologic treatment options in Alzheimer's disease: optimizing disease management.
Topics: Acetylcholine; Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Disease Management; Donepezil; Drug Therapy, Combination; Excitatory Amino Acid Antagonists; Galantamine; Glutamic Acid; Humans; Indans; Memantine; Nootropic Agents; Phenylcarbamates; Piperidines; Receptors, N-Methyl-D-Aspartate; Rivastigmine; Severity of Illness Index; Tacrine; Treatment Outcome | 2005 |
[Pharmacological therapy in Alzheimer's disease. Current clinical practice in The Netherlands].
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Excitatory Amino Acid Antagonists; Galantamine; Humans; Memantine; Netherlands; Phenylcarbamates; Rivastigmine; Treatment Outcome | 2005 |
Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Indans; Phenylcarbamates; Piperidines; Randomized Controlled Trials as Topic; Rivastigmine; Treatment Outcome | 2005 |
Efficacy of rivastigmine in Alzheimer's disease patients with rapid disease progression: results of a meta-analysis.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Humans; Neuroprotective Agents; Neuropsychological Tests; Phenylcarbamates; Psychomotor Performance; Randomized Controlled Trials as Topic; Rivastigmine; Treatment Outcome | 2005 |
Rivastigmine for Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Cognition Disorders; Dementia; Expert Testimony; Humans; Meta-Analysis as Topic; Models, Biological; Neuroprotective Agents; Phenylcarbamates; Predictive Value of Tests; Randomized Controlled Trials as Topic; Rivastigmine | 2005 |
Drug therapy of dementia in elderly patients. A review.
Topics: Aged; Alzheimer Disease; Dementia; Donepezil; Galantamine; Humans; Indans; Memantine; Neuroprotective Agents; Phenylcarbamates; Piperidines; Randomized Controlled Trials as Topic; Rivastigmine | 2005 |
Effect of rivastigmine in the treatment of behavioral disturbances associated with dementia: review of neuropsychiatric impairment in Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Humans; Mental Disorders; Meta-Analysis as Topic; Neuroprotective Agents; Phenylcarbamates; Rivastigmine | 2005 |
Clinical trials in mild cognitive impairment: lessons for the future.
Topics: Aged; Alzheimer Disease; Anti-Inflammatory Agents; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition Disorders; Donepezil; Galantamine; Humans; Indans; Lactones; Neuropsychological Tests; Phenylcarbamates; Piperidines; Rivastigmine; Severity of Illness Index; Sulfones; Vitamin E | 2006 |
A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Donepezil; Galantamine; Humans; Indans; Phenylcarbamates; Piperidines; Psychiatric Status Rating Scales; Quality of Life; Randomized Controlled Trials as Topic; Rivastigmine; Treatment Outcome | 2006 |
Circadian cholinergic rhythms: implications for cholinesterase inhibitor therapy.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Circadian Rhythm; Donepezil; Galantamine; Humans; Indans; Phenylcarbamates; Piperidines; Rivastigmine; Sleep; Sleep, REM | 2006 |
The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cost-Benefit Analysis; Donepezil; Dopamine Agents; Evidence-Based Medicine; Female; Galantamine; Humans; Indans; Male; Memantine; Neuroprotective Agents; Nootropic Agents; Phenylcarbamates; Piperidines; Rivastigmine; Treatment Outcome; United Kingdom | 2006 |
Cholinesterase inhibitors for Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Indans; Nootropic Agents; Phenylcarbamates; Piperidines; Randomized Controlled Trials as Topic; Rivastigmine | 2006 |
Dementia.
Topics: Alzheimer Disease; Benzodiazepines; Dementia; Donepezil; Galantamine; Ginkgo biloba; Humans; Indans; Memantine; Nootropic Agents; Olanzapine; Phenylcarbamates; Physostigmine; Phytotherapy; Piperidines; Rivastigmine; Selegiline; Tacrine | 2005 |
Current and emerging pharmacological treatment options for dementia.
Topics: Acetylcholine; Alzheimer Disease; Cholinesterase Inhibitors; Dementia; Donepezil; Galantamine; Humans; Indans; Lewy Body Disease; Neurodegenerative Diseases; Neuroprotective Agents; Parkinson Disease; Phenylcarbamates; Piperidines; Rivastigmine; Tacrine | 2006 |
Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Animals; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Indans; Male; Molecular Biology; Phenylcarbamates; Piperidines; Plaque, Amyloid; Positron-Emission Tomography; Randomized Controlled Trials as Topic; Rivastigmine; tau Proteins | 2006 |
Do caregivers' experiences correspond with the concerns raised in the literature? Ethical issues relating to anti-dementia drugs.
Topics: Aged; Alzheimer Disease; Attitude to Health; Caregivers; Cholinesterase Inhibitors; Decision Making; Early Diagnosis; Ethics, Clinical; Female; Humans; Male; Middle Aged; Phenylcarbamates; Psychiatric Status Rating Scales; Rivastigmine; Third-Party Consent; Withholding Treatment | 2006 |
[Pharmacotherapy for Alzheimer's disease].
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Indans; Memantine; Neuroprotective Agents; Nootropic Agents; Phenylcarbamates; Piperidines; Rivastigmine; Treatment Outcome | 2006 |
[Medical treatment of Alzheimer's disease].
Topics: Activities of Daily Living; Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition; Dementia, Vascular; Disease Progression; Donepezil; Evidence-Based Medicine; Galantamine; Humans; Indans; Lewy Body Disease; Memantine; Nootropic Agents; Parkinson Disease; Phenylcarbamates; Piperidines; Randomized Controlled Trials as Topic; Rivastigmine; Treatment Outcome | 2006 |
The application of evidence-based principles of care in older persons (issue 5): Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Evidence-Based Medicine; Geriatric Assessment; Humans; Indans; Mental Disorders; Nootropic Agents; Phenylcarbamates; Piperidines; Positron-Emission Tomography; Rivastigmine; Tacrine | 2007 |
Potential ethnic modifiers in the assessment and treatment of Alzheimer's disease: challenges for the future.
Topics: Aged; Alzheimer Disease; Cross-Cultural Comparison; Donepezil; Ethnicity; Galantamine; Humans; Indans; Nootropic Agents; Phenylcarbamates; Piperidines; Randomized Controlled Trials as Topic; Rivastigmine; Thiazoles; White People | 2007 |
[Cholinesterase inhibitors and Alzheimer's disease: meta-analysis of the verification of effectiveness, origin and bias of results in published studies].
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Evidence-Based Medicine; Galantamine; Humans; Indans; Phenylcarbamates; Piperidines; Publication Bias; Randomized Controlled Trials as Topic; Rivastigmine; Severity of Illness Index; Treatment Outcome | 2007 |
Rivastigmine tartrate with a focus on dementia associated with Parkinson's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Dementia; Humans; Nausea; Parkinson Disease; Phenylcarbamates; Rivastigmine; Tremor; Vomiting | 2007 |
Pharmacokinetic rationale for the rivastigmine patch.
Topics: Administration, Cutaneous; Alzheimer Disease; Cholinesterase Inhibitors; Humans; Phenylcarbamates; Rivastigmine | 2007 |
Rivastigmine in dementia associated with Parkinson's disease and Alzheimer's disease: similarities and differences.
Topics: Activities of Daily Living; Alzheimer Disease; Double-Blind Method; Hallucinations; Humans; Lewy Body Disease; Mental Status Schedule; Multicenter Studies as Topic; Neuropsychological Tests; Parkinson Disease; Phenylcarbamates; Randomized Controlled Trials as Topic; Rivastigmine; Treatment Outcome | 2007 |
[Acetylcholinesterase inhibitors for dementia--an update].
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Dementia; Donepezil; Galantamine; Humans; Indans; Lewy Body Disease; Multicenter Studies as Topic; Neuroprotective Agents; Nootropic Agents; Parkinson Disease; Phenylcarbamates; Piperidines; Randomized Controlled Trials as Topic; Rivastigmine; Time Factors | 2007 |
Modelling disease progression in Alzheimer's disease: a review of modelling methods used for cost-effectiveness analysis.
Topics: Alzheimer Disease; Cost-Benefit Analysis; Disease Progression; Donepezil; Galantamine; Humans; Indans; Memantine; Models, Economic; Phenylcarbamates; Piperidines; Rivastigmine | 2007 |
Rivastigmine transdermal patch: in the treatment of dementia of the Alzheimer's type.
Topics: Administration, Cutaneous; Alzheimer Disease; Cholinesterase Inhibitors; Clinical Trials as Topic; Humans; Phenylcarbamates; Rivastigmine; Treatment Outcome | 2007 |
[Are anti-dementia drugs worthwhile?].
Topics: Activities of Daily Living; Alzheimer Disease; Antiparkinson Agents; Cholinesterase Inhibitors; Cost-Benefit Analysis; Donepezil; Dopamine Agents; Drug Therapy, Combination; Economics, Medical; Excitatory Amino Acid Antagonists; Galantamine; Germany; Health Policy; Humans; Indans; Memantine; Meta-Analysis as Topic; Neuroprotective Agents; Nootropic Agents; Parasympathomimetics; Phenylcarbamates; Piperidines; Randomized Controlled Trials as Topic; Rivastigmine; Time Factors | 2007 |
Recent developments in cholinesterases inhibitors for Alzheimer's disease treatment.
Topics: Alkaloids; Alzheimer Disease; Binding Sites; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Indans; Indole Alkaloids; Isoquinolines; Phenylcarbamates; Physostigmine; Piperidines; Propidium; Rivastigmine; Steroids; Tacrine | 2007 |
A rivastigmine patch for the treatment of Alzheimer's disease and Parkinson's disease dementia.
Topics: Alzheimer Disease; Dementia; Humans; Neuroprotective Agents; Parkinson Disease; Phenylcarbamates; Rivastigmine | 2007 |
Rivastigmine in the treatment of Alzheimer's disease: an update.
Topics: Alzheimer Disease; Behavior; Clinical Trials as Topic; Humans; Lewy Body Disease; Neuroprotective Agents; Phenylcarbamates; Rivastigmine | 2007 |
[Cholinesterase inhibitors in the treatment of dementia--are they useful in clinical practice?].
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Dementia; Dementia, Vascular; Donepezil; Evidence-Based Medicine; Galantamine; Humans; Indans; Lewy Body Disease; Phenylcarbamates; Piperidines; Rivastigmine; Time Factors; Treatment Outcome | 2008 |
Pharmacologic management of Alzheimer disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Drug Therapy, Combination; Galantamine; Humans; Indans; Memantine; N-Methylaspartate; Nootropic Agents; Phenylcarbamates; Piperidines; Rivastigmine | 2008 |
[Treatment of Alzheimer's disease: status quo and future considerations].
Topics: Acetylcholine; Alzheimer Disease; Amyloid beta-Peptides; Behavioral Symptoms; Choline; Cholinesterase Inhibitors; Cognition; Donepezil; Drug Design; Galantamine; Glutamic Acid; Humans; Indans; Phenylcarbamates; Piperidines; Receptors, N-Methyl-D-Aspartate; Risk Factors; Rivastigmine | 2008 |
Brain selective inhibition of acetylcholinesterase: a novel approach to therapy for Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Blood-Brain Barrier; Brain; Carbamates; Cats; Cholinesterase Inhibitors; Hemodynamics; Hippocampus; Humans; Motor Activity; Nerve Tissue Proteins; Phenylcarbamates; Rats; Rivastigmine; Saimiri; Salivation | 1993 |
New therapeutic approaches to Alzheimer's disease.
Topics: Alzheimer Disease; Antioxidants; Carbamates; Cholinergic Agents; Cholinesterase Inhibitors; Cognition Disorders; Donepezil; Humans; Indans; Phenylcarbamates; Piperidines; Rivastigmine; Tacrine; Trichlorfon | 1996 |
[Therapeutic agents for Alzheimer's disease].
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; Donepezil; Humans; Indans; Monoamine Oxidase Inhibitors; Neuropeptides; Phenylcarbamates; Piperidines; Receptor, Muscarinic M1; Receptors, Muscarinic; Rivastigmine; Spiro Compounds; Tacrine | 1998 |
New therapeutic approaches to cognitive impairment.
Topics: Aged; Alzheimer Disease; Antioxidants; Carbamates; Cholinesterase Inhibitors; Cognition Disorders; Dementia; Donepezil; Humans; Indans; Monoamine Oxidase Inhibitors; Phenylcarbamates; Piperidines; Rivastigmine; Tacrine; Trichlorfon | 1998 |
Rivastigmine. A review of its use in Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; Drug Interactions; Humans; Learning; Neuroprotective Agents; Phenylcarbamates; Rivastigmine; Sleep; Substance-Related Disorders | 1998 |
Treatment of Alzheimer's disease: an evaluation of the cholinergic approach.
Topics: Acetylcholine; Alzheimer Disease; Animals; Carbamates; Chemical and Drug Induced Liver Injury; Cholinergic Agents; Cholinergic Fibers; Cholinesterase Inhibitors; Clinical Trials as Topic; Donepezil; Double-Blind Method; Drug Evaluation, Preclinical; Humans; Indans; Nootropic Agents; Phenylcarbamates; Piperidines; Randomized Controlled Trials as Topic; Receptors, Cholinergic; Receptors, Muscarinic; Receptors, Nicotinic; Rivastigmine; Tacrine | 1999 |
[New therapies in neurology, but who benefits?].
Topics: Alzheimer Disease; Amyotrophic Lateral Sclerosis; Antiviral Agents; Carbamates; Humans; Interferon-beta; Migraine Disorders; Multiple Sclerosis; Nervous System Diseases; Netherlands; Neuroprotective Agents; Outcome Assessment, Health Care; Phenylcarbamates; Riluzole; Rivastigmine; Sumatriptan; Vasoconstrictor Agents | 1999 |
Rivastigmine, a new-generation cholinesterase inhibitor for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; Humans; Multicenter Studies as Topic; Neuroprotective Agents; Phenylcarbamates; Rats; Rivastigmine | 2000 |
Rivastigmine for Alzheimer's disease.
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Cognition Disorders; Humans; Phenylcarbamates; Rivastigmine; Severity of Illness Index | 2000 |
Rivastigmine for Alzheimer's disease.
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Humans; Neuroprotective Agents; Phenylcarbamates; Randomized Controlled Trials as Topic; Rivastigmine | 2000 |
Potential savings in the cost of caring for Alzheimer's disease. Treatment with rivastigmine.
Topics: Aged; Alzheimer Disease; Carbamates; Cost Savings; Economics, Pharmaceutical; Female; Health Care Costs; Humans; Institutionalization; Intelligence Tests; Male; Neuroprotective Agents; Phenylcarbamates; Probability; Proportional Hazards Models; Rivastigmine; Severity of Illness Index; Survival Rate | 2000 |
Rivastigmine for Alzheimer's disease.
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Cognition Disorders; Humans; Phenylcarbamates; Randomized Controlled Trials as Topic; Rivastigmine; Severity of Illness Index | 2000 |
Therapeutic strategies in Alzheimer's disease: M1 muscarinic agonists.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Apoptosis; Carbamates; Cheirogaleidae; Disease Models, Animal; Humans; Muscarinic Agonists; Neuroprotective Agents; Phenylcarbamates; Piperidines; Receptor, Muscarinic M1; Receptors, Muscarinic; Rivastigmine; Signal Transduction; tau Proteins; Thiazoles | 2000 |
Cholinesterase inhibitors stabilize Alzheimer's disease.
Topics: Alzheimer Disease; Brain; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition; Donepezil; Galantamine; Humans; Indans; Phenylcarbamates; Piperidines; Rivastigmine; Tacrine; Trichlorfon | 2000 |
Cholinesterase inhibitors for Alzheimer's disease.
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; Cost-Benefit Analysis; Donepezil; Humans; Indans; Phenylcarbamates; Piperidines; Rivastigmine; Tacrine | 2001 |
Brief review: rivastigmine, a second cholinesterase inhibitor.
Topics: Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Humans; Lewy Body Disease; Neuroprotective Agents; Phenylcarbamates; Randomized Controlled Trials as Topic; Rivastigmine | 2001 |
[Evaluation of the therapeutic effects in individual patients with Alzheimer disease].
Topics: Activities of Daily Living; Alzheimer Disease; Carbamates; Cognition; Humans; Netherlands; Nootropic Agents; Phenylcarbamates; Practice Guidelines as Topic; Psychiatric Status Rating Scales; Rivastigmine; Severity of Illness Index; Social Behavior; Treatment Outcome | 2001 |
Clinical and cost-effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review.
Topics: Alzheimer Disease; Carbamates; Cost-Benefit Analysis; Donepezil; Galantamine; Humans; Indans; Neuroprotective Agents; Nootropic Agents; Phenylcarbamates; Piperidines; Rivastigmine | 2001 |
Rivastigmine. A pharmacoeconomic review of its use in Alzheimer's disease.
Topics: Activities of Daily Living; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Cognition; Health Care Costs; Humans; Phenylcarbamates; Rivastigmine | 2001 |
Review of rivastigmine and its clinical applications in Alzheimer's disease and related disorders.
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; Drug Interactions; Humans; Neuroprotective Agents; Patient Selection; Phenylcarbamates; Rivastigmine | 2001 |
Use of cholinesterase inhibitors for treatment of Alzheimer disease.
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Indans; Phenylcarbamates; Piperidines; Rivastigmine; Tacrine | 2001 |
[Current strategies of pathogenetic therapy of Alzheimer's disease].
Topics: Aged; Alzheimer Disease; Amino Acids; Aminoquinolines; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; Donepezil; Dopamine Agents; Estrogens; Ginkgo biloba; Humans; Indans; Memantine; Monoamine Oxidase Inhibitors; Multicenter Studies as Topic; Neuronal Plasticity; Neuroprotective Agents; Neurotransmitter Agents; Nicergoline; Nootropic Agents; Phenylcarbamates; Phytotherapy; Piperidines; Piracetam; Pyrithioxin; Rivastigmine; Selegiline; Tacrine; Time Factors | 2001 |
[Anticholinesterase agents in Alzheimer's disease].
Topics: Alzheimer Disease; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Carbamates; Cholinesterase Inhibitors; Diagnosis, Differential; Disease Progression; Donepezil; Drug Therapy, Combination; Estrogen Replacement Therapy; Galantamine; Humans; Indans; Nootropic Agents; Phenylcarbamates; Piperidines; Prognosis; Rivastigmine; Treatment Outcome | 2001 |
[A comparison of cholinesterase inhibitors and ginkgo extract in treatment of Alzheimer dementia].
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Donepezil; Double-Blind Method; Female; Ginkgo biloba; Humans; Indans; Male; Middle Aged; Neuropsychological Tests; Phenylcarbamates; Phytotherapy; Piperidines; Plant Extracts; Randomized Controlled Trials as Topic; Rivastigmine; Trichlorfon | 2001 |
Advances in the treatment of Alzheimer's disease: benefits of dual cholinesterase inhibition.
Topics: Acetylcholinesterase; Alzheimer Disease; Butyrylcholinesterase; Carbamates; Cholinesterase Inhibitors; Humans; Phenylcarbamates; Rivastigmine | 2002 |
Understanding changes in cholinergic function: implications for treating dementia.
Topics: Activities of Daily Living; Alzheimer Disease; Carbamates; Cholinergic Fibers; Cholinesterase Inhibitors; Dementia; Humans; Lewy Body Disease; Mental Disorders; Neuroprotective Agents; Neuropsychological Tests; Parkinson Disease; Phenylcarbamates; Rivastigmine; Severity of Illness Index; Treatment Outcome | 2002 |
[Perspectives for drug treatment in Alzheimer's disease].
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Donepezil; Drug Therapy, Combination; Galantamine; Humans; Indans; Nootropic Agents; Phenylcarbamates; Piperidines; Rivastigmine; Tacrine | 2001 |
The clinical benefits of rivastigmine may reflect its dual inhibitory mode of action: an hypothesis.
Topics: Aged; Alzheimer Disease; Butyrylcholinesterase; Carbamates; Cholinesterase Inhibitors; Dementia; Humans; Neuroprotective Agents; Phenylcarbamates; Rivastigmine | 2002 |
Guidelines for managing Alzheimer's disease: Part II. Treatment.
Topics: Advance Directives; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Disease Progression; Donepezil; Humans; Indans; Lorazepam; Patient Education as Topic; Phenylcarbamates; Piperidines; Risperidone; Rivastigmine | 2002 |
Understanding and managing behavioural symptoms in Alzheimer's disease and related dementias: focus on rivastigmine.
Topics: Acetylcholine; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Cognitive Behavioral Therapy; Disease Progression; Donepezil; Galantamine; Humans; Indans; Neuroprotective Agents; Phenylcarbamates; Physostigmine; Piperidines; Rivastigmine; Tacrine; Time Factors; Treatment Outcome | 2002 |
Clinical use of cholinomimetic agents: a review.
Topics: Administration, Oral; Adult; Aged; Alzheimer Disease; Brain Injuries; Carbamates; Clinical Trials as Topic; Cytidine Diphosphate Choline; Donepezil; Female; Follow-Up Studies; Humans; Indans; Injections, Intravenous; Injury Severity Score; Male; Middle Aged; Parasympathomimetics; Phenylcarbamates; Physostigmine; Piperidines; Rivastigmine; Severity of Illness Index; Tacrine; Treatment Outcome | 2002 |
140 trial(s) available for rivastigmine and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
Comparative Bioavailability Study of a Novel Multi-Day Patch Formulation of Rivastigmine (Twice Weekly) with Exelon® Transdermal Patch (Daily)- A Randomized Clinical Trial.
Topics: Adult; Alzheimer Disease; Biological Availability; Cholinesterase Inhibitors; Humans; Male; Phenylcarbamates; Rivastigmine; Transdermal Patch | 2022 |
Sixteen-Week Interventional Study to Evaluate the Clinical Effects and Safety of Rivastigmine Capsules in Chinese Patients with Alzheimer's Disease.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Female; Humans; Male; Middle Aged; Nausea; Rivastigmine; Severity of Illness Index; Treatment Outcome; Vomiting | 2019 |
Rivastigmine improves dual-task gait velocity in patients with Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Female; Gait; Humans; Male; Prospective Studies; Rivastigmine; Task Performance and Analysis | 2021 |
Efficacy and tolerability of rivastigmine patch therapy in patients with mild-to-moderate Alzheimer's dementia associated with minimal and moderate ischemic white matter hyperintensities: A multicenter prospective open-label clinical trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Brain; Cholinesterase Inhibitors; Female; Humans; Male; Middle Aged; Neuroprotective Agents; Republic of Korea; Rivastigmine; Severity of Illness Index; Transdermal Patch; Treatment Outcome; White Matter | 2017 |
Effect of Idalopirdine as Adjunct to Cholinesterase Inhibitors on Change in Cognition in Patients With Alzheimer Disease: Three Randomized Clinical Trials.
Topics: Accidental Falls; Aged; Aged, 80 and over; Alzheimer Disease; Benzylamines; Cholinesterase Inhibitors; Cognition; Donepezil; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Galantamine; Humans; Indans; Indoles; Male; Middle Aged; Piperidines; Rivastigmine; Serotonin Antagonists; Treatment Failure | 2018 |
Rivastigmine patch and massage for Alzheimer's disease patients.
Topics: Activities of Daily Living; Aged, 80 and over; Alzheimer Disease; Behavioral Symptoms; Cholinesterase Inhibitors; Cognition; Female; Humans; Interpersonal Relations; Male; Massage; Mental Status Schedule; Phenylcarbamates; Rivastigmine; Tomography, X-Ray Computed; Transdermal Patch | 2013 |
Rivastigmine patch for treatment of Alzheimer's disease in clinical practice in Thailand.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Male; Middle Aged; Phenylcarbamates; Prospective Studies; Rivastigmine; Severity of Illness Index; Thailand; Transdermal Patch; Treatment Outcome | 2013 |
Efficacy of rivastigmine in comparison to ginkgo for treating Alzheimer's dementia.
Topics: Aged; Alzheimer Disease; Analysis of Variance; Cholinesterase Inhibitors; Disease Progression; Double-Blind Method; Female; Ginkgo biloba; Humans; Male; Middle Aged; Phenylcarbamates; Phytotherapy; Rivastigmine; Treatment Outcome | 2012 |
A 24-week, randomized, controlled trial of rivastigmine patch 13.3 mg/24 h versus 4.6 mg/24 h in severe Alzheimer's dementia.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Double-Blind Method; Female; Humans; Male; Middle Aged; Neuroprotective Agents; Phenylcarbamates; Prospective Studies; Rivastigmine; Severity of Illness Index; Transdermal Patch | 2013 |
Efficacy of higher dose 13.3 mg/24 h rivastigmine patch on instrumental activities of daily living in patients with mild-to-moderate Alzheimer's disease.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Personal Autonomy; Phenylcarbamates; Rivastigmine; Severity of Illness Index; Transdermal Patch; Treatment Outcome | 2013 |
Differential effects of current specific treatments on behavioral and psychological symptoms in patients with Alzheimer's disease: a 12-month, randomized, open-label trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Behavioral Symptoms; Cholinesterase Inhibitors; Dementia; Donepezil; Excitatory Amino Acid Antagonists; Female; Galantamine; Humans; Indans; Longitudinal Studies; Male; Memantine; Mental Disorders; Phenylcarbamates; Piperidines; Psychiatric Status Rating Scales; Rivastigmine | 2014 |
Efficacy of higher-dose 13.3 mg/24 h (15 cm2) rivastigmine patch on the Alzheimer's Disease Assessment Scale-cognitive subscale: domain and individual item analysis.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Brief Psychiatric Rating Scale; Cholinesterase Inhibitors; Cognition; Dose-Response Relationship, Drug; Double-Blind Method; Factor Analysis, Statistical; Female; Humans; Male; Middle Aged; Neuroprotective Agents; Phenylcarbamates; Rivastigmine; Severity of Illness Index; Transdermal Patch | 2014 |
Retrospective study on the benefits of combined Memantine and cholinEsterase inhibitor treatMent in AGEd Patients affected with Alzheimer's Disease: the MEMAGE study.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Comorbidity; Donepezil; Female; Galantamine; Humans; Indans; Italy; Male; Memantine; Middle Aged; Nootropic Agents; Phenylcarbamates; Piperidines; Psychiatric Status Rating Scales; Retrospective Studies; Rivastigmine; Time Factors; Treatment Outcome | 2014 |
High-dose cholinergic therapy with rivastigmine patch does not prolong QTc time in patients with Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Electrophysiological Phenomena; Heart; Humans; Long QT Syndrome; Phenylcarbamates; Rivastigmine; Transdermal Patch | 2014 |
Dopaminergic modulation of cortical plasticity in Alzheimer's disease patients.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Dopamine Agonists; Female; Humans; Male; Motor Cortex; Neuronal Plasticity; Phenylcarbamates; Rivastigmine; Tetrahydronaphthalenes; Thiophenes; Transcranial Magnetic Stimulation | 2014 |
Rivastigmine transdermal patch and physical exercises for Alzheimer's disease: a randomized clinical trial.
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Caregivers; Cognition; Exercise Therapy; Female; Humans; Male; Neuroprotective Agents; Phenylcarbamates; Psychiatric Status Rating Scales; Quality of Life; Rivastigmine; Severity of Illness Index; Transdermal Patch; Treatment Outcome | 2014 |
Effect of rivastigmine or memantine add-on therapy is affected by butyrylcholinesterase genotype in patients with probable Alzheimer's disease.
Topics: Aged; Alleles; Alzheimer Disease; Apolipoprotein E4; Butyrylcholinesterase; Female; Genetic Testing; Genotype; Humans; Male; Memantine; Middle Aged; Neuroprotective Agents; Odds Ratio; Rivastigmine; Transdermal Patch | 2015 |
A pilot randomized controlled trial evaluating an integrated treatment of rivastigmine transdermal patch and cognitive stimulation in patients with Alzheimer's disease.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Cognitive Behavioral Therapy; Combined Modality Therapy; Female; Follow-Up Studies; Geriatric Assessment; Humans; Male; Middle Aged; Neuroprotective Agents; Pilot Projects; Psychiatric Status Rating Scales; Risk Factors; Rivastigmine; Transdermal Patch | 2015 |
Evaluating high-dose rivastigmine patch in severe Alzheimer's disease: analyses with concomitant memantine usage as a factor.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Case-Control Studies; Dopamine Agents; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Memantine; Neuroprotective Agents; Phenylcarbamates; Psychiatric Status Rating Scales; Quality of Life; Rivastigmine; Transdermal Patch; Treatment Outcome | 2015 |
Evaluating Response to High-Dose 13.3 mg/24 h Rivastigmine Patch in Patients with Severe Alzheimer's Disease.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Male; Mental Status Schedule; Middle Aged; Predictive Value of Tests; Rivastigmine; ROC Curve; Treatment Outcome | 2015 |
Cognitive Efficacy (SIB) of 13.3 Versus 4.6 mg/24 h Rivastigmine Patch in Severe Alzheimer's Disease.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Double-Blind Method; Female; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Retrospective Studies; Rivastigmine; Severity of Illness Index; Transdermal Patch | 2016 |
Rivastigmine Patch in Chinese Patients with Probable Alzheimer's disease: A 24-week, Randomized, Double-Blind Parallel-Group Study Comparing Rivastigmine Patch (9.5 mg/24 h) with Capsule (6 mg Twice Daily).
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Asian People; Cognition Disorders; Double-Blind Method; Drug Administration Routes; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Mental Status Schedule; Middle Aged; Neuroprotective Agents; Retrospective Studies; Rivastigmine; Statistics, Nonparametric; Transdermal Patch; Treatment Outcome | 2016 |
Effects on agitation with rivastigmine patch monotherapy and combination therapy with memantine in mild to moderate Alzheimer's disease: a multicenter 24-week prospective randomized open-label study (the Korean EXelon Patch and combination with mEmantine
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Alzheimer Disease; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Factor Analysis, Statistical; Female; Follow-Up Studies; Humans; Male; Memantine; Multivariate Analysis; Prospective Studies; Psychomotor Agitation; Republic of Korea; Risk Assessment; Rivastigmine; Severity of Illness Index; Time Factors; Treatment Outcome | 2017 |
Adherence and Tolerability of Alzheimer's Disease Medications: A Pragmatic Randomized Trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Drug Costs; Drug-Related Side Effects and Adverse Reactions; Ethnicity; Female; Galantamine; Humans; Indans; Indiana; Male; Medication Adherence; Piperidines; Rivastigmine | 2017 |
Long-term rivastigmine treatment in a routine clinical setting.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neuropsychological Tests; Nootropic Agents; Phenylcarbamates; Prospective Studies; Rivastigmine; Severity of Illness Index; Sweden; Treatment Outcome | 2009 |
[The treatment of Alzheimer's disease in patients with comorbid somatic pathology].
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Dementia, Vascular; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Phenylcarbamates; Rivastigmine; Somatoform Disorders | 2008 |
Improvement of spontaneous speech in early stage Alzheimer's with rivastigmine.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinergic Agents; Cognition; Female; Humans; Male; Phenylcarbamates; Reference Values; Rivastigmine; Speech | 2009 |
Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients.
Topics: Acetylcholinesterase; Aged; Aged, 80 and over; Alzheimer Disease; Brain; Butyrylcholinesterase; Cholinesterase Inhibitors; Cholinesterases; Donepezil; Down-Regulation; Enzyme-Linked Immunosorbent Assay; Female; Galantamine; Humans; Indans; Male; Middle Aged; Phenylcarbamates; Piperidines; Rivastigmine; Treatment Outcome | 2009 |
[Transdermal rivastigmine patch in outpatient services in Austria: a naturalistic study in 103 patients with Alzheimer dementia].
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Female; Follow-Up Studies; Humans; Male; Mental Status Schedule; Phenylcarbamates; Rivastigmine; Treatment Outcome | 2009 |
Progression from mild cognitive impairment to Alzheimer's disease: effects of sex, butyrylcholinesterase genotype, and rivastigmine treatment.
Topics: Alzheimer Disease; Biomarkers; Butyrylcholinesterase; Cholinesterase Inhibitors; Cognition; Cognition Disorders; Disease Progression; Female; Genotype; Humans; Male; Neuroprotective Agents; Pharmacogenetics; Phenylcarbamates; Placebos; Retrospective Studies; Rivastigmine; Treatment Outcome | 2009 |
[Results of the open multicenter prospective study of safety and tolerability of rivastigmine (exelon) in different titration regimes in mild and moderate Alzheimer's disease].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Female; Follow-Up Studies; Humans; Male; Middle Aged; Patient Satisfaction; Phenylcarbamates; Prospective Studies; Psychometrics; Rivastigmine; Severity of Illness Index; Titrimetry; Treatment Outcome | 2009 |
Effects of gender on response to treatment with rivastigmine in mild cognitive impairment: A post hoc statistical modeling approach.
Topics: Aged; Alzheimer Disease; Cognition Disorders; Disease Progression; Female; Humans; Male; Middle Aged; Neuroprotective Agents; Phenylcarbamates; Proportional Hazards Models; Rivastigmine; Sex Factors | 2009 |
A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer's disease: a post hoc analysis.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Algorithms; Alzheimer Disease; Antiparkinson Agents; Cholinesterase Inhibitors; Donepezil; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Indans; Male; Memantine; Middle Aged; Neuroprotective Agents; Phenylcarbamates; Piperidines; Rivastigmine; Severity of Illness Index; Time Factors; Treatment Outcome | 2010 |
Rivastigmine transdermal patch skin tolerability: results of a 1-year clinical trial in patients with mild-to-moderate Alzheimer's disease.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Double-Blind Method; Humans; Middle Aged; Phenylcarbamates; Rivastigmine; Skin | 2010 |
Effects of rivastigmine in Alzheimer's disease patients with and without hallucinations.
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Analysis of Variance; Cognition; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Female; Hallucinations; Humans; Male; Mental Status Schedule; Neuroprotective Agents; Phenylcarbamates; Placebo Effect; Rivastigmine; Severity of Illness Index; Time Factors; Treatment Outcome | 2010 |
Effects of rivastigmine transdermal patch and capsule on aspects of clinical global impression of change in Alzheimer's disease: a retrospective analysis.
Topics: Administration, Cutaneous; Administration, Oral; Aged; Aged, 80 and over; Alzheimer Disease; Behavior; Capsules; Double-Blind Method; Female; Humans; Male; Mental Processes; Middle Aged; Neuroprotective Agents; Neuropsychological Tests; Phenylcarbamates; Randomized Controlled Trials as Topic; Retrospective Studies; Rivastigmine; Treatment Outcome | 2010 |
[Oral galantamine versus rivastigmine transdermal patch: a descriptive study at a memory clinic in The Netherlands].
Topics: Administration, Cutaneous; Administration, Oral; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Female; Galantamine; Humans; Male; Memory; Middle Aged; Phenylcarbamates; Rivastigmine; Treatment Outcome | 2010 |
The ACTION study: methodology of a trial to evaluate safety and efficacy of a higher dose rivastigmine transdermal patch in severe Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Clinical Protocols; Cognition; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Neuroprotective Agents; Neuropsychological Tests; Phenylcarbamates; Placebos; Rivastigmine; Severity of Illness Index; Transdermal Patch; Treatment Outcome | 2010 |
Assessing the cost-effectiveness of the rivastigmine transdermal patch for Alzheimer's disease in the UK using MMSE- and ADL-based models.
Topics: Alzheimer Disease; Brief Psychiatric Rating Scale; Cost-Benefit Analysis; Disease Progression; Female; Humans; Institutionalization; Male; Models, Economic; Neuroprotective Agents; Phenylcarbamates; Quality-Adjusted Life Years; Regression Analysis; Rivastigmine; Social Support; Transdermal Patch; United Kingdom | 2011 |
Galantamine (Reminyl) once daily outcome and satisfaction survey (RODOS) in mild to moderate Alzheimer's disease: a study in a real life population.
Topics: Aged; Alzheimer Disease; Caregivers; Cholinesterase Inhibitors; Cognition; Delayed-Action Preparations; Donepezil; Female; Galantamine; Humans; Indans; Male; Patient Satisfaction; Phenylcarbamates; Piperidines; Rivastigmine; Treatment Outcome | 2011 |
Evaluation of the convenience of changing the rivastigmine administration route in patients with Alzheimer disease.
Topics: Administration, Cutaneous; Administration, Oral; Aged; Alzheimer Disease; Cholinesterase Inhibitors; Female; Humans; Male; Phenylcarbamates; Rivastigmine | 2011 |
Impact of rivastigmine patch and capsules on activities of daily living in Alzheimer's disease.
Topics: Activities of Daily Living; Administration, Oral; Aged; Aged, 80 and over; Alzheimer Disease; Capsules; Double-Blind Method; Female; Humans; Male; Middle Aged; Neuroprotective Agents; Phenylcarbamates; Prospective Studies; Rivastigmine; Time Factors; Transdermal Patch; Treatment Outcome | 2011 |
Dose effects associated with rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer's disease.
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Neuroprotective Agents; Phenylcarbamates; Retrospective Studies; Rivastigmine; Transdermal Patch; Treatment Outcome | 2011 |
Efficacy of rivastigmine transdermal patch on activities of daily living: item responder analyses.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Double-Blind Method; Female; Humans; Male; Middle Aged; Phenylcarbamates; Quality of Life; Retrospective Studies; Rivastigmine; Transdermal Patch | 2011 |
Tolerability and efficacy of memantine add-on therapy to rivastigmine transdermal patches in mild to moderate Alzheimer's disease: a multicenter, randomized, open-label, parallel-group study.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Alzheimer Disease; Antiparkinson Agents; Drug Therapy, Combination; Female; Humans; Male; Memantine; Middle Aged; Neuroprotective Agents; Phenylcarbamates; Rivastigmine; Severity of Illness Index; Transdermal Patch; Treatment Outcome | 2011 |
Effect of cholinergic stimulation in early Alzheimer's disease - functional imaging during a recognition memory task.
Topics: Aged; Alzheimer Disease; Brain Mapping; Cholinesterase Inhibitors; Double-Blind Method; Female; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Male; Memory; Pattern Recognition, Visual; Phenylcarbamates; Rivastigmine | 2011 |
A 24-week, multicentre, open evaluation of the clinical effectiveness of the rivastigmine patch in patients with probable Alzheimer's disease.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Female; Humans; Male; Medication Adherence; Neuroprotective Agents; Phenylcarbamates; Rivastigmine; Transdermal Patch; Treatment Outcome | 2011 |
Chronic treatment with rivastigmine in patients with Alzheimer's disease: a study on primary motor cortex excitability tested by 5 Hz-repetitive transcranial magnetic stimulation.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Case-Control Studies; Electromyography; Evoked Potentials, Motor; Female; Functional Laterality; Humans; Longitudinal Studies; Male; Mental Status Schedule; Motor Cortex; Muscle, Skeletal; Neuroprotective Agents; Phenylcarbamates; Reaction Time; Rivastigmine; Transcranial Magnetic Stimulation | 2012 |
Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Double-Blind Method; Female; Humans; Male; Middle Aged; Neuroprotective Agents; Phenylcarbamates; Retrospective Studies; Rivastigmine; Transdermal Patch | 2011 |
Randomized, double-blind, parallel-group, 48-week study for efficacy and safety of a higher-dose rivastigmine patch (15 vs. 10 cm²) in Alzheimer's disease.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Disease Progression; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Phenylcarbamates; Rivastigmine; Transdermal Patch; Treatment Outcome | 2012 |
Response to rivastigmine transdermal patch or memantine plus rivastigmine patch is affected by apolipoprotein E genotype in Alzheimer patients.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Apolipoproteins E; Cholinesterase Inhibitors; Drug Therapy, Combination; Female; Genotype; Humans; Male; Memantine; Middle Aged; Phenylcarbamates; Prospective Studies; Rivastigmine; Transdermal Patch | 2012 |
Functional response to cholinesterase inhibitor therapy in a naturalistic Alzheimer's disease cohort.
Topics: Activities of Daily Living; Age Factors; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Disabled Persons; Donepezil; Female; Galantamine; Humans; Indans; Linear Models; Male; Middle Aged; Neuropsychological Tests; Phenylcarbamates; Piperidines; Rivastigmine; Treatment Outcome | 2012 |
Transdermal is better than oral: observational research of the satisfaction of caregivers of patients with Alzheimer's disease treated with rivastigmine.
Topics: Administration, Cutaneous; Administration, Oral; Aged; Aged, 80 and over; Alzheimer Disease; Caregivers; Cross-Sectional Studies; Data Interpretation, Statistical; Educational Status; Female; Humans; Male; Marital Status; Middle Aged; Neuroprotective Agents; Neuropsychological Tests; Patient Compliance; Patient Satisfaction; Phenylcarbamates; Rivastigmine; Surveys and Questionnaires | 2013 |
Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit.
Topics: Acetylcholinesterase; Aged; Aged, 80 and over; Alzheimer Disease; Butyrylcholinesterase; Carbamates; Cholinesterase Inhibitors; Cognition; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Neuropsychological Tests; Phenylcarbamates; Rivastigmine | 2002 |
Long-term effects of rivastigmine in moderately severe Alzheimer's disease: does early initiation of therapy offer sustained benefits?
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Carbamates; Double-Blind Method; Female; Humans; Male; Phenylcarbamates; Rivastigmine; Time | 2002 |
Impact of Alzheimer's disease and rivastigmine treatment on activities of daily living over the course of mild to moderately severe disease.
Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Carbamates; Double-Blind Method; Humans; Middle Aged; Phenylcarbamates; Rivastigmine | 2002 |
Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months.
Topics: Acetylcholinesterase; Aged; Alzheimer Disease; Attention; Butyrylcholinesterase; Carbamates; Cholinesterase Inhibitors; Cholinesterases; Colorimetry; Dose-Response Relationship, Drug; Enzyme Activation; Female; Humans; Immunoblotting; Isoenzymes; Male; Memory; Middle Aged; Neuropsychological Tests; Phenylcarbamates; Rivastigmine; Time; Treatment Outcome; Up-Regulation | 2002 |
Correlates of dropout, efficacy, and adverse events in treatment with acetylcholinesterase inhibitors in Korean patients with Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Donepezil; Female; Humans; Indans; Male; Middle Aged; Patient Dropouts; Phenylcarbamates; Piperidines; Prospective Studies; Rivastigmine | 2002 |
[Rivastigmine in current clinical practice in patients with mild to moderate Alzheimer's disease].
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Cognition Disorders; Drug Tolerance; Female; Humans; Male; Middle Aged; Phenylcarbamates; Prospective Studies; Rivastigmine; Severity of Illness Index | 2002 |
Regional effects of donepezil and rivastigmine on cortical acetylcholinesterase activity in Alzheimer's disease.
Topics: Acetylcholinesterase; Aged; Alzheimer Disease; Carbamates; Cerebral Cortex; Cholinesterase Inhibitors; Donepezil; Dose-Response Relationship, Drug; Female; Frontal Lobe; Humans; Indans; Magnetic Resonance Imaging; Male; Parietal Lobe; Phenylcarbamates; Piperidines; Reproducibility of Results; Rivastigmine; Temporal Lobe; Tomography, Emission-Computed | 2002 |
Cholinesterase inhibitor rivastigmine enhance the mitochondrial electron transport chain in lymphocytes of patients with Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Electron Transport; Female; Humans; Lymphocytes; Male; Mitochondria; Neuroprotective Agents; Phenylcarbamates; Reference Values; Rivastigmine | 2003 |
Rivastigmine in patients with Alzheimer's disease and concurrent hypertension.
Topics: Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Double-Blind Method; Female; Humans; Hypertension; Male; Phenylcarbamates; Rivastigmine; Treatment Outcome | 2002 |
No additional benefit of HRT on response to rivastigmine in menopausal women with AD.
Topics: Activities of Daily Living; Administration, Cutaneous; Administration, Oral; Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Estradiol; Female; France; Hormone Replacement Therapy; Humans; Menopause; Neuropsychological Tests; Phenylcarbamates; Progesterone; Rivastigmine; Treatment Outcome | 2003 |
Cerebrospinal fluid levels of biomarkers and activity of acetylcholinesterase (AChE) and butyrylcholinesterase in AD patients before and after treatment with different AChE inhibitors.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Biomarkers; Butyrylcholinesterase; Carbamates; Cholinesterase Inhibitors; Donepezil; Enzyme-Linked Immunosorbent Assay; Galantamine; Humans; Indans; Peptide Fragments; Phenylcarbamates; Phosphorylation; Piperidines; Rivastigmine; tau Proteins | 2002 |
Cerebral glucose metabolism, cerebrospinal fluid-beta-amyloid1-42 (CSF-Abeta42), tau and apolipoprotein E genotype in long-term rivastigmine and tacrine treated Alzheimer disease (AD) patients.
Topics: Aged; Alzheimer Disease; Amyloid beta-Peptides; Apolipoprotein E2; Apolipoprotein E4; Apolipoproteins E; Biomarkers; Brain; Carbamates; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Female; Genotype; Glucose; Humans; Male; Middle Aged; Peptide Fragments; Phenylcarbamates; Rivastigmine; Tacrine; tau Proteins | 2003 |
Serum cholesterol levels modulate long-term efficacy of cholinesterase inhibitors in Alzheimer disease.
Topics: Aged; Alzheimer Disease; Apolipoproteins E; Carbamates; Cholesterol; Cholinesterase Inhibitors; Disease Progression; Donepezil; Female; Genotype; Humans; Indans; Male; Neuropsychological Tests; Nootropic Agents; Phenylcarbamates; Piperidines; Rivastigmine | 2003 |
Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial.
Topics: Adult; Aged; Aged, 80 and over; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Cognition; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Neuroprotective Agents; Neuropsychological Tests; Patient Dropouts; Phenylcarbamates; Rivastigmine; Treatment Outcome | 2003 |
Effects of acetyl-L-carnitine in Alzheimer's disease patients unresponsive to acetylcholinesterase inhibitors.
Topics: Acetylcarnitine; Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Donepezil; Drug Therapy, Combination; Female; Humans; Indans; Male; Nootropic Agents; Phenylcarbamates; Pilot Projects; Piperidines; Rivastigmine | 2003 |
The effect of cholinesterase inhibitors on the regional blood flow in patients with Alzheimer's disease and vascular dementia.
Topics: Acetylcholine; Aged; Alzheimer Disease; Auditory Perception; Carbamates; Cerebrovascular Circulation; Cholinesterase Inhibitors; Dementia, Vascular; Female; Frontal Lobe; Humans; Learning; Magnetic Resonance Imaging; Male; Phenylcarbamates; Rivastigmine; Temporal Lobe; Tomography, Emission-Computed, Single-Photon; Treatment Outcome; Up-Regulation | 2003 |
[Oestro-progestagen treatment combined with rivastigmine in menopausal women suffering from Alzheimer's disease. The results of a 28-weeks controlled study].
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Carbamates; Combined Modality Therapy; Double-Blind Method; Estrogens; Female; Humans; Middle Aged; Neuroprotective Agents; Neuropsychological Tests; Phenylcarbamates; Placebos; Postmenopause; Progestins; Rivastigmine | 2003 |
Short-term effects of acetylcholinesterase inhibitor treatment on EEG and memory performance in Alzheimer patients: an open, controlled trial.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Donepezil; Electroencephalography; Female; Humans; Indans; Male; Memory; Memory Disorders; Middle Aged; Neuroprotective Agents; Nootropic Agents; Phenylcarbamates; Piperidines; Rivastigmine; Theta Rhythm; Time Factors; Treatment Outcome | 2003 |
Potential long-term effects of rivastigmine on disease progression may be linked to drug effects on vascular changes in Alzheimer brains.
Topics: Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Disease Progression; Female; Humans; Hypertension; Male; Medical Records; Neuroprotective Agents; Phenylcarbamates; Rivastigmine; Treatment Outcome | 2003 |
Prediction of treatment response to rivastigmine in Alzheimer's dementia.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Brain; Carbamates; Cholinesterase Inhibitors; Cognition Disorders; Drug Administration Schedule; Electroencephalography; Female; Humans; Male; Memory, Short-Term; Neuropsychological Tests; Phenylcarbamates; Prospective Studies; Rivastigmine; Severity of Illness Index; Theta Rhythm | 2004 |
Preserved cognitive function after 12 months of treatment with rivastigmine in mild Alzheimer's disease in comparison with untreated AD and MCI patients.
Topics: Aged; Alzheimer Disease; Apolipoproteins E; Attention; Carbamates; Case-Control Studies; Chi-Square Distribution; Cholinesterases; Cognition Disorders; Female; Follow-Up Studies; Humans; Male; Neuroprotective Agents; Neuropsychological Tests; Phenylcarbamates; Rivastigmine; Statistics as Topic; Time Factors | 2004 |
Behavioral symptoms in mild cognitive impairment.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Behavioral Symptoms; Carbamates; Cholinesterase Inhibitors; Cognition Disorders; Female; Humans; Male; Middle Aged; Neuropsychological Tests; Phenylcarbamates; Rivastigmine | 2004 |
Effectiveness and safety of cholinesterase inhibitors in elderly subjects with Alzheimer's disease: a "real world" study.
Topics: Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Cognition Disorders; Donepezil; Female; Galantamine; Humans; Indans; Male; Neuropsychological Tests; Phenylcarbamates; Piperidines; Rivastigmine; Severity of Illness Index | 2004 |
A 12-month study of the efficacy of rivastigmine in patients with advanced moderate Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Disability Evaluation; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Male; Mental Status Schedule; Middle Aged; Neuroprotective Agents; Neuropsychological Tests; Phenylcarbamates; Rivastigmine; Turkey | 2005 |
Long-term effects of rivastigmine treatment on neuropsychiatric and behavioral disturbances in nursing home residents with moderate to severe Alzheimer's disease: results of a 52-week open-label study.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alzheimer Disease; Cognition Disorders; Dose-Response Relationship, Drug; Female; Humans; Male; Mental Status Schedule; Neuroprotective Agents; Neuropsychological Tests; Nursing Homes; Phenylcarbamates; Prospective Studies; Rivastigmine; Severity of Illness Index; Treatment Outcome | 2004 |
An open-label, comparative study of rivastigmine, donepezil and galantamine in a real-world setting.
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Female; Galantamine; Humans; Indans; Male; Mental Status Schedule; Phenylcarbamates; Piperidines; Rivastigmine; Treatment Outcome | 2004 |
Benefits of cognitive-motor intervention in MCI and mild to moderate Alzheimer disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Caregivers; Cholinesterase Inhibitors; Cognition Disorders; Cognitive Behavioral Therapy; Combined Modality Therapy; Donepezil; Female; Follow-Up Studies; Humans; Indans; Male; Middle Aged; Patient Satisfaction; Patients; Phenylcarbamates; Physical Therapy Modalities; Piperidines; Psychomotor Disorders; Rivastigmine; Single-Blind Method; Treatment Outcome | 2004 |
Rivastigmine: an open-label, observational study of safety and effectiveness in treating patients with Alzheimer's disease for up to 5 years.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Double-Blind Method; Female; Humans; Male; Middle Aged; Phenylcarbamates; Prospective Studies; Rivastigmine; Severity of Illness Index; Time Factors | 2005 |
Differential efficacy of treatment with acetylcholinesterase inhibitors in patients with mild and moderate Alzheimer's disease over a 6-month period.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Drug Administration Schedule; Female; Galantamine; Humans; Indans; Male; Middle Aged; Neuropsychological Tests; Phenylcarbamates; Piperidines; Prospective Studies; Retrospective Studies; Rivastigmine; Severity of Illness Index; Time Factors | 2005 |
Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial.
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Cholinesterase Inhibitors; Cognition Disorders; Dibenzothiazepines; Double-Blind Method; Humans; Middle Aged; Phenylcarbamates; Psychomotor Agitation; Quetiapine Fumarate; Rivastigmine; Treatment Failure | 2005 |
Rivastigmine in the treatment of dementia in Alzheimer's disease in adults with Down syndrome.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Down Syndrome; Female; Humans; Male; Middle Aged; Nootropic Agents; Phenylcarbamates; Rivastigmine; Treatment Outcome | 2005 |
[ApoE genotype and efficacy of neurotrophic and cholinergic therapy in Alzheimer's disease].
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Amino Acids; Apolipoproteins E; Cholinesterase Inhibitors; Female; Follow-Up Studies; Genotype; Humans; Male; Middle Aged; Nerve Growth Factors; Neuropsychological Tests; Nootropic Agents; Phenylcarbamates; Rivastigmine | 2005 |
A cohort study of effectiveness of acetylcholinesterase inhibitors in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Cohort Studies; Donepezil; Female; Follow-Up Studies; Galantamine; Humans; Indans; Italy; Male; Middle Aged; Phenylcarbamates; Piperidines; Rivastigmine; Time Factors; Treatment Outcome | 2005 |
Longitudinal PET evaluation of cerebral glucose metabolism in rivastigmine treated patients with mild Alzheimer's disease.
Topics: Adult; Aged; Alzheimer Disease; Brain; Cholinesterase Inhibitors; Cognition; Energy Metabolism; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Glucose; Humans; Longitudinal Studies; Male; Neuropsychological Tests; Phenylcarbamates; Positron-Emission Tomography; Radiopharmaceuticals; Receptors, Nicotinic; Rivastigmine; Severity of Illness Index | 2006 |
Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Double-Blind Method; Female; Humans; Indans; Male; Middle Aged; Phenylcarbamates; Piperidines; Rivastigmine; Time Factors; Treatment Outcome | 2005 |
Treatment persistency with rivastigmine and donepezil in a large state medicaid program.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Female; Humans; Indans; Male; Patient Compliance; Phenylcarbamates; Piperidines; Research Design; Rivastigmine | 2005 |
Rivastigmine in vascular dementia.
Topics: Acetylcholinesterase; Activities of Daily Living; Aged; Alzheimer Disease; Butyrylcholinesterase; Cholinesterase Inhibitors; Cognition Disorders; Dementia, Vascular; Double-Blind Method; Drug Administration Schedule; Humans; Neuropsychological Tests; Phenylcarbamates; Pilot Projects; Rivastigmine; Severity of Illness Index | 2003 |
Efficacy of rivastigmine on activities of daily living in Sri Lankan patients with Alzheimer disease and on improving caregiver burden: a prospective study.
Topics: Adult; Aged; Alzheimer Disease; Caregivers; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Middle Aged; Phenylcarbamates; Probability; Prospective Studies; Quality of Life; Reference Values; Risk Assessment; Rivastigmine; Severity of Illness Index; Single-Blind Method; Sri Lanka; Stress, Psychological; Treatment Outcome | 2005 |
Effects of rivastigmine treatment on the neuropsychiatric and behavioral disturbances of nursing home residents with moderate to severe probable Alzheimer's disease: a 26-week, multicenter, open-label study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Behavioral Symptoms; Cholinesterase Inhibitors; Drug Administration Schedule; Female; Homes for the Aged; Humans; Inpatients; Male; Neuroprotective Agents; Neuropsychological Tests; Neurotic Disorders; Nursing Homes; Phenylcarbamates; Prospective Studies; Rivastigmine; Severity of Illness Index; Time Factors; Treatment Outcome | 2005 |
Effects of switching from an AChE inhibitor to a dual AChE-BuChE inhibitor in patients with Alzheimer's disease.
Topics: Acetylcholinesterase; Aged; Aged, 80 and over; Alzheimer Disease; Butyrylcholinesterase; Cholinesterase Inhibitors; Female; Humans; Mental Status Schedule; Phenylcarbamates; Prospective Studies; Rivastigmine; Treatment Outcome | 2005 |
Cognitive rehabilitation combined with drug treatment in Alzheimer's disease patients: a pilot study.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Anxiety; Caregivers; Cholinesterase Inhibitors; Cognition Disorders; Cognitive Behavioral Therapy; Depression; Female; Humans; Male; Mental Status Schedule; Middle Aged; Phenylcarbamates; Pilot Projects; Rivastigmine; Treatment Outcome | 2005 |
Rivastigmine monotherapy and combination therapy with memantine in patients with moderately severe Alzheimer's disease who failed to benefit from previous cholinesterase inhibitor treatment.
Topics: Aged; Alzheimer Disease; Antiparasitic Agents; Cholinesterase Inhibitors; Drug Therapy, Combination; Female; Humans; Male; Memantine; Neuroprotective Agents; Phenylcarbamates; Prospective Studies; Rivastigmine; Treatment Outcome | 2006 |
Short-term treatment with rivastigmine and plasma levels of Abeta peptides in Alzheimer's disease.
Topics: Age Factors; Aged; Aged, 80 and over; Alzheimer Disease; Amyloid beta-Peptides; Cholinesterase Inhibitors; Enzyme-Linked Immunosorbent Assay; Female; Humans; Male; Phenylcarbamates; Rivastigmine; Time Factors | 2005 |
Beneficial effect of cholinesterase inhibitor medications on recognition memory performance in mild to moderate Alzheimer's disease: preliminary findings.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Female; Humans; Indans; Male; Memory Disorders; Mental Recall; Mental Status Schedule; Neuropsychological Tests; Phenylcarbamates; Piperidines; Retention, Psychology; Rivastigmine; Verbal Learning | 2006 |
Transdermal rivastigmine treatment does not worsen impaired performance of complex motions in patients with Alzheimer's disease.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Alzheimer Disease; Attention; Cognition Disorders; Female; Humans; Male; Middle Aged; Movement; Neuroprotective Agents; Phenylcarbamates; Psychomotor Performance; Reaction Time; Rivastigmine | 2006 |
Quetiapine and rivastigmine for agitation in Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Dibenzothiazepines; Disease Progression; Double-Blind Method; Humans; Phenylcarbamates; Psychomotor Agitation; Quetiapine Fumarate; Rivastigmine | 2006 |
Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease.
Topics: Age Factors; Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Donepezil; Female; Humans; Indans; Male; Middle Aged; Neuroprotective Agents; Nootropic Agents; Phenylcarbamates; Piperidines; Retrospective Studies; Rivastigmine; Severity of Illness Index; Treatment Outcome | 2006 |
Acetylcholinesterase inhibitors and sleep architecture in patients with Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Female; Galantamine; Humans; Indans; Male; Middle Aged; Phenylcarbamates; Piperidines; Polysomnography; Rivastigmine; Sleep Stages; Sleep Wake Disorders | 2006 |
Changes in metabolite ratios after treatment with rivastigmine in Alzheimer's disease: a nonrandomised controlled trial with magnetic resonance spectroscopy.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Biotransformation; Brain; Brain Chemistry; Cholinesterase Inhibitors; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neuropsychological Tests; Nootropic Agents; Phenylcarbamates; Psychiatric Status Rating Scales; Rivastigmine | 2006 |
Effect of butyrylcholinesterase genotype on the response to rivastigmine or donepezil in younger patients with Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Butyrylcholinesterase; Cholinesterase Inhibitors; Donepezil; Female; Genetic Variation; Genotype; Heterozygote; Humans; Indans; Male; Middle Aged; Phenylcarbamates; Piperidines; Retrospective Studies; Rivastigmine; Treatment Outcome | 2006 |
A large, naturalistic, community-based study of rivastigmine in mild-to-moderate AD: the EXTEND Study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Behavior; Caregivers; Cholinesterase Inhibitors; Cognition; Dose-Response Relationship, Drug; Female; Humans; Male; Personal Autonomy; Phenylcarbamates; Prospective Studies; Psychiatric Status Rating Scales; Rivastigmine; Severity of Illness Index; Treatment Outcome | 2006 |
Identification of responders and reactive domains to rivastigmine in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cognition Disorders; Female; Humans; Male; Middle Aged; Neuroprotective Agents; Neuropsychological Tests; Phenylcarbamates; Prospective Studies; Rivastigmine; Time Factors; Treatment Outcome | 2007 |
Changes in brain 11C-nicotine binding sites in patients with mild Alzheimer's disease following rivastigmine treatment as assessed by PET.
Topics: Acetylcholinesterase; Aged; Alzheimer Disease; Brain; Butyrylcholinesterase; Carbon Radioisotopes; Cholinesterase Inhibitors; Cognition; Female; Humans; Male; Nicotine; Phenylcarbamates; Positron-Emission Tomography; Radiopharmaceuticals; Receptors, Nicotinic; Rivastigmine; Severity of Illness Index; Time Factors; Treatment Outcome | 2007 |
Rivastigmine: a placebo controlled trial of twice daily and three times daily regimens in patients with Alzheimer's disease.
Topics: Administration, Oral; Aged; Alzheimer Disease; Anxiety; Cognition; Dizziness; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Headache; Humans; Male; Phenylcarbamates; Rivastigmine; Treatment Outcome | 2007 |
Domain-specific improvement of cognition on memantine in patients with Alzheimer's disease treated with rivastigmine.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Attention; Cholinesterase Inhibitors; Cognition; Cognition Disorders; Drug Therapy, Combination; Excitatory Amino Acid Antagonists; Female; Humans; Male; Memantine; Memory; Phenylcarbamates; Pilot Projects; Receptors, N-Methyl-D-Aspartate; Rivastigmine; Severity of Illness Index; Treatment Outcome | 2007 |
Risperidone and rivastigmine and agitated behaviour in severe Alzheimer's disease: a randomised double blind placebo controlled study.
Topics: Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Phenylcarbamates; Psychomotor Agitation; Risperidone; Rivastigmine | 2007 |
A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease--rivastigmine patch versus capsule.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Alzheimer Disease; Capsules; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Drug Eruptions; Female; Humans; Male; Middle Aged; Phenylcarbamates; Rivastigmine; Treatment Outcome | 2007 |
Caregiver preference for rivastigmine patch relative to capsules for treatment of probable Alzheimer's disease.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Capsules; Caregivers; Choice Behavior; Cost of Illness; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Phenylcarbamates; Rivastigmine; Treatment Outcome | 2007 |
Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Cholinesterase Inhibitors; Cognition Disorders; Disease Progression; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neuropsychological Tests; Phenylcarbamates; Rivastigmine; Tremor; Vomiting | 2007 |
Pharmacokinetics and pharmacodynamics of the novel daily rivastigmine transdermal patch compared with twice-daily capsules in Alzheimer's disease patients.
Topics: Administration, Cutaneous; Administration, Oral; Aged; Alzheimer Disease; Benzylamines; Butyrylcholinesterase; Capsules; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Models, Biological; Phenethylamines; Phenols; Phenylcarbamates; Rivastigmine; Treatment Outcome | 2008 |
Omega-3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms.
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Analysis of Variance; Apolipoproteins E; Cholinesterase Inhibitors; Depression; Dietary Supplements; Donepezil; Double-Blind Method; Fatty Acids, Omega-3; Female; Galantamine; Genotype; Humans; Indans; Male; Phenylcarbamates; Piperidines; Psychiatric Status Rating Scales; Rivastigmine; Statistics, Nonparametric; Treatment Outcome | 2008 |
A randomised double-blind placebo-controlled trial of folic acid supplementation of cholinesterase inhibitors in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Analysis of Variance; Chi-Square Distribution; Cholinesterase Inhibitors; Dietary Supplements; Donepezil; Double-Blind Method; Female; Folic Acid; Folic Acid Deficiency; Galantamine; Homocysteine; Humans; Indans; Male; Mental Status Schedule; Phenylcarbamates; Piperidines; Placebos; Rivastigmine; Treatment Outcome; Vitamin B Complex; Vitamins | 2008 |
IDEAL: a 6-month, double-blind, placebo-controlled study of the first skin patch for Alzheimer disease.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Alzheimer Disease; Area Under Curve; Cholinesterase Inhibitors; Double-Blind Method; Drug Delivery Systems; Female; Follow-Up Studies; Humans; International Cooperation; Male; Mental Status Schedule; Middle Aged; Neuropsychological Tests; Phenylcarbamates; Placebos; Rivastigmine; Statistics, Nonparametric; Treatment Outcome | 2007 |
Caregiver preference for rivastigmine patches versus capsules for the treatment of Alzheimer disease.
Topics: Activities of Daily Living; Administration, Cutaneous; Aged; Aged, 80 and over; Alzheimer Disease; Caregivers; Cholinesterase Inhibitors; Female; Humans; Male; Middle Aged; Patient Compliance; Patient Satisfaction; Phenylcarbamates; Rivastigmine; Surveys and Questionnaires | 2007 |
Plasma Abeta levels as predictors of response to rivastigmine treatment in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Amyloid beta-Peptides; Analysis of Variance; Apolipoproteins E; Female; Humans; Linear Models; Male; Neuroprotective Agents; Peptide Fragments; Phenylcarbamates; Psychometrics; Rivastigmine | 2007 |
Does serotonin augmentation have any effect on cognition and activities of daily living in Alzheimer's dementia? A double-blind, placebo-controlled clinical trial.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Cholinesterase Inhibitors; Cognition; Double-Blind Method; Drug Therapy, Combination; Female; Fluoxetine; Humans; Male; Middle Aged; Phenylcarbamates; Psychiatric Status Rating Scales; Psychometrics; Rivastigmine; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index | 2007 |
Rivastigmine exposure provided by a transdermal patch versus capsules.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Alzheimer Disease; Capsules; Cholinesterase Inhibitors; Female; Humans; Male; Phenylcarbamates; Rivastigmine | 2007 |
Neuropsychological rehabilitation in mild and moderate Alzheimer's disease patients.
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Cognitive Behavioral Therapy; Female; Humans; Male; Memory Disorders; Neuroprotective Agents; Neuropsychological Tests; Phenylcarbamates; Rivastigmine; Severity of Illness Index; Treatment Outcome; Verbal Learning | 2007 |
Safety/tolerability trial of SDZ ENA 713 in patients with probable Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Phenylcarbamates; Prospective Studies; Rivastigmine | 1996 |
Dose-dependent CSF acetylcholinesterase inhibition by SDZ ENA 713 in Alzheimer's disease.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alzheimer Disease; Area Under Curve; Carbamates; Cerebrospinal Fluid; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Phenylcarbamates; Rivastigmine | 1998 |
Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Cognition Disorders; Disease Progression; Double-Blind Method; Female; Health Status; Humans; Male; Middle Aged; Phenylcarbamates; Prospective Studies; Rivastigmine | 1999 |
A phase II study in patients with Alzheimer's disease to assess the preliminary efficacy and maximum tolerated dose of rivastigmine (Exelon).
Topics: Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Double-Blind Method; Electrocardiography; Female; Humans; Male; Neuroprotective Agents; Phenylcarbamates; Psychiatric Status Rating Scales; Rivastigmine | 1999 |
Drug treatment of Alzheimer's disease and responders to rivastigmine beyond 12 weeks.
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Humans; Mental Status Schedule; Neuroprotective Agents; Phenylcarbamates; Rivastigmine; Scotland; Time Factors; Treatment Failure; Treatment Outcome | 1999 |
An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Dementia, Vascular; Female; Humans; Male; Middle Aged; Neuropsychological Tests; Phenylcarbamates; Risk Factors; Rivastigmine; Treatment Outcome | 2000 |
Savings in the cost of caring for patients with Alzheimer's disease in Canada: an analysis of treatment with rivastigmine.
Topics: Aged; Algorithms; Alzheimer Disease; Canada; Carbamates; Cholinesterase Inhibitors; Cognition; Cost Savings; Cost-Benefit Analysis; Disease Progression; Female; Humans; Male; Middle Aged; Models, Economic; Neuroprotective Agents; Phenylcarbamates; Proportional Hazards Models; Psychiatric Status Rating Scales; Quality-Adjusted Life Years; Rivastigmine | 2000 |
A 52-week study of the efficacy of rivastigmine in patients with mild to moderately severe Alzheimer's disease.
Topics: Age Factors; Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Cognition; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Phenylcarbamates; Rivastigmine; Time Factors; Treatment Outcome | 2000 |
Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Disease Progression; Double-Blind Method; Female; Humans; Linear Models; Male; Phenylcarbamates; Predictive Value of Tests; Prognosis; Rivastigmine; Treatment Outcome | 2001 |
Short-term rivastigmine treatment reduces EEG slow-wave power in Alzheimer patients.
Topics: Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Electroencephalography; Female; Humans; Male; Neuroprotective Agents; Phenylcarbamates; Psychiatric Status Rating Scales; Rivastigmine | 2001 |
Pharmacokinetic-pharmacodynamic modeling of rivastigmine, a cholinesterase inhibitor, in patients with Alzheimer's disease.
Topics: Acetylcholinesterase; Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Female; Humans; Male; Middle Aged; Models, Biological; Neuropsychological Tests; Patients; Phenylcarbamates; Rivastigmine | 2001 |
Brain metabolic and clinical effects of rivastigmine in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Brain; Brain Chemistry; Carbamates; Double-Blind Method; Female; Fluorodeoxyglucose F18; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neuroprotective Agents; Phenylcarbamates; Radiopharmaceuticals; Rivastigmine; Tomography, Emission-Computed | 2001 |
An open-label study to evaluate the safety, tolerability and efficacy of rivastigmine in patients with mild to moderate probable Alzheimer's disease in the community setting.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Carbamates; Disease Progression; Female; Humans; Male; Neuroprotective Agents; Phenylcarbamates; Rivastigmine | 2002 |
Rivastigmine in outpatient services: experience of 114 neurologists in Austria.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Austria; Carbamates; Cognition; Disease Progression; Female; Humans; Male; Neuroprotective Agents; Neuropsychological Tests; Outpatients; Phenylcarbamates; Psychiatric Status Rating Scales; Rivastigmine; Treatment Outcome | 2002 |
Cerebral blood flow and cognitive responses to rivastigmine treatment in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Carbamates; Cerebrovascular Circulation; Cholinesterase Inhibitors; Cluster Analysis; Cognition; Female; Humans; Longitudinal Studies; Male; Neuropsychological Tests; Phenylcarbamates; Prospective Studies; Radiopharmaceuticals; Rivastigmine; Technetium Tc 99m Exametazime; Time Factors; Tomography, Emission-Computed, Single-Photon | 2002 |
Estimation of the absolute bioavailability of rivastigmine in patients with mild to moderate dementia of the Alzheimer's type.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alzheimer Disease; Area Under Curve; Biological Availability; Carbamates; Cholinesterase Inhibitors; Cross-Over Studies; Dose-Response Relationship, Drug; Female; Gas Chromatography-Mass Spectrometry; Humans; Infusions, Intravenous; Male; Middle Aged; Models, Biological; Phenylcarbamates; Rivastigmine | 2002 |
Electrocardiographic effects of rivastigmine.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Bradycardia; Carbamates; Cardiovascular System; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Electrocardiography; Female; Heart Diseases; Heart Rate; Humans; Male; Middle Aged; Phenylcarbamates; Rivastigmine; Tachycardia | 2002 |
Efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Donepezil; Female; Humans; Indans; Male; Middle Aged; Neuroprotective Agents; Nootropic Agents; Phenylcarbamates; Piperidines; Prospective Studies; Rivastigmine; Severity of Illness Index; Treatment Failure; Treatment Outcome | 2002 |
Pharmacologic and clinicopharmacologic properties of SDZ ENA 713, a centrally selective acetylcholinesterase inhibitor.
Topics: Alzheimer Disease; Animals; Carbamates; Cholinesterase Inhibitors; Humans; Male; Phenylcarbamates; Physostigmine; Placebos; Rats; Rivastigmine | 1991 |
397 other study(ies) available for rivastigmine and Acute Confusional Senile Dementia
| Article | Year |
|---|---|
Novel dual inhibitors of AChE and MAO derived from hydroxy aminoindan and phenethylamine as potential treatment for Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Binding Sites; Butyrylcholinesterase; Carbamates; Cattle; Cholinesterase Inhibitors; Humans; Indans; Models, Molecular; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Pargyline; Phenethylamines; Propylamines; Structure-Activity Relationship | 2002 |
Structural determinants of Torpedo californica acetylcholinesterase inhibition by the novel and orally active carbamate based anti-alzheimer drug ganstigmine (CHF-2819).
Topics: Acetylcholinesterase; Administration, Oral; Alkaloids; Alzheimer Disease; Animals; Binding Sites; Brain; Carbamates; Cholinesterase Inhibitors; Crystallization; Crystallography, X-Ray; Drug Evaluation, Preclinical; Enzyme Activation; Male; Mice; Models, Molecular; Molecular Conformation; Stereoisomerism; Structure-Activity Relationship; Torpedo | 2006 |
6-Hydroxy- and 6-methoxy-beta-carbolines as acetyl- and butyrylcholinesterase inhibitors.
Topics: Acetylcholinesterase; Alzheimer Disease; Butyrylcholinesterase; Carbolines; Cholinesterase Inhibitors; Galantamine; Humans; Inhibitory Concentration 50; Phenylcarbamates; Physostigmine; Rivastigmine; Serotonin | 2006 |
Novel class of quinone-bearing polyamines as multi-target-directed ligands to combat Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Binding Sites; Butyrylcholinesterase; Cell Line; Cholinesterase Inhibitors; Humans; Ligands; Models, Molecular; NAD(P)H Dehydrogenase (Quinone); Oxidative Stress; Polyamines; Protein Binding; Quinones; Reactive Oxygen Species; Structure-Activity Relationship; Substrate Specificity | 2007 |
Site-activated multifunctional chelator with acetylcholinesterase and neuroprotective-neurorestorative moieties for Alzheimer's therapy.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Brain; Cell Line, Tumor; Cell Survival; Chelating Agents; Cholinesterase Inhibitors; Drug Design; Humans; Hydroxyquinolines; Metals; Neuroprotective Agents; Piperazines; Prodrugs; Rats | 2009 |
Synthesis of novel purine nucleosides towards a selective inhibition of human butyrylcholinesterase.
Topics: Alzheimer Disease; Butyrylcholinesterase; Cell Line; Cell Survival; Cholinesterase Inhibitors; Fibroblasts; Glycosylation; Humans; Purine Nucleosides; Stereoisomerism | 2009 |
(+)-Arisugacin A--computational evidence of a dual binding site covalent inhibitor of acetylcholinesterase.
Topics: Alzheimer Disease; Binding Sites; Cholinesterase Inhibitors; Computer Simulation; Inhibitory Concentration 50; Models, Biological; Models, Molecular; Molecular Structure; Pyrans | 2011 |
Synthesis and biological evaluation of novel N,N'-bis-methylenedioxybenzyl-alkylenediamines as bivalent anti-Alzheimer disease ligands.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Benzophenones; Cells, Cultured; Curcumin; Diamines; Enzyme Activation; Enzyme Inhibitors; Humans; Inhibitory Concentration 50; Ligands; Methylene Chloride | 2011 |
Quinolizidinyl derivatives of bi- and tricyclic systems as potent inhibitors of acetyl- and butyrylcholinesterase with potential in Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Butyrylcholinesterase; Cattle; Cholinesterase Inhibitors; Crystallography, X-Ray; Dose-Response Relationship, Drug; Erythrocytes; Models, Molecular; Molecular Structure; Quinolizidines; Stereoisomerism; Structure-Activity Relationship | 2011 |
Exploiting the lipoic acid structure in the search for novel multitarget ligands against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Butyrylcholinesterase; Cell Line; Cholinesterase Inhibitors; Drug Discovery; Humans; Ligands; Peptide Fragments; Protein Multimerization; Protein Structure, Secondary; Thioctic Acid | 2011 |
Lead optimization studies towards the discovery of novel carbamates as potent AChE inhibitors for the potential treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Carbamates; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Discovery; Mice; Models, Molecular; Molecular Dynamics Simulation; Molecular Structure; Structure-Activity Relationship | 2012 |
Carbamate derivatives of indolines as cholinesterase inhibitors and antioxidants for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Antioxidants; Apoptosis; Carbamates; Chickens; Cholinesterase Inhibitors; Humans; Indoles; Neurons | 2012 |
Design, synthesis and biological evaluation of coumarin alkylamines as potent and selective dual binding site inhibitors of acetylcholinesterase.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Binding Sites; Butyrylcholinesterase; Cattle; Cholinesterase Inhibitors; Coumarins; Horses; Humans | 2013 |
Design, synthesis and evaluation of novel 4-dimethylamine flavonoid derivatives as potential multi-functional anti-Alzheimer agents.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Butyrylcholinesterase; Cholinesterase Inhibitors; Dimethylamines; Drug Design; Flavonoids; Humans; Molecular Docking Simulation; Structure-Activity Relationship | 2013 |
Cannabinoid agonists showing BuChE inhibition as potential therapeutic agents for Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Butyrylcholinesterase; Cannabinoid Receptor Agonists; Cholinesterase Inhibitors; Computational Biology; Drug Design; Horses; Humans; Indazoles; Ligands; Molecular Docking Simulation; Molecular Structure; Radioligand Assay; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2 | 2014 |
Evaluation of nicotine and cotinine analogs as potential neuroprotective agents for Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Cell Survival; Cells, Cultured; Cotinine; Humans; Neurons; Neuroprotective Agents; Nicotine; Peptide Fragments; Rats; Receptors, N-Methyl-D-Aspartate | 2014 |
Design, synthesis and evaluation of rivastigmine and curcumin hybrids as site-activated multitarget-directed ligands for Alzheimer's disease therapy.
Topics: Acetylcholinesterase; Alzheimer Disease; Butyrylcholinesterase; Cholinesterase Inhibitors; Curcumin; Dose-Response Relationship, Drug; Drug Design; Ligands; Molecular Docking Simulation; Molecular Structure; Phenylcarbamates; Rivastigmine; Structure-Activity Relationship | 2014 |
Multifunctional scutellarin-rivastigmine hybrids with cholinergic, antioxidant, biometal chelating and neuroprotective properties for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Antioxidants; Apigenin; Blood-Brain Barrier; Butyrylcholinesterase; Carbamates; Cell Line; Chelating Agents; Cholinesterase Inhibitors; Cognition; Glucuronates; Humans; Mice; Molecular Docking Simulation; Neuroprotective Agents; Rats | 2015 |
Design, synthesis and evaluation of scutellarein-O-alkylamines as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amines; Amyloid beta-Peptides; Animals; Antioxidants; Apigenin; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Design; Humans; Hydrogen Peroxide; Memory Disorders; Mice; Models, Molecular; Molecular Structure; PC12 Cells; Peptide Fragments; Rats; Scopolamine; Structure-Activity Relationship | 2015 |
Design, synthesis, and biological evaluation of scutellarein carbamate derivatives as potential multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Antioxidants; Apigenin; Brain; Butyrylcholinesterase; Carbamates; Chelating Agents; Cholinesterase Inhibitors; Drug Design; Female; Humans; Male; Memory; Mice; Molecular Targeted Therapy; Neuroprotective Agents; PC12 Cells; Rats | 2015 |
Synthesis, biological evaluation and molecular modeling of new tetrahydroacridine derivatives as potential multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acridines; Alzheimer Disease; Cholinesterase Inhibitors; Drug Design; Humans; Models, Molecular; Structure-Activity Relationship | 2015 |
Synthesis, pharmacological assessment, molecular modeling and in silico studies of fused tricyclic coumarin derivatives as a new family of multifunctional anti-Alzheimer agents.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Antioxidants; Binding Sites; Butyrylcholinesterase; Chemistry Techniques, Synthetic; Cholinesterase Inhibitors; Computer Simulation; Coumarins; Drug Evaluation, Preclinical; Galantamine; Humans; Hydrogen Peroxide; Male; Mice, Inbred BALB C; Models, Molecular; Neuroprotective Agents; Neurotoxicity Syndromes | 2016 |
Design and discovery of Novel Thiazole acetamide derivatives as anticholinesterase agent for possible role in the management of Alzheimer's.
Topics: Acetamides; Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Binding Sites; Butyrylcholinesterase; Cell Survival; Cholinesterase Inhibitors; Drug Design; Drug Evaluation, Preclinical; HeLa Cells; Humans; Inhibitory Concentration 50; Molecular Docking Simulation; Protein Binding; Protein Structure, Tertiary; Structure-Activity Relationship; Thiazoles | 2016 |
Pterostilbene-O-acetamidoalkylbenzylamines derivatives as novel dual inhibitors of cholinesterase with anti-β-amyloid aggregation and antioxidant properties for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Benzylamines; Butyrylcholinesterase; Cholinesterase Inhibitors; Cholinesterases; Dose-Response Relationship, Drug; Humans; Molecular Structure; Peptide Fragments; Protein Aggregates; Protein Aggregation, Pathological; Stilbenes; Structure-Activity Relationship | 2016 |
Synthesis and screening of triazolopyrimidine scaffold as multi-functional agents for Alzheimer's disease therapies.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Butyrylcholinesterase; Cell Line, Tumor; Cell Survival; Chemistry Techniques, Synthetic; Cholinesterase Inhibitors; Drug Evaluation, Preclinical; Humans; Kinetics; Molecular Docking Simulation; Peptide Fragments; Protein Aggregates; Protein Conformation; Pyrimidines | 2016 |
Design, synthesis and in vitro evaluation of benzothiazole-based ureas as potential ABAD/17β-HSD10 modulators for Alzheimer's disease treatment.
Topics: 3-Hydroxyacyl CoA Dehydrogenases; Alzheimer Disease; Animals; Benzothiazoles; Cell Survival; CHO Cells; Cricetulus; Dose-Response Relationship, Drug; Drug Design; Enzyme Inhibitors; Humans; Molecular Structure; Structure-Activity Relationship; Urea | 2016 |
Design and synthesis of novel anti-Alzheimer's agents: Acridine-chromenone and quinoline-chromenone hybrids.
Topics: Acridines; Alzheimer Disease; Animals; Cholinesterase Inhibitors; Cholinesterases; Chromones; Dose-Response Relationship, Drug; Drug Design; Humans; Models, Molecular; Molecular Structure; Neuroprotective Agents; PC12 Cells; Quinolines; Rats; Structure-Activity Relationship | 2016 |
Fatty Acid Amide Hydrolase (FAAH), Acetylcholinesterase (AChE), and Butyrylcholinesterase (BuChE): Networked Targets for the Development of Carbamates as Potential Anti-Alzheimer's Disease Agents.
Topics: Acetylcholinesterase; Alzheimer Disease; Amidohydrolases; Butyrylcholinesterase; Carbamates; Cell Line, Tumor; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Models, Molecular; Molecular Structure; Structure-Activity Relationship | 2016 |
Discovery and Structure-Activity Relationships of a Highly Selective Butyrylcholinesterase Inhibitor by Structure-Based Virtual Screening.
Topics: Alzheimer Disease; Butyrylcholinesterase; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Discovery; Drug Evaluation, Preclinical; Humans; Models, Molecular; Molecular Structure; Structure-Activity Relationship | 2016 |
Discovery of novel rivastigmine-hydroxycinnamic acid hybrids as multi-targeted agents for Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Cholinesterase Inhibitors; Coumaric Acids; Drug Discovery; Humans; In Vitro Techniques; Neuroprotective Agents; Rivastigmine; Structure-Activity Relationship | 2017 |
Design, synthesis, biological evaluation, and molecular modeling studies of chalcone-rivastigmine hybrids as cholinesterase inhibitors.
Topics: Acetylcholinesterase; Alzheimer Disease; Butyrylcholinesterase; Catalytic Domain; Cell Line, Tumor; Chalcones; Cholinesterase Inhibitors; Humans; Hydrogen Bonding; Kinetics; Molecular Docking Simulation; Molecular Dynamics Simulation; Oxidative Stress; Reactive Oxygen Species; Rivastigmine; Structure-Activity Relationship | 2017 |
Novel tacrine-1,2,3-triazole hybrids: In vitro, in vivo biological evaluation and docking study of cholinesterase inhibitors.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Butyrylcholinesterase; Cell Death; Cell Line; Cell Line, Tumor; Cholinesterase Inhibitors; Humans; Kinetics; Male; Memory Disorders; Molecular Docking Simulation; Neurons; Neuroprotective Agents; Rats; Rats, Wistar; Structure-Activity Relationship; Tacrine; Triazoles | 2017 |
Synthesis of novel chromenones linked to 1,2,3-triazole ring system: Investigation of biological activities against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Benzopyrans; Cell Death; Cholinesterase Inhibitors; Humans; Molecular Docking Simulation; Neuroprotective Agents; PC12 Cells; Rats; Triazoles | 2017 |
Design, synthesis and biological evaluation of 4'-aminochalcone-rivastigmine hybrids as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Blood-Brain Barrier; Chalcones; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Design; Humans; Molecular Docking Simulation; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Rivastigmine; Structure-Activity Relationship; Swine | 2017 |
Donepezil-Based Central Acetylcholinesterase Inhibitors by Means of a "Bio-Oxidizable" Prodrug Strategy: Design, Synthesis, and in Vitro Biological Evaluation.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid; Animals; Cholinesterase Inhibitors; Donepezil; Drug Design; Female; Humans; Indans; Mice; Molecular Docking Simulation; Piperidines; Prodrugs | 2017 |
Hydroxy-substituted trans-cinnamoyl derivatives as multifunctional tools in the context of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Cinnamates; Dose-Response Relationship, Drug; Free Radical Scavengers; Glycogen Synthase Kinase 3 beta; Molecular Structure; Stereoisomerism; Structure-Activity Relationship | 2017 |
Nature-based molecules combined with rivastigmine: A symbiotic approach for the synthesis of new agents against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Biological Products; Butyrylcholinesterase; Cell Death; Cell Line, Tumor; Cell Survival; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Free Radical Scavengers; Glutamic Acid; Humans; Molecular Structure; Neuroprotective Agents; Peptide Fragments; Protein Aggregates; Rivastigmine; Structure-Activity Relationship | 2017 |
Multi-target-directed ligands for treating Alzheimer's disease: Butyrylcholinesterase inhibitors displaying antioxidant and neuroprotective activities.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Butyrylcholinesterase; Caco-2 Cells; Cell Line, Tumor; Cholinesterase Inhibitors; Drug Design; Humans; Ligands; Models, Molecular; Neuroprotective Agents; Piperidines | 2018 |
Discovery of novel 2,5-dihydroxyterephthalamide derivatives as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Butyrylcholinesterase; Chelating Agents; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Discovery; Humans; Models, Molecular; Molecular Structure; Peptide Fragments; Phthalimides; Protein Aggregates; Structure-Activity Relationship | 2018 |
Tackling neuroinflammation and cholinergic deficit in Alzheimer's disease: Multi-target inhibitors of cholinesterases, cyclooxygenase-2 and 15-lipoxygenase.
Topics: Acetylcholine; Alzheimer Disease; Animals; Cell Line; Cholinesterase Inhibitors; Cyclooxygenase 2 Inhibitors; Drug Design; Humans; Inflammation; Lipoxygenase Inhibitors; Mice; Molecular Docking Simulation; Neurons; PC12 Cells; Rats; Semicarbazides; Triazoles | 2019 |
Design and development of multitarget-directed N-Benzylpiperidine analogs as potential candidates for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid Precursor Protein Secretases; Animals; Aspartic Acid Endopeptidases; Blood-Brain Barrier; Cell Line, Tumor; Cholinesterase Inhibitors; Cognitive Dysfunction; Drug Design; Humans; Mice; Piperidines; Protein Aggregation, Pathological; Structure-Activity Relationship | 2019 |
Design, synthesis, and evaluation of isoflavone analogs as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Blood-Brain Barrier; Butyrylcholinesterase; Cell Line; Cell Survival; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Design; Humans; Inflammation; Isoflavones; Lipopolysaccharides; Male; Mice; Mice, Inbred ICR; Models, Molecular; Molecular Structure; Neuroprotective Agents; Receptors, Histamine H3; Structure-Activity Relationship | 2019 |
Design, synthesis, in-silico and biological evaluation of novel chalcone-O-carbamate derivatives as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Butyrylcholinesterase; Chalcones; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Design; Eels; Female; Horses; Humans; Male; Maze Learning; Mice; Mice, Inbred Strains; Models, Molecular; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Peptide Fragments; Protein Aggregates; Rats; Structure-Activity Relationship | 2019 |
Design, synthesis, in-silico and biological evaluation of novel chalcone derivatives as multi-function agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Butyrylcholinesterase; Chalcone; Cholinesterase Inhibitors; Drug Design; Eels; Horses; Humans; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Neuroprotective Agents; Peptide Fragments; Protein Aggregates | 2019 |
Discovery of δ-sultone-fused pyrazoles for treating Alzheimer's disease: Design, synthesis, biological evaluation and SAR studies.
Topics: Alzheimer Disease; Butyrylcholinesterase; Cholinesterase Inhibitors; Drug Design; Humans; Molecular Docking Simulation; Naphthalenesulfonates; Pyrazoles; Structure-Activity Relationship | 2019 |
Design and development of molecular hybrids of 2-pyridylpiperazine and 5-phenyl-1,3,4-oxadiazoles as potential multifunctional agents to treat Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid Precursor Protein Secretases; Animals; Antioxidants; Blood-Brain Barrier; Butyrylcholinesterase; Cholinesterase Inhibitors; Cognitive Dysfunction; Female; Humans; Kinetics; Molecular Docking Simulation; Neuroprotective Agents; Oxadiazoles; Piperazines; Protein Aggregates; Pyridines; Rats, Wistar; Structure-Activity Relationship | 2019 |
Design and synthesis of H
Topics: Alzheimer Disease; Animals; Antioxidants; Cell Line; Dose-Response Relationship, Drug; Drug Design; Humans; Hydrogen Sulfide; Isothiocyanates; Lipopolysaccharides; Mice; Microglia; Molecular Structure; Neurons; Neuroprotective Agents; Rivastigmine; Structure-Activity Relationship; Sulfides; Sulfoxides; Thiocyanates | 2019 |
Highly Selective Butyrylcholinesterase Inhibitors with Tunable Duration of Action by Chemical Modification of Transferable Carbamate Units Exhibit Pronounced Neuroprotective Effect in an Alzheimer's Disease Mouse Model.
Topics: Alzheimer Disease; Animals; Butyrylcholinesterase; Carbamates; Cholinesterase Inhibitors; Disease Models, Animal; Mice; Neuroprotective Agents | 2019 |
Synthesis, in vitro and in vivo biological evaluation of novel graveolinine derivatives as potential anti-Alzheimer agents.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Behavior, Animal; Butyrylcholinesterase; Cell Survival; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Electrophorus; Hep G2 Cells; Horses; Humans; Male; Methoxsalen; Mice; Molecular Structure; PC12 Cells; Peptide Fragments; Rats; Structure-Activity Relationship | 2020 |
Apigenin-rivastigmine hybrids as multi-target-directed liagnds for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Apigenin; Butyrylcholinesterase; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Humans; Ligands; Microsomes, Liver; Molecular Docking Simulation; Molecular Structure; Neuroprotective Agents; Rats; Rivastigmine; Structure-Activity Relationship; Zebrafish | 2020 |
The development of advanced structural framework as multi-target-directed ligands for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Aluminum Chloride; Alzheimer Disease; Amyloid beta-Peptides; Animals; Butyrylcholinesterase; Cholinesterase Inhibitors; Donepezil; Dose-Response Relationship, Drug; Drug Development; Humans; Ligands; Molecular Structure; Neuroprotective Agents; Oxidative Stress; Peptide Fragments; Structure-Activity Relationship; Zebrafish | 2020 |
Design, synthesis and biological evaluation of novel O-carbamoyl ferulamide derivatives as multi-target-directed ligands for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Amides; Amyloid beta-Peptides; Animals; Cell Line; Cell Survival; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Design; Humans; Ligands; Mice; Mice, Inbred Strains; Microsomes, Liver; Molecular Structure; Peptide Fragments; Positron Emission Tomography Computed Tomography; Protein Aggregates; Rats; Structure-Activity Relationship; Zebrafish | 2020 |
Acylhydrazones as isoniazid derivatives with multi-target profiles for the treatment of Alzheimer's disease: Radical scavenging, myeloperoxidase/acetylcholinesterase inhibition and biometal chelation.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Antioxidants; Biphenyl Compounds; Chelating Agents; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Electrophorus; Humans; Hydrazones; Molecular Docking Simulation; Molecular Structure; Neuroprotective Agents; Peroxidase; Picrates; Structure-Activity Relationship | 2020 |
MicroRNA-Based Multitarget Approach for Alzheimer's Disease: Discovery of the First-In-Class Dual Inhibitor of Acetylcholinesterase and MicroRNA-15b Biogenesis.
Topics: Acetylcholinesterase; Alzheimer Disease; Caco-2 Cells; Cholinesterase Inhibitors; Drug Discovery; Humans; MicroRNAs; Models, Molecular; Molecular Targeted Therapy; Nucleic Acid Conformation; Protein Conformation | 2020 |
Design, synthesis, and multitargeted profiling of N-benzylpyrrolidine derivatives for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amnesia; Amyloid beta-Peptides; Animals; Butyrylcholinesterase; Cell Line, Tumor; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Design; Female; Humans; Male; Models, Molecular; Molecular Structure; Neuroprotective Agents; Pyrrolidines; Rats; Rats, Wistar; Scopolamine; Structure-Activity Relationship | 2020 |
Pleiotropic prodrugs: Design of a dual butyrylcholinesterase inhibitor and 5-HT
Topics: Alzheimer Disease; Animals; Butyrylcholinesterase; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Design; Electrophorus; Humans; Locomotion; Male; Mice; Models, Molecular; Molecular Structure; Prodrugs; Receptors, Serotonin; Structure-Activity Relationship | 2021 |
2-Propargylamino-naphthoquinone derivatives as multipotent agents for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Drug Design; Humans; Naphthoquinones; Structure-Activity Relationship | 2021 |
Novel 3-benzylidene/benzylphthalide Mannich base derivatives as potential multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Benzofurans; Benzylidene Compounds; Blood-Brain Barrier; Butyrylcholinesterase; Cholinesterase Inhibitors; Copper; Dose-Response Relationship, Drug; Electrophorus; Female; Humans; Male; Mannich Bases; Mice; Mice, Inbred Strains; Models, Molecular; Molecular Structure; Neuroprotective Agents; PC12 Cells; Peptide Fragments; Protein Aggregates; Rats; Structure-Activity Relationship | 2021 |
Design and synthesis of garlic-related unsymmetrical thiosulfonates as potential Alzheimer's disease therapeutics: In vitro and in silico study.
Topics: Acetylcholinesterase; Alzheimer Disease; Butyrylcholinesterase; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Design; Garlic; Humans; Molecular Docking Simulation; Molecular Structure; Neuroprotective Agents; Structure-Activity Relationship; Thiosulfonic Acids | 2021 |
Synthesis, biological evaluation and molecular modeling of benzofuran piperidine derivatives as Aβ antiaggregant.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Benzofurans; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Humans; Models, Molecular; Molecular Structure; Neuroprotective Agents; Piperidines; Protein Aggregates; Protein Aggregation, Pathological; Structure-Activity Relationship | 2021 |
Novel cannabidiol-carbamate hybrids as selective BuChE inhibitors: Docking-based fragment reassembly for the development of potential therapeutic agents against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Binding Sites; Blood-Brain Barrier; Butyrylcholinesterase; Cannabidiol; Carbamates; Cell Line, Tumor; Cell Survival; Cholinesterase Inhibitors; Drug Design; Humans; Kinetics; Maze Learning; Mice; Mice, Inbred ICR; Molecular Docking Simulation; Neuroprotective Agents; Structure-Activity Relationship | 2021 |
Development of novel 2-aminoalkyl-6-(2-hydroxyphenyl)pyridazin-3(2H)-one derivatives as balanced multifunctional agents against Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Cholinesterase Inhibitors; Drug Design; Mice; Protein Aggregates; Structure-Activity Relationship | 2022 |
Development of naringenin-O-carbamate derivatives as multi-target-directed liagnds for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Antioxidants; Butyrylcholinesterase; Carbamates; Cell Line; Cell Survival; Cholinesterase Inhibitors; Copper; Dose-Response Relationship, Drug; Drug Development; Flavanones; Humans; Molecular Structure; Neuroprotective Agents; Peptide Fragments; Protein Aggregates; Rats; Structure-Activity Relationship | 2022 |
Synthesis, biological evaluation, and molecular modeling simulations of new heterocyclic hybrids as multi-targeted anti-Alzheimer's agents.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Cholinesterase Inhibitors; Donepezil; Drug Design; Humans; Models, Molecular; Neuroprotective Agents; Tacrine | 2022 |
Effectiveness of the 10 cm
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Humans; Middle Aged; Rivastigmine; Treatment Outcome | 2021 |
Donepezil Regulates LPS and Aβ-Stimulated Neuroinflammation through MAPK/NLRP3 Inflammasome/STAT3 Signaling.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Astrocytes; Cells, Cultured; Cholinesterase Inhibitors; Cytokines; Disease Models, Animal; Donepezil; Inflammasomes; Inflammation; Lipopolysaccharides; Male; MAP Kinase Signaling System; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microglia; Mitogen-Activated Protein Kinases; NLR Family, Pyrin Domain-Containing 3 Protein; Rivastigmine; STAT3 Transcription Factor | 2021 |
Cholinesterase inhibitors for the treatment of dementia: real-life data in Hungary.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Humans; Hungary; Rivastigmine | 2022 |
The listed, delisted, and sustainability of therapeutic medicines for dementia patients: the study is specific to South Korea.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Humans; Indans; Memantine; Phenylcarbamates; Piperidines; Rivastigmine | 2022 |
Increased MYD88 blood transcript in a mouse model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Disease Models, Animal; Disease Progression; Humans; Inflammation; Mice; Mice, Transgenic; Myeloid Differentiation Factor 88; Rivastigmine | 2022 |
Analysis of treatment pattern of anti-dementia medications in newly diagnosed Alzheimer's dementia using OMOP CDM.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Indans; Memantine; Phenylcarbamates; Piperidines; Rivastigmine | 2022 |
Thermosensitive in situ hydrogels of rivastigmine-loaded lipid-based nanosystems for nose-to-brain delivery: characterisation, biocompatibility, and drug deposition studies.
Topics: Acetylcholinesterase; Alzheimer Disease; Brain; Cholinesterase Inhibitors; Drug Carriers; Drug Liberation; Humans; Hydrogels; Lipids; Nanostructures; Particle Size; Rivastigmine | 2022 |
Targeting the Beta-2-Adrenergic Receptor and the Risk of Developing Alzheimer's Disease: A Retrospective Inception Cohort Study.
Topics: Aged; Alzheimer Disease; Animals; Cholinesterase Inhibitors; Cohort Studies; Donepezil; Humans; Retrospective Studies; Rivastigmine | 2022 |
First Donepezil Transdermal Patch Approved for Alzheimer Disease.
Topics: Administration, Cutaneous; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Humans; Indans; Nootropic Agents; Rivastigmine; Transdermal Patch | 2022 |
Differential neuroprotective effect of curcuminoid formulations in aluminum chloride-induced Alzheimer's disease.
Topics: Acetylcholinesterase; Aluminum Chloride; Alzheimer Disease; Amyloid Precursor Protein Secretases; Animals; Biomarkers; Complex Mixtures; Diarylheptanoids; Disease Models, Animal; Humans; Interleukin-1alpha; Interleukin-1beta; Neuroprotective Agents; Rivastigmine; RNA, Messenger; Tumor Necrosis Factor-alpha | 2022 |
The Influence of Selected Antipsychotic Drugs on Biochemical Aspects of Alzheimer's Disease.
Topics: Alzheimer Disease; Antipsychotic Agents; Cholinesterase Inhibitors; Endothelial Cells; Hemolysis; Humans; Quetiapine Fumarate; Rivastigmine | 2022 |
Drug Distribution in Brain and Cerebrospinal Fluids in Relation to IC
Topics: Acetylcholinesterase; Aged; Aging; Alzheimer Disease; Amyloid Precursor Protein Secretases; Brain; Butyrylcholinesterase; Cholinesterase Inhibitors; Humans; Indans; Piperidines; Rivastigmine | 2022 |
In silico analyses of acetylcholinesterase (AChE) and its genetic variants in interaction with the anti-Alzheimer drug Rivastigmine.
Topics: Acetylcholinesterase; Alzheimer Disease; Genome-Wide Association Study; Humans; Molecular Docking Simulation; Molecular Dynamics Simulation; Rivastigmine | 2022 |
Iranian thyme honey plays behavioral, cellular and molecular important roles as an amazing preventive and therapeutic agent in the brain of Alzheimer's rat model.
Topics: Alzheimer Disease; Animals; Antioxidants; Disease Models, Animal; Hippocampus; Honey; Humans; Iran; Maze Learning; Oxidative Stress; Rats; Rivastigmine; Thymus Plant | 2022 |
Risk of Serious Adverse Events Associated With Individual Cholinesterase Inhibitors Use in Older Adults With Dementia: A Population-Based Cohort Study.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cohort Studies; Donepezil; Female; Galantamine; Humans; Indans; Male; Medicare; Phenylcarbamates; Piperidines; Retrospective Studies; Rivastigmine; United States | 2022 |
Hypoxic and Hypercapnic Responses in Transgenic Murine Model of Alzheimer's Disease Overexpressing Human AβPP: The Effects of Pretreatment with Memantine and Rivastigmine.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Disease Models, Animal; Humans; Hypercapnia; Hypoxia; Memantine; Mice; Mice, Transgenic; Quality of Life; Respiration; Rivastigmine | 2022 |
Novel donepezil-chalcone-rivastigmine hybrids as potential multifunctional anti-Alzheimer's agents: Design, synthesis, in vitro biological evaluation, in vivo and in silico studies.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Chalcone; Chalcones; Chalones; Cholinesterase Inhibitors; Donepezil; Drug Design; Neuroprotective Agents; Positron Emission Tomography Computed Tomography; Rats; Rivastigmine; Structure-Activity Relationship | 2022 |
Corpus callosum anatomical changes in Alzheimer patients and the effect of acetylcholinesterase inhibitors on corpus callosum morphometry.
Topics: Acetylcholinesterase; Alzheimer Disease; Cholinesterase Inhibitors; Corpus Callosum; Donepezil; Female; Humans; Magnetic Resonance Imaging; Male; Rivastigmine | 2022 |
Dysphagia Risk in Patients Prescribed Rivastigmine: A Systematic Analysis of FDA Adverse Event Reporting System.
Topics: Acetylcholinesterase; Alzheimer Disease; Butyrylcholinesterase; Cholinesterase Inhibitors; Clozapine; Deglutition Disorders; Donepezil; Galantamine; Humans; Memantine; Penicillamine; Risk Management; Rivastigmine; United States; United States Food and Drug Administration | 2022 |
Phytochemicals-based Therapeutics against Alzheimer's Disease: An Update.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Donepezil; Humans; Phytochemicals; Quality of Life; Rivastigmine | 2022 |
Real-world effects of anti-dementia treatment on mortality in patients with Alzheimer´s dementia.
Topics: Alzheimer Disease; Donepezil; Female; Galantamine; Humans; Indans; Male; Phenylcarbamates; Piperidines; Retrospective Studies; Rivastigmine | 2022 |
In silico and in vitro studies confirm Ondansetron as a novel acetylcholinesterase and butyrylcholinesterase inhibitor.
Topics: Acetylcholinesterase; Alzheimer Disease; Butyrylcholinesterase; Cholinesterase Inhibitors; Humans; Molecular Docking Simulation; Ondansetron; Rivastigmine; Structure-Activity Relationship; Tacrine | 2023 |
Topics: Acetylcholinesterase; Alzheimer Disease; Cholinesterase Inhibitors; Humans; Molecular Docking Simulation; Molecular Dynamics Simulation; Receptors, N-Methyl-D-Aspartate; Riluzole; Rivastigmine | 2023 |
Improper Application of a Rivastigmine Patch to the Back of the Neck Induced Toxic Symptoms.
Topics: Aged, 80 and over; Alzheimer Disease; Female; Humans; Rivastigmine; Transdermal Patch | 2023 |
Usmarapride (SUVN-D4010), a 5-HT
Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Donepezil; Rats; Rivastigmine; Serotonin | 2023 |
Rivastigmine-Benzimidazole Hybrids as Promising Multitarget Metal-Modulating Compounds for Potential Treatment of Neurodegenerative Diseases.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Benzimidazoles; Chelating Agents; Cholinesterase Inhibitors; Ferric Compounds; Humans; Monoamine Oxidase; Neuroblastoma; Neurodegenerative Diseases; Rivastigmine | 2023 |
The effect of single and repeated doses of rivastigmine on gastric myoelectric activity in experimental pigs.
Topics: Alzheimer Disease; Animals; Cholinesterase Inhibitors; Electromyography; Female; Gastrointestinal Tract; Humans; Infant; Phenylcarbamates; Rivastigmine; Stomach | 2023 |
Rivastigmine-DHA ion-pair complex improved loading in hybrid nanoparticles for better amyloid inhibition and nose-to-brain targeting in Alzheimer's.
Topics: Administration, Intranasal; Alzheimer Disease; Brain; Docosahexaenoic Acids; Humans; Nanoparticles; Polymers; Rivastigmine | 2023 |
Development of novel salicylic acid-donepezil-rivastigmine hybrids as multifunctional agents for the treatment of Alzheimer's disease.
Topics: Acetylcholinesterase; Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Humans; Neuroprotective Agents; Rivastigmine; Structure-Activity Relationship | 2023 |
Mitochondrial Effects of Hydromethylthionine, Rivastigmine and Memantine in Tau-Transgenic Mice.
Topics: Alzheimer Disease; Animals; Cholinesterase Inhibitors; Memantine; Mice; Mice, Transgenic; Mitochondria; Rivastigmine; tau Proteins | 2023 |
Prevalence of treated patients with Alzheimer's disease: current trends and COVID-19 impact.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; COVID-19; Donepezil; Female; Galantamine; Humans; Indans; Male; Memantine; Pandemics; Phenylcarbamates; Piperidines; Prevalence; Retrospective Studies; Rivastigmine | 2023 |
Valine conjugated polymeric nanocarriers for targeted co-delivery of rivastigmine and quercetin in rat model of Alzheimer disease.
Topics: Alzheimer Disease; Animals; Drug Carriers; HEK293 Cells; Humans; Neuroblastoma; Polyesters; Polyethylene Glycols; Polymers; Quercetin; Rats; Rivastigmine | 2023 |
Bioassays guided isolation of berberine from Berberis lycium and its neuroprotective role in aluminium chloride induced rat model of Alzheimer's disease combined with insilico molecular docking.
Topics: Acetylcholinesterase; Aluminum Chloride; Alzheimer Disease; Amyloid Precursor Protein Secretases; Animals; Berberine; Berberis; Dopamine; Lycium; Methanol; Molecular Docking Simulation; Neuroprotective Agents; Rats; Rivastigmine; Serotonin | 2023 |
ApoE3 Anchored Liposomal Delivery of Rivastigmine for Brain Delivery: Formulation, Characterization, and In Vivo Pharmacokinetic Evaluation.
Topics: Acetylcholinesterase; Alzheimer Disease; Apolipoprotein E3; Brain; Cholinesterase Inhibitors; Humans; Lipopolysaccharides; Liposomes; Particle Size; Rivastigmine; Tissue Distribution | 2023 |
Risk of rhabdomyolysis with donepezil compared with rivastigmine or galantamine: a population-based cohort study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Female; Galantamine; Hospitalization; Humans; Male; Ontario; Retrospective Studies; Rhabdomyolysis; Risk Assessment; Rivastigmine | 2019 |
Hypoxic-conditioned medium from adipose tissue mesenchymal stem cells improved neuroinflammation through alternation of toll like receptor (TLR) 2 and TLR4 expression in model of Alzheimer's disease rats.
Topics: Adipose Tissue; Alzheimer Disease; Amyloid beta-Peptides; Animals; Cholinesterase Inhibitors; Culture Media, Conditioned; Disease Models, Animal; Hippocampus; Hypoxia; Inflammation; Interleukin-1beta; Learning; Male; Maze Learning; Mesenchymal Stem Cells; Peptide Fragments; Rats; Rats, Wistar; Recognition, Psychology; Rivastigmine; Spatial Memory; Toll-Like Receptor 2; Toll-Like Receptor 4; Tumor Necrosis Factor-alpha | 2020 |
Cholinesterase as a Target for Drug Development in Alzheimer's Disease.
Topics: Acetylcholine; Alzheimer Disease; Cholinesterase Inhibitors; Cholinesterases; Donepezil; Drug Development; Galantamine; Humans; Memantine; Rivastigmine | 2020 |
Effects of the online computerized cognitive training program BEYNEX on the cognitive tests of individuals with subjective cognitive impairment and Alzheimer’s disease on rivastigmine therapy
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cognition; Cognitive Dysfunction; Female; Humans; Male; Middle Aged; Rivastigmine; Therapy, Computer-Assisted | 2020 |
[Several issues analysis on the treatment of Alzheimer's disease with rivastigmine transdermal patch].
Topics: Alzheimer Disease; Humans; Rivastigmine; Transdermal Patch; Treatment Outcome | 2020 |
In Vitro and in Vivo Optimization of Phase Sensitive Smart Polymer for Controlled Delivery of Rivastigmine for Treatment of Alzheimer's Disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Drug Carriers; Drug Compounding; Drug Liberation; Humans; Hydrophobic and Hydrophilic Interactions; Kinetics; Phase Transition; Polylactic Acid-Polyglycolic Acid Copolymer; Rivastigmine; Solvents; Stimuli Responsive Polymers | 2020 |
Probing the interaction of Rivastigmine Tartrate, an important Alzheimer's drug, with serum albumin: Attempting treatment of Alzheimer's disease.
Topics: Algorithms; Alzheimer Disease; Binding Sites; Humans; Hydrogen Bonding; Molecular Conformation; Molecular Docking Simulation; Molecular Dynamics Simulation; Protein Binding; Rivastigmine; Serum Albumin; Spectrum Analysis; Structure-Activity Relationship; Thermodynamics | 2020 |
Medical interventions suppressed progression of advanced Alzheimer's disease more than mild Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Disease Progression; Donepezil; Female; Galantamine; Humans; Japan; Male; Memantine; Mental Status and Dementia Tests; Retrospective Studies; Rivastigmine | 2020 |
Rivastigmine modifies the α-secretase pathway and potentially early Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Amyloid Precursor Protein Secretases; Animals; Aspartic Acid Endopeptidases; Humans; Mice; Prohibitins; Rats; Rivastigmine | 2020 |
Mechanisms of Anticholinesterase Interference with Tau Aggregation Inhibitor Activity in a Tau-Transgenic Mouse Model.
Topics: Alzheimer Disease; Animals; Brain; Cholinesterase Inhibitors; Disease Models, Animal; Drug Interactions; Methylene Blue; Mice; Mice, Transgenic; Protein Aggregates; Rivastigmine; tau Proteins | 2020 |
An in vitro study on the interaction of the anti-Alzheimer drug rivastigmine with human erythrocytes.
Topics: Acetylcholinesterase; Alzheimer Disease; Calorimetry, Differential Scanning; Cell Shape; Cholinesterase Inhibitors; Dimyristoylphosphatidylcholine; Erythrocyte Membrane; Erythrocytes; Humans; Microscopy, Electron, Scanning; Models, Molecular; Phosphatidylethanolamines; Phospholipids; Rivastigmine; Spectrometry, Fluorescence; X-Ray Diffraction | 2020 |
Downregulation of serum miR-106b: a potential biomarker for Alzheimer disease.
Topics: Alzheimer Disease; Biomarkers; Down-Regulation; Humans; MicroRNAs; Rivastigmine | 2022 |
Pharmaceutical Treatment for Alzheimer's Disease and Related Dementias: Utilization and Disparities.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Dementia; Donepezil; Dopamine Agents; Female; Galantamine; Healthcare Disparities; Humans; Male; Medicare; Memantine; Nootropic Agents; Patient Acceptance of Health Care; Rivastigmine; Treatment Outcome; United States | 2020 |
Rivastigmine in Parkinson's Disease Dementia with Orthostatic Hypotension.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Female; Humans; Hypotension; Male; Middle Aged; Neuroprotective Agents; Neuropsychological Tests; Parkinson Disease; Rivastigmine | 2021 |
Gas-phase basicity and proton affinity measurements of Alzheimer's disease drugs by the extended kinetic method and a theoretical investigation.
Topics: Alzheimer Disease; Curcumin; Galantamine; Humans; Neuroprotective Agents; Protons; Rivastigmine; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry | 2020 |
Evaluation of rivastigmine in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Brain; Cholinesterase Inhibitors; Cognition; Female; Humans; Male; Rivastigmine | 2021 |
Therapeutic Potential of Multifunctional Derivatives of Cholinesterase Inhibitors.
Topics: Alzheimer Disease; Animals; Cholinesterase Inhibitors; Donepezil; Galantamine; Rivastigmine; Tacrine | 2021 |
Post-market utilization patterns of Alzheimer's disease treatments in South Korea: comparison with countries with universal health coverage.
Topics: Alzheimer Disease; Australia; Cholinesterase Inhibitors; Donepezil; Galantamine; Global Health; Humans; Memantine; Product Surveillance, Postmarketing; Republic of Korea; Rivastigmine; Universal Health Care | 2021 |
The CITIMERIVA Study: CITIcoline plus MEmantina plus RIVAstigmine in Older Patients Affected with Alzheimer's Disease.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Case-Control Studies; Cholinesterase Inhibitors; Cognition; Comorbidity; Cytidine Diphosphate Choline; Female; Humans; Italy; Male; Memantine; Retrospective Studies; Rivastigmine | 2021 |
Pharmacogenetic and Association Studies on the Influence of HLA Alleles and Rivastigmine on the Iranian Patients with Late-Onset Alzheimer's Disease.
Topics: Aged; Alleles; Alzheimer Disease; Apolipoprotein E4; Case-Control Studies; Female; Genetic Association Studies; Genetic Predisposition to Disease; HLA Antigens; Humans; Iran; Male; Pharmacogenetics; Rivastigmine | 2021 |
Nutritional Status in Patients with Probable Alzheimer's Disease: Effect of Rivastigmine.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cross-Sectional Studies; Female; Humans; Male; Malnutrition; Nutrition Assessment; Nutritional Status; Rivastigmine | 2021 |
The Efficacy of Transdermal Rivastigmine in Mild to Moderate Alzheimer's Disease with Concomitant Small Vessel Cerebrovascular Disease: Findings from an Open-Label Study.
Topics: Activities of Daily Living; Administration, Cutaneous; Aged; Alzheimer Disease; Cerebral Small Vessel Diseases; Cognition; Female; Humans; Male; Neuroprotective Agents; Rivastigmine; Treatment Outcome | 2021 |
Rivastigmine attenuates the Alzheimer's disease related protein degradation and apoptotic neuronal death signalling.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Antibiotics, Antineoplastic; Apoptosis; Cognitive Dysfunction; Endoplasmic Reticulum Stress; Male; Neuroprotective Agents; Proteolysis; Rats; Rats, Sprague-Dawley; Rivastigmine; Streptozocin | 2021 |
Design, development and in-vitro/in-vivo evaluation of intranasally delivered Rivastigmine and N-Acetyl Cysteine loaded bifunctional niosomes for applications in combinative treatment of Alzheimer's disease.
Topics: Acetylcysteine; Administration, Intranasal; Alzheimer Disease; Animals; Brain; Cholinesterase Inhibitors; Delayed-Action Preparations; Drug Combinations; Drug Evaluation, Preclinical; Drug Liberation; Free Radical Scavengers; Humans; Liposomes; Male; Models, Animal; Nasal Mucosa; Particle Size; Rats; Rivastigmine; Sheep | 2021 |
Early Start of Anti-Dementia Medication Delays Transition to 24-Hour Care in Alzheimer's Disease Patients: A Finnish Nationwide Cohort Study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cohort Studies; Donepezil; Female; Finland; Galantamine; Humans; Male; Memantine; Nootropic Agents; Nursing Homes; Retrospective Studies; Rivastigmine; Time-to-Treatment | 2021 |
New Coumarin Derivatives as Cholinergic and Cannabinoid System Modulators.
Topics: Alzheimer Disease; Amidohydrolases; Amyloid beta-Peptides; Animals; Blood-Brain Barrier; Cannabinoids; Carbamates; Chemistry, Pharmaceutical; Cholinergic Agents; Coumarins; Drug Design; Endocannabinoids; Enzyme Inhibitors; Humans; Inhibitory Concentration 50; Molecular Docking Simulation; Protein Conformation; Rats; Receptors, Cannabinoid; Receptors, Cholinergic; Rivastigmine | 2021 |
Pharmacokinetic and pharmacodynamic evaluation of nasal liposome and nanoparticle based rivastigmine formulations in acute and chronic models of Alzheimer's disease.
Topics: Administration, Intranasal; Alzheimer Disease; Animals; Area Under Curve; Biological Availability; Cholinesterase Inhibitors; Colchicine; Disease Models, Animal; Liposomes; Male; Maze Learning; Memory Disorders; Models, Biological; Nanoparticles; Rats; Rats, Wistar; Rivastigmine; Scopolamine | 2021 |
Systematic development of lectin conjugated microspheres for nose-to-brain delivery of rivastigmine for the treatment of Alzheimer's disease.
Topics: Adhesiveness; Administration, Intranasal; Alzheimer Disease; Animals; Brain; Cellulose; Chitosan; Cholinesterase Inhibitors; Drug Compounding; Drug Delivery Systems; Drug Liberation; Goats; In Vitro Techniques; Lectins; Microspheres; Nasal Mucosa; Particle Size; Rivastigmine | 2021 |
Real-world Utilisation of the Rivastigmine Transdermal Patches Accompanying the Use of Risk Minimisation Tools in Patients with Dementia.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Female; Humans; Male; Medication Adherence; Neuroprotective Agents; Patient Education as Topic; Rivastigmine; Transdermal Patch | 2021 |
The Association Between Use of Rivastigmine and Pneumonia: Systematic Analysis of FDA Adverse Event Reporting System.
Topics: Adverse Drug Reaction Reporting Systems; Aged; Alzheimer Disease; Cholinesterase Inhibitors; Databases, Factual; Donepezil; Female; Galantamine; Humans; Male; Nootropic Agents; Pneumonia; Rivastigmine; Sex Factors; United States; United States Food and Drug Administration | 2021 |
Acute cholinergic syndrome in a patient with mild Alzheimer's type dementia who had applied a large number of rivastigmine transdermal patches on her body.
Topics: Administration, Cutaneous; Aged, 80 and over; Alzheimer Disease; Blood Pressure; Cholinesterase Inhibitors; Drug Overdose; Female; Heart Rate; Humans; Hypertension; Neurotoxicity Syndromes; Rivastigmine; Severity of Illness Index; Tachycardia, Sinus; Transdermal Patch | 2017 |
Factors affecting therapeutic response to Rivastigmine in Alzheimer's disease patients in Taiwan.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Female; Humans; Male; Middle Aged; Neuroprotective Agents; Pilot Projects; Rivastigmine; Taiwan; Treatment Outcome | 2017 |
Improvement in behavioral and psychological symptoms of dementia by rivastigmine patch in a group of Italian elderly patients with Alzheimer's disease.
Topics: Acetylcholinesterase; Administration, Cutaneous; Aged; Alzheimer Disease; Brain; Butyrylcholinesterase; Cholinesterase Inhibitors; Cognition; Female; GPI-Linked Proteins; Humans; Italy; Male; Mental Health; Mental Status and Dementia Tests; Retrospective Studies; Rivastigmine; Time Factors; Transdermal Patch; Treatment Outcome | 2017 |
Assessing the binding of cholinesterase inhibitors by docking and molecular dynamics studies.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Hydrogen Bonding; Indans; Molecular Conformation; Molecular Dynamics Simulation; Piperidines; Rivastigmine; Torpedo | 2017 |
Utilization of Western medicine and traditional Chinese medicine among patients with Alzheimer's disease in Taiwan: a nationwide population-based study.
Topics: Age Factors; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Drugs, Chinese Herbal; Female; Humans; Indans; Male; Medicine, Chinese Traditional; Middle Aged; Piperidines; Rivastigmine; Sex Factors; Taiwan; Time-to-Treatment; Urbanization | 2017 |
Discovery of Novel Pyrazolopyrimidinone Derivatives as Phosphodiesterase 9A Inhibitors Capable of Inhibiting Butyrylcholinesterase for Treatment of Alzheimer's Disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Butyrylcholinesterase; Cell Line, Tumor; Cholinesterase Inhibitors; Drug Design; Drug Evaluation, Preclinical; Humans; Inhibitory Concentration 50; Ligands; Models, Molecular; Molecular Docking Simulation; Molecular Structure; Oxidative Stress; Peptide Fragments; Phosphodiesterase Inhibitors; Protein Aggregation, Pathological; Protein Conformation; Pyrazolones; Pyrimidinones; Rivastigmine | 2017 |
A very low dose of rivastigmine-induced Pisa syndrome in a clozapine-treated patient.
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Cholinesterase Inhibitors; Clozapine; Drug Therapy, Combination; Dystonic Disorders; Female; Humans; Rivastigmine; Schizophrenia | 2018 |
A chiral enantioseparation generic strategy for anti-Alzheimer and antifungal drugs by short end injection capillary electrophoresis using an experimental design approach.
Topics: Alzheimer Disease; Antifungal Agents; Cyclodextrins; Donepezil; Electrophoresis, Capillary; Indans; Injections; Piperidines; Rivastigmine; Stereoisomerism | 2018 |
Formulation and In-vivo Pharmacokinetic Consideration of Intranasal Microemulsion and Mucoadhesive Microemulsion of Rivastigmine for Brain Targeting.
Topics: Administration, Intranasal; Adsorption; Alzheimer Disease; Animals; Biological Availability; Biological Transport; Blood-Brain Barrier; Brain; Chitosan; Cholinesterase Inhibitors; Cholinesterases; Chromatography, High Pressure Liquid; Drug Compounding; Drug Delivery Systems; Drug Liberation; Emulsions; Humans; Isotope Labeling; Nasal Mucosa; Rats; Rats, Sprague-Dawley; Rivastigmine; Solubility; Tissue Distribution | 2018 |
Effect of cholinergic treatment depends on cholinergic integrity in early Alzheimer's disease.
Topics: Acetates; Acetylcholinesterase; Aged; Aged, 80 and over; Alzheimer Disease; Case-Control Studies; Cerebral Cortex; Cholinergic Agents; Cognitive Dysfunction; Female; Humans; Magnetic Resonance Imaging; Male; Mental Status Schedule; Middle Aged; Neuropsychological Tests; Oxygen; Piperidines; Positron-Emission Tomography; Rivastigmine | 2018 |
Safety and Efficacy of Anti-dementia Agents in the Extremely Elderly Patients with Dementia.
Topics: Activities of Daily Living; Aged, 80 and over; Alzheimer Disease; Donepezil; Exanthema; Female; Humans; Indans; Male; Medication Adherence; Nausea; Neuropsychological Tests; Nootropic Agents; Piperidines; Retrospective Studies; Rivastigmine; Treatment Outcome | 2018 |
The Impact of a Long-Term Rivastigmine and Donepezil Treatment on All-Cause Mortality in Patients With Alzheimer's Disease.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Female; Humans; Longitudinal Studies; Male; Models, Statistical; Mortality; Rivastigmine; Time Factors | 2018 |
[Design, synthesis and evaluation of 4-pyridinylthiazole-2-amines as acetylcholinesterase inhibitors].
Topics: Acetylcholinesterase; Alzheimer Disease; Amines; Butyrylcholinesterase; Cholinesterase Inhibitors; Drug Design; Rivastigmine; Structure-Activity Relationship | 2016 |
Gender Differences in Neuropsychiatric Symptoms in Mild to Moderate Alzheimer's Disease Patients Undergoing Switch of Cholinesterase Inhibitors: A Post Hoc Analysis of the EVOLUTION Study.
Topics: Administration, Oral; Aged; Alzheimer Disease; Behavioral Symptoms; Cholinesterase Inhibitors; Cognition; Drug Substitution; Female; Humans; Italy; Male; Mental Competency; Mental Status and Dementia Tests; Psychological Techniques; Rivastigmine; Sex Factors; Transdermal Patch; Treatment Outcome | 2018 |
France Will No More Reimburse Available Symptomatic Drugs Against Alzheimer's Disease.
Topics: Alzheimer Disease; France; Humans; Neuroprotective Agents; Rivastigmine | 2018 |
Influence of Acetylcholinesterase Inhibitors Used in Alzheimer's Disease Treatment on the Activity of Antioxidant Enzymes and the Concentration of Glutathione in
Topics: Alzheimer Disease; Antioxidants; Cholinesterase Inhibitors; Donepezil; Fluorides; Glutathione; Humans; Oxidation-Reduction; Oxidative Stress; Reactive Oxygen Species; Rivastigmine; THP-1 Cells | 2018 |
Skinfold thickness for rivastigmine patch application in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Female; Humans; Male; Middle Aged; Phenethylamines; Phenols; Rivastigmine; Skinfold Thickness | 2019 |
The transition from vivid dreams over floccillations and visual hallucinations to complete delirium in a geriatric patient at the dawn of Alzheimer's dementia: beneficial role of rivastigmine.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Delirium; Disease Progression; Hallucinations; Humans; Male; Rivastigmine | 2019 |
Efficacy of rivastigmine transdermal therapy on low food intake in patients with Alzheimer's disease: The Attitude Towards Food Consumption in Alzheimer's Disease Patients Revive with Rivastigmine Effects study.
Topics: Aged, 80 and over; Alzheimer Disease; Appetite; Attitude to Health; Body Weight; Cholinesterase Inhibitors; Cognitive Dysfunction; Eating; Female; Humans; Male; Mental Status and Dementia Tests; Rivastigmine; Severity of Illness Index; Transdermal Patch; Treatment Outcome | 2019 |
A 48-Week, Multicenter, Open-Label, Observational Study Evaluating Oral Rivastigmine in Patients with Mild-to-Moderate Alzheimer's Disease in Taiwan.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Prospective Studies; Research Design; Rivastigmine; Taiwan; Treatment Outcome | 2019 |
Effect of CYP2D6 and CYP3A4 Genotypes on the Efficacy of Cholinesterase Inhibitors in Southern Chinese Patients With Alzheimer's Disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Donepezil; Female; Follow-Up Studies; Galantamine; Genotype; Hong Kong; Humans; Male; Pharmacogenetics; Pharmacogenomic Testing; Rivastigmine | 2019 |
Behavioral and Biochemical Implications of Dendrimeric Rivastigmine in Memory-Deficit and Alzheimer's Induced Rodents.
Topics: Acetylcholinesterase; Alzheimer Disease; Animals; Brain; Bridged-Ring Compounds; Disease Models, Animal; Drug Combinations; Maze Learning; Memory Disorders; Mice; Motor Skills; Organometallic Compounds; Polysaccharides; Rats; Rats, Wistar; Rivastigmine; Rotarod Performance Test; Scopolamine; Spatial Memory | 2019 |
One-Year Persistence with Donepezil, Memantine, and Rivastigmine in More than 66,000 Elderly Patients Followed in Poland.
Topics: Aged; Alzheimer Disease; Donepezil; Drug Utilization Review; Female; Humans; Male; Medication Adherence; Memantine; Middle Aged; Neuroprotective Agents; Outcome Assessment, Health Care; Poland; Practice Patterns, Physicians'; Rivastigmine | 2019 |
Is drug treatment for dementia followed up in primary care? A Swedish study of dementia clinics and referring primary care centres.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Dementia; Dementia, Vascular; Donepezil; Female; Galantamine; Humans; Indans; Male; Medical Records; Memantine; Nootropic Agents; Phenylcarbamates; Piperidines; Practice Guidelines as Topic; Practice Patterns, Physicians'; Primary Health Care; Retrospective Studies; Rivastigmine; Sweden; Treatment Outcome | 2013 |
Acute dystonic reaction with rivastigmine.
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Cholinesterase Inhibitors; Diazepam; Dose-Response Relationship, Drug; Dystonic Disorders; Female; Humans; Magnetic Resonance Imaging; Muscle Relaxants, Central; Phenylcarbamates; Rivastigmine; Transdermal Patch; Treatment Outcome | 2013 |
Blood pro-inflammatory cytokines in Alzheimer's disease in relation to the use of acetylcholinesterase inhibitors.
Topics: Age Factors; Aged; Aged, 80 and over; Alzheimer Disease; Case-Control Studies; Cholinesterase Inhibitors; Donepezil; Enzyme-Linked Immunosorbent Assay; Female; Galantamine; Humans; Indans; Interleukin-1beta; Interleukin-6; Male; Phenylcarbamates; Piperidines; Rivastigmine; Sex Factors; Tumor Necrosis Factor-alpha | 2013 |
Real-life effectiveness and tolerability of the rivastigmine transdermal patch in patients with mild-to-moderate Alzheimer's disease: the EMBRACE study.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Alzheimer Disease; Female; Humans; Male; Neuroprotective Agents; Phenylcarbamates; Prospective Studies; Rivastigmine; Severity of Illness Index; Treatment Outcome | 2013 |
A longitudinal study of risk factors for community-based home help services in Alzheimer's disease: the influence of cholinesterase inhibitor therapy.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Chi-Square Distribution; Cholinesterase Inhibitors; Donepezil; Female; Galantamine; Home Care Services; Humans; Indans; Linear Models; Longitudinal Studies; Male; Middle Aged; Neuropsychological Tests; Phenylcarbamates; Piperidines; Proportional Hazards Models; Prospective Studies; Risk Factors; Rivastigmine; Treatment Outcome | 2013 |
From high doses of oral rivastigmine to transdermal rivastigmine patches: user experience and satisfaction among caregivers of patients with mild to moderate Alzheimer disease.
Topics: Aged; Alzheimer Disease; Caregivers; Cholinesterase Inhibitors; Cross-Sectional Studies; Female; Humans; Male; Middle Aged; Neuroprotective Agents; Patient Satisfaction; Phenylcarbamates; Rivastigmine; Transdermal Patch | 2014 |
Atrial flutter in a patient with Alzheimer dementia treated by rivastigmine.
Topics: Aged; Alzheimer Disease; Atrial Flutter; Female; Humans; Neuroprotective Agents; Phenylcarbamates; Rivastigmine | 2013 |
Utility of an effect size analysis for communicating treatment effectiveness: a case study of cholinesterase inhibitors for Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Area Under Curve; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Indans; Phenylcarbamates; Piperidines; Randomized Controlled Trials as Topic; Rivastigmine; Treatment Outcome | 2013 |
[Exacerbation of psoriasiform lesions by a gamma-secretase inhibitor].
Topics: Adrenal Cortex Hormones; Aged; Alanine; Alzheimer Disease; Amyloid Precursor Protein Secretases; Azepines; Clinical Trials, Phase III as Topic; Drug Therapy, Combination; Early Termination of Clinical Trials; Female; Humans; Keratinocytes; Memantine; Models, Biological; Nootropic Agents; Phenylcarbamates; Psoriasis; Receptors, Notch; Rivastigmine; Signal Transduction | 2013 |
Sex and ESR1 genotype may influence the response to treatment with donepezil and rivastigmine in patients with Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Brief Psychiatric Rating Scale; Cholinesterase Inhibitors; Donepezil; Estrogen Receptor alpha; Female; Gene Frequency; Genetic Predisposition to Disease; Genotype; Humans; Indans; Male; Middle Aged; Phenylcarbamates; Piperidines; Polymorphism, Single Nucleotide; Rivastigmine; Sex Factors | 2014 |
CaMKII activity is essential for improvement of memory-related behaviors by chronic rivastigmine treatment.
Topics: Alzheimer Disease; Animals; Animals, Outbred Strains; CA1 Region, Hippocampal; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Calcium-Calmodulin-Dependent Protein Kinase Type 4; Cholinesterase Inhibitors; Denervation; Disease Models, Animal; Long-Term Potentiation; Male; Memory; Memory Disorders; Mice; Olfactory Bulb; Phenylcarbamates; Rivastigmine | 2014 |
Nose to brain microemulsion-based drug delivery system of rivastigmine: formulation and ex-vivo characterization.
Topics: Administration, Intranasal; Alzheimer Disease; Animals; Biological Availability; Brain; Cholinesterase Inhibitors; Cilia; Drug Compounding; Drug Delivery Systems; Emulsions; Excipients; Goats; Hydrogen-Ion Concentration; Nasal Mucosa; Particle Size; Rivastigmine; Solubility; Tissue Distribution; Viscosity | 2015 |
Cognitive and affective changes in mild to moderate Alzheimer's disease patients undergoing switch of cholinesterase inhibitors: a 6-month observational study.
Topics: Alzheimer Disease; Apathy; Cholinesterase Inhibitors; Cognitive Dysfunction; Depression; Drug Substitution; Humans; Italy; Mood Disorders; Phenylcarbamates; Rivastigmine; Socioeconomic Factors | 2014 |
The transdermal formulation of rivastigmine improves caregiver burden and treatment adherence of patients with Alzheimer's disease under daily practice conditions.
Topics: Aged; Alzheimer Disease; Caregivers; Cost of Illness; Female; Humans; Male; Medication Adherence; Neuroprotective Agents; Prospective Studies; Rivastigmine; Surveys and Questionnaires; Transdermal Patch | 2014 |
Antidementia drug use among community-dwelling individuals with Alzheimer's disease in Finland: a nationwide register-based study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cohort Studies; Diagnostic and Statistical Manual of Mental Disorders; Donepezil; Drug Monitoring; Drug Prescriptions; Drug Therapy, Combination; Excitatory Amino Acid Antagonists; Female; Finland; Follow-Up Studies; Galantamine; Guideline Adherence; Humans; Indans; Male; Memantine; Nootropic Agents; Phenylcarbamates; Piperidines; Practice Guidelines as Topic; Proportional Hazards Models; Registries; Rivastigmine | 2014 |
Formulations: friendly, fast, forgiving and flexible.
Topics: Alzheimer Disease; Female; Humans; Male; Medication Adherence; Neuroprotective Agents; Rivastigmine | 2014 |
Novel L-lactide-depsipeptide polymeric carrier for enhanced brain uptake of rivastigmine in treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Cells, Cultured; Depsipeptides; Drug Carriers; Drug Evaluation, Preclinical; Hemolysis; Humans; Male; Materials Testing; Neuroprotective Agents; Phenylcarbamates; Polyesters; Rats; Rats, Wistar; Rivastigmine; Tissue Distribution | 2014 |
Which rivastigmine formula is better for heart in elderly patients with Alzheimer's disease: oral or patch?
Topics: Administration, Oral; Aged; Aged, 80 and over; Alzheimer Disease; Arrhythmias, Cardiac; Cholinesterase Inhibitors; Electrocardiography; Female; Humans; Hypotension; Male; Phenylcarbamates; Retrospective Studies; Rivastigmine; Transdermal Patch | 2014 |
Reduced N-acetylaspartate to creatine ratio in the posterior cingulate correlates with cognition in Alzheimer's disease following four months of rivastigmine treatment.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Aspartic Acid; Cholinesterase Inhibitors; Cognition Disorders; Creatine; Female; Gyrus Cinguli; Humans; Magnetic Resonance Imaging; Male; Neuropsychological Tests; Phenylcarbamates; Rivastigmine | 2015 |
FOXO1 locus and acetylcholinesterase inhibitors in elderly patients with Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Brain; Cholinesterase Inhibitors; Donepezil; Female; Forkhead Box Protein O1; Forkhead Transcription Factors; Galantamine; Gene Frequency; Genetic Loci; Genotype; Haplotypes; Humans; Indans; Male; Oxidative Stress; Phenylcarbamates; Piperidines; Prospective Studies; Rivastigmine | 2014 |
Effectiveness of switching to the rivastigmine transdermal patch from oral cholinesterase inhibitors: a naturalistic prospective study in Alzheimer's disease.
Topics: Administration, Cutaneous; Administration, Oral; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Female; Humans; Male; Neuropsychological Tests; Rivastigmine; Transdermal Patch; Treatment Outcome | 2015 |
Butyrylcholinesterase: K variant, plasma activity, molecular forms and rivastigmine treatment in Alzheimer's disease in a Southern Brazilian population.
Topics: Alzheimer Disease; Brazil; Butyrylcholinesterase; Case-Control Studies; Cholinesterase Inhibitors; Disease Progression; Humans; Rivastigmine | 2015 |
Treatment with rivastigmine or galantamine and risk of urinary incontinence: results from a Dutch database study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cohort Studies; Cross-Over Studies; Databases, Factual; Female; Follow-Up Studies; Galantamine; Humans; Longitudinal Studies; Male; Netherlands; Risk Factors; Rivastigmine; Treatment Outcome; Urinary Incontinence | 2015 |
Skin reactions at the application site of rivastigmine patch (4.6 mg/24 h, 9.5 mg/24 h or 13.3 mg/24 h): a qualitative analysis of clinical studies in patients with Alzheimer's disease.
Topics: Administration, Cutaneous; Aged; Alzheimer Disease; Dose-Response Relationship, Drug; Drug Eruptions; Female; Humans; Incidence; Male; Neuroprotective Agents; Randomized Controlled Trials as Topic; Rivastigmine; Severity of Illness Index; Transdermal Patch | 2015 |
Factors Associated with Greater Adherence to and Satisfaction with Transdermal Rivastigmine in Patients with Alzheimer's Disease and Their Caregivers.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Alzheimer Disease; Caregivers; Cholinesterase Inhibitors; Female; Humans; Male; Medication Adherence; Middle Aged; Patient Satisfaction; Rivastigmine; Surveys and Questionnaires; Transdermal Patch | 2015 |
VGF expression by T lymphocytes in patients with Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Biomarkers; CD3 Complex; Cell Proliferation; Cells, Cultured; Female; Flow Cytometry; Glycated Hemoglobin; Humans; Immunosuppressive Agents; Male; Nerve Growth Factors; Neuroprotective Agents; Rivastigmine; Sirolimus; T-Lymphocytes | 2015 |
Pharmacogenetic Study on the Impact of Rivastigmine Concerning Genetic Variants of A2M and IL-6 Genes on Iranian Alzheimer's Patients.
Topics: Aged; Aged, 80 and over; alpha-Macroglobulins; Alzheimer Disease; Cholinesterase Inhibitors; Female; Follow-Up Studies; Genetic Variation; Humans; Interleukin-6; Iran; Male; Pharmacogenomic Testing; Rivastigmine | 2016 |
Long-Term Response to Cholinesterase Inhibitor Treatment Is Related to Functional MRI Response in Alzheimer's Disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Brain; Brain Mapping; Cholinesterase Inhibitors; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neuropsychological Tests; Rivastigmine | 2015 |
A Case Report on Dyskinesia Following Rivastigmine Patch 13.3 mg/24 hours for Alzheimer's Disease: Perspective in the Movement Disorders Spectrum Following Use of Cholinesterase Inhibitors.
Topics: Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Dyskinesias; Electroencephalography; Female; Humans; Neuroimaging; Phenylcarbamates; Rivastigmine; Transdermal Patch; Treatment Outcome; Withholding Treatment | 2015 |
Adverse Drug Reactions Reported With Cholinesterase Inhibitors: An Analysis of 16 Years of Individual Case Safety Reports From VigiBase.
Topics: Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Drug-Related Side Effects and Adverse Reactions; Europe; Female; Galantamine; Humans; Indans; Male; Medication Errors; North America; Pharmacovigilance; Piperidines; Rivastigmine; World Health Organization | 2015 |
Effects of cholinesterase inhibitor on brain activation in Alzheimer's patients measured with functional near-infrared spectroscopy.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Brain; Cholinesterase Inhibitors; Cognition; Female; Humans; Male; Middle Aged; Neuropsychological Tests; Psychomotor Performance; Rivastigmine; Spectroscopy, Near-Infrared; Speech; Treatment Outcome | 2015 |
Clinical Benefits of Rivastigmine in the Real World Dementia Clinics of the Okayama Rivastigmine Study (ORS).
Topics: Aged, 80 and over; Alzheimer Disease; Donepezil; Female; Humans; Indans; Male; Mental Status Schedule; Nootropic Agents; Piperidines; Psychiatric Status Rating Scales; Retrospective Studies; Rivastigmine; Severity of Illness Index; Time Factors; Treatment Outcome | 2015 |
Clinical Benefits for Older Alzheimer's Disease Patients: Okayama Late Dementia Study (OLDS).
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Donepezil; Female; Follow-Up Studies; Galantamine; Humans; Indans; Japan; Male; Memantine; Piperidines; Retrospective Studies; Rivastigmine; Treatment Outcome | 2015 |
Expression of HLA-DR, CD80, and CD86 in Healthy Aging and Alzheimer's Disease.
Topics: Adult; Aged; Aging; Alzheimer Disease; Analysis of Variance; Antigens, CD; B7-1 Antigen; B7-2 Antigen; Cholinesterase Inhibitors; Female; HLA-DR Antigens; Humans; Lipopolysaccharide Receptors; Male; Middle Aged; Monocytes; Rivastigmine; Young Adult | 2015 |
Real-world evaluation of compliance and preference in Alzheimer's disease treatment.
Topics: Administration, Cutaneous; Administration, Oral; Aged; Aged, 80 and over; Alzheimer Disease; Asia; Attitude of Health Personnel; Caregivers; Cholinesterase Inhibitors; Donepezil; Female; Galantamine; Humans; Indans; Male; Medication Adherence; Memantine; Middle East; Patient Preference; Physicians; Piperidines; Prospective Studies; Rivastigmine | 2015 |
Adverse Effects of Cholinesterase Inhibitors in Dementia, According to the Pharmacovigilance Databases of the United-States and Canada.
Topics: Adverse Drug Reaction Reporting Systems; Alzheimer Disease; Canada; Cholinesterase Inhibitors; Databases, Factual; Dementia; Donepezil; Galantamine; Humans; Indans; Pharmacovigilance; Piperidines; Rivastigmine; United States; United States Food and Drug Administration | 2015 |
[The acquisition of medication to treat Alzheimer's disease in Brazil: an analysis of federal purchases, 2008-2013].
Topics: Aged; Alzheimer Disease; Brazil; Female; Health Expenditures; Humans; Male; Middle Aged; Neuroprotective Agents; Population Dynamics; Prevalence; Rivastigmine | 2015 |
Role of P-glycoprotein in mediating rivastigmine effect on amyloid-β brain load and related pathology in Alzheimer's disease mouse model.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Disease Models, Animal; Disks Large Homolog 4 Protein; Humans; Mice; Mice, Transgenic; Rats; Rivastigmine; Synaptosomal-Associated Protein 25 | 2016 |
Mild versus moderate stages of Alzheimer's disease: three-year outcomes in a routine clinical setting of cholinesterase inhibitor therapy.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Donepezil; Female; Galantamine; Humans; Indans; Male; Mental Status Schedule; Piperidines; Prospective Studies; Rivastigmine; Severity of Illness Index; Treatment Outcome | 2016 |
Efficacy of rivastigmine tartrate, transdermal system, in Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Humans; Nausea; Rivastigmine; Transdermal Patch; Vomiting | 2016 |
Preliminary evidence that rivastigmine-induced inhibition of serum butyrylcholinesterase activity improves behavioral symptoms in Japanese patients with Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Behavioral Symptoms; Butyrylcholinesterase; Cholinesterase Inhibitors; Female; Geriatric Assessment; Humans; Japan; Male; Neuropsychological Tests; Prospective Studies; Rivastigmine; Treatment Outcome | 2017 |
Cerebral White Matter Changes on Therapeutic Response to Rivastigmine in Alzheimer's Disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Female; Humans; Magnetic Resonance Imaging; Male; Mental Status and Dementia Tests; Middle Aged; Neuroprotective Agents; Odds Ratio; Rivastigmine; Severity of Illness Index; Treatment Outcome; White Matter | 2016 |
The CITIRIVAD Study: CITIcoline plus RIVAstigmine in Elderly Patients Affected with Dementia Study.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Case-Control Studies; Cholinesterase Inhibitors; Cognition; Cytidine Diphosphate Choline; Female; Humans; Male; Neuropsychological Tests; Retrospective Studies; Rivastigmine; Transdermal Patch | 2016 |
In Vitro Effects of Cognitives and Nootropics on Mitochondrial Respiration and Monoamine Oxidase Activity.
Topics: Alzheimer Disease; Animals; Brain; Cholinesterase Inhibitors; Cognition; Donepezil; Galantamine; Indans; Memantine; Mitochondria; Monoamine Oxidase; Nootropic Agents; Oxygen Consumption; Piperidines; Rivastigmine; Swine | 2017 |
Use of antidementia drugs and risk of pneumonia in older persons with Alzheimer's disease.
Topics: Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Female; Finland; Galantamine; Hospitalization; Humans; Indans; Male; Memantine; Middle Aged; Piperidines; Pneumonia; Risk; Rivastigmine | 2017 |
Cholinergic Modification of Neurogenesis and Gliosis Improves the Memory of AβPPswe/PSEN1dE9 Alzheimer's Disease Model Mice Fed a High-Fat Diet.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Body Weight; Cells, Cultured; Cholinesterase Inhibitors; Conditioning, Psychological; Diabetes Mellitus, Type 2; Diet, High-Fat; Disease Models, Animal; Gliosis; Humans; Insulin; Maze Learning; Memory Disorders; Mice; Mice, Inbred C57BL; Mice, Transgenic; Neurogenesis; Neurons; Presenilin-1; Rivastigmine | 2017 |
Caregiver Preference and Treatment Compliance in Patients with Mild-to-Moderate Alzheimer's Disease in South Korea: RECAP Study Results.
Topics: Aged; Alzheimer Disease; Caregivers; Consumer Behavior; Female; Humans; Male; Middle Aged; Neuroprotective Agents; Patient Compliance; Prospective Studies; Psychiatric Status Rating Scales; Republic of Korea; Rivastigmine | 2017 |
Influence of Memantine on Continuous Treatment with Rivastigmine Patches-Retrospective Study Using the Logistic Regression Analysis.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Drug Therapy, Combination; Female; Humans; Logistic Models; Male; Memantine; Middle Aged; Patient Compliance; Retrospective Studies; Rivastigmine; Transdermal Patch | 2017 |
Therapeutic effects of drug switching between acetylcholinesterase inhibitors in patients with Alzheimer's disease.
Topics: Activities of Daily Living; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Drug Substitution; Galantamine; Humans; Retrospective Studies; Rivastigmine; Treatment Outcome | 2017 |
Tolerability of Cholinesterase Inhibitors: A Population-Based Study of Persistence, Adherence, and Switching.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Drug Tolerance; Female; Galantamine; Humans; Indans; Male; Medication Adherence; Piperidines; Rivastigmine | 2017 |
Different clinical effect of four antidementia drugs for Alzheimer's disease patients depending on white matter severity.
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Donepezil; Female; Galantamine; Humans; Male; Memantine; Nootropic Agents; Rivastigmine; Severity of Illness Index; Treatment Outcome; White Matter | 2017 |
Comparison of cholinesterase inhibitor utilization patterns and associated health care costs in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Databases, Factual; Donepezil; Drug Costs; Female; Follow-Up Studies; Galantamine; Health Care Costs; Humans; Indans; Male; Multivariate Analysis; Patient Compliance; Phenylcarbamates; Piperidines; Practice Patterns, Physicians'; Retrospective Studies; Rivastigmine | 2008 |
Variability of AChE, BChE, and ChAT genes in the late-onset form of Alzheimer's disease and relationships with response to treatment with Donepezil and Rivastigmine.
Topics: Acetylcholinesterase; Aged; Aged, 80 and over; Alzheimer Disease; Butyrylcholinesterase; Case-Control Studies; Choline O-Acetyltransferase; Cholinesterase Inhibitors; Donepezil; Female; Gene Frequency; Genotype; Humans; Indans; Male; Middle Aged; Phenylcarbamates; Piperidines; Polymorphism, Single Nucleotide; Rivastigmine | 2009 |
[Alzheimer type dementia].
Topics: Alzheimer Disease; Apolipoprotein E4; Diagnosis, Differential; Disease Progression; Donepezil; Humans; Indans; Memantine; Neuroprotective Agents; Neuropsychological Tests; Nootropic Agents; Phenylcarbamates; Piperidines; Risk Factors; Rivastigmine | 2008 |
[A transdermal patch of rivastigmine (Exelon)].
Topics: Administration, Cutaneous; Alzheimer Disease; Cholinesterase Inhibitors; Humans; Phenylcarbamates; Rivastigmine | 2008 |
A new way of data interpretation for cognition tests in rats used to characterise six choline esterase inhibitors with heterocyclic nitrogen bridgehead structure. Application in Alzheimer therapy.
Topics: Alzheimer Disease; Animals; Cholinesterase Inhibitors; Cognition; Data Interpretation, Statistical; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Exploratory Behavior; Female; Heterocyclic Compounds; Maze Learning; Memory; Muscarinic Antagonists; Nootropic Agents; Phenylcarbamates; Psychomotor Performance; Rats; Rats, Wistar; Rivastigmine; Scopolamine | 2008 |
Simultaneous determination of galantamine, rivastigmine and NAP 226-90 in plasma by MEKC and its application in Alzheimer's disease.
Topics: Adult; Alzheimer Disease; Benzylamines; Buffers; Cholinesterase Inhibitors; Chromatography, Micellar Electrokinetic Capillary; Drug Monitoring; Galantamine; Humans; Male; Phenethylamines; Phenols; Phenylcarbamates; Phosphoric Acids; Reproducibility of Results; Rivastigmine; Sensitivity and Specificity; Solvents; Surface-Active Agents | 2009 |
Adherence to cholinesterase inhibitors in patients with Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Female; Galantamine; Humans; Indans; Male; Medication Adherence; Middle Aged; Phenylcarbamates; Piperidines; Rivastigmine | 2009 |
[Treatment of degenerative dementia disorders--who should be treated?].
Topics: Aged; Alzheimer Disease; Antiparkinson Agents; Cholinesterase Inhibitors; Dementia; Dopamine Agents; Drug Therapy, Combination; Evidence-Based Medicine; Humans; Lewy Body Disease; Memantine; Middle Aged; Neuroprotective Agents; Parkinson Disease; Patient Selection; Phenylcarbamates; Rivastigmine | 2009 |
Effects of cholinesterase inhibition on brain white matter volume in Alzheimer's disease.
Topics: Acetylcholinesterase; Aged; Aged, 80 and over; Alzheimer Disease; Brain; Brain Mapping; Cholinesterase Inhibitors; Cytoprotection; Disease Progression; Donepezil; Drug Synergism; Drug Therapy, Combination; Female; Galantamine; Humans; Image Processing, Computer-Assisted; Indans; Magnetic Resonance Imaging; Male; Nerve Fibers, Myelinated; Neural Pathways; Neuroprotective Agents; Phenylcarbamates; Piperidines; Rivastigmine; Treatment Outcome | 2009 |
Predicting time to nursing home placement based on activities of daily living scores--a modelling analysis using data on Alzheimer's disease patients receiving rivastigmine or donepezil.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Disease Progression; Donepezil; Female; Forecasting; Humans; Indans; Male; Middle Aged; Neuroprotective Agents; Nursing Homes; Patient Transfer; Phenylcarbamates; Piperidines; Proportional Hazards Models; Prospective Studies; Psychometrics; Randomized Controlled Trials as Topic; Risk Assessment; Rivastigmine; Severity of Illness Index | 2009 |
Persistence with cholinesterase inhibitor therapy for dementia: an observational administrative health database study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Databases, Factual; Delayed-Action Preparations; Dementia; Donepezil; Follow-Up Studies; Galantamine; Humans; Indans; Medication Adherence; Phenylcarbamates; Piperidines; Rivastigmine | 2009 |
Safety and tolerability of rivastigmine capsule with memantine in patients with probable Alzheimer's disease: a 26-week, open-label, prospective trial (Study ENA713B US32).
Topics: Activities of Daily Living; Administration, Oral; Aged; Aged, 80 and over; Alzheimer Disease; Antiparkinson Agents; Blood Pressure; Capsules; Cholinesterase Inhibitors; Cognition; Dizziness; Drug Therapy, Combination; Excitatory Amino Acid Antagonists; Female; Humans; Incidence; Male; Memantine; Middle Aged; Nausea; Phenylcarbamates; Pilot Projects; Prospective Studies; Rivastigmine; Vomiting | 2010 |
International price comparisons of Alzheimer's drugs: a way to close the affordability gap.
Topics: Aged; Alzheimer Disease; Cross-Cultural Comparison; Developing Countries; Donepezil; Drug Costs; Economics; Galantamine; Humans; Income; Indans; India; Memantine; Mexico; Nootropic Agents; Phenylcarbamates; Piperidines; Rivastigmine; United States | 2009 |
Current treatments of Alzheimer disease: are main caregivers satisfied with the drug treatments received by their patients?
Topics: Aged; Alzheimer Disease; Caregivers; Cholinesterase Inhibitors; Cross-Sectional Studies; Donepezil; Excitatory Amino Acid Antagonists; Female; Galantamine; Humans; Indans; Male; Memantine; Middle Aged; Neuropsychological Tests; Nootropic Agents; Patient Compliance; Patient Satisfaction; Phenylcarbamates; Piperidines; Psychiatric Status Rating Scales; Psychometrics; Rivastigmine; Socioeconomic Factors; Spain; Surveys and Questionnaires | 2009 |
Use of pralidoxime without atropine in rivastigmine (carbamate) toxicity.
Topics: Administration, Cutaneous; Aged, 80 and over; Alzheimer Disease; Atropine; Cholinesterase Inhibitors; Cholinesterase Reactivators; Drug Overdose; Female; Humans; Phenylcarbamates; Pralidoxime Compounds; Rivastigmine; Treatment Outcome | 2009 |
Cholinesterase inhibitors and incidence of bradycardia in patients with dementia in the veterans affairs new England healthcare system.
Topics: Alzheimer Disease; Bradycardia; Cholinesterase Inhibitors; Cross-Sectional Studies; Dementia; Donepezil; Dose-Response Relationship, Drug; Drug Therapy, Combination; Galantamine; Heart Rate; Hospitals, Veterans; Humans; Incidence; Indans; Massachusetts; Nootropic Agents; Phenylcarbamates; Piperidines; Risk; Rivastigmine; Veterans | 2009 |
Safety/Tolerability and efficacy of rivastigmine in taiwanese patients with Alzheimer's disease: a prospective post-marketing surveillance study.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Female; Humans; Male; Middle Aged; Patient Satisfaction; Phenylcarbamates; Product Surveillance, Postmarketing; Rivastigmine | 2009 |
Hepatitis with cholestasis caused by rivastigmine transdermal patch.
Topics: Aged, 80 and over; Alzheimer Disease; Chemical and Drug Induced Liver Injury; Cholestasis; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Phenylcarbamates; Risk Assessment; Rivastigmine; Severity of Illness Index; Withholding Treatment | 2009 |
Maculopapular eruption to rivastigmine's transdermal patch application and successful oral desensitization.
Topics: Administration, Cutaneous; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Desensitization, Immunologic; Drug Hypersensitivity; Exanthema; Female; Humans; Hypersensitivity, Delayed; Phenylcarbamates; Rivastigmine; Skin Tests | 2010 |
Alzheimer's disease: Seeing the signs early.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Disease Progression; Galantamine; Humans; Memantine; Neuroprotective Agents; Nootropic Agents; Phenylcarbamates; Primary Health Care; Psychometrics; Rivastigmine; Time Factors | 2009 |
A novel effect of rivastigmine on pre-synaptic proteins and neuronal viability in a neurodegeneration model of fetal rat primary cortical cultures and its implication in Alzheimer's disease.
Topics: Actins; Adenosine Triphosphate; Alzheimer Disease; Animals; Cell Enlargement; Cell Survival; Cells, Cultured; Cerebral Cortex; Dose-Response Relationship, Drug; Embryo, Mammalian; Ethidium; Gene Expression Regulation; Glial Fibrillary Acidic Protein; Indoles; L-Lactate Dehydrogenase; Nerve Degeneration; Neurons; Neuroprotective Agents; Phenylcarbamates; Rats; Rats, Sprague-Dawley; Rivastigmine; Synaptophysin; Synaptosomal-Associated Protein 25; tau Proteins; Time Factors | 2010 |
Effects of donepezil, galantamine and rivastigmine in 938 Italian patients with Alzheimer's disease: a prospective, observational study.
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Apolipoproteins E; Cholinesterase Inhibitors; Cognition; Donepezil; Female; Galantamine; Genetic Variation; Genotype; Humans; Indans; Italy; Male; Outcome Assessment, Health Care; Phenylcarbamates; Piperidines; Prospective Studies; Psychiatric Status Rating Scales; Rivastigmine; Severity of Illness Index; Time Factors; Treatment Outcome | 2010 |
Drug treatment of Alzheimer's disease patients leads to expression changes in peripheral blood cells.
Topics: Alzheimer Disease; Analysis of Variance; Blood Cells; Cholinesterase Inhibitors; Clinical Trials as Topic; Donepezil; Galantamine; Gene Expression Regulation; Genome-Wide Association Study; Humans; Indans; Microarray Analysis; Phenylcarbamates; Piperidines; Principal Component Analysis; Rivastigmine; RNA | 2010 |
Effects of rivastigmine on common symptomatology of Alzheimer's disease (EXPLORE).
Topics: Alzheimer Disease; Caregivers; Cholinesterase Inhibitors; Humans; Neuroprotective Agents; Phenylcarbamates; Physicians; Prospective Studies; Rivastigmine; Surveys and Questionnaires; Treatment Outcome | 2010 |
Lower Barthel Index scores predict less prescription of pharmacological therapy in elderly patients with Alzheimer disease.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Comorbidity; Donepezil; Drug Utilization; Female; Galantamine; Geriatric Assessment; Humans; Indans; Male; Memantine; Middle Aged; Neuropsychological Tests; Nootropic Agents; Phenylcarbamates; Piperidines; Psychiatric Status Rating Scales; Psychotropic Drugs; Rivastigmine; Socioeconomic Factors | 2010 |
Treatment of apathy in Alzheimer's disease with transdermal rivastigmine: report of three cases.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Alzheimer Disease; Apathy; Female; Humans; Neuroprotective Agents; Neuropsychological Tests; Phenylcarbamates; Rivastigmine | 2010 |
Effects of oral rivastigmine on cognitive domains in mild-to-moderate Alzheimer's disease.
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Data Interpretation, Statistical; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Language; Male; Memory; Neuropsychological Tests; Phenylcarbamates; Placebos; Randomized Controlled Trials as Topic; Retrospective Studies; Rivastigmine; Treatment Outcome | 2010 |
Anticholinesterase duration in the Australian veteran population.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Australia; Cholinesterase Inhibitors; Donepezil; Female; Follow-Up Studies; Galantamine; Humans; Indans; Male; Medication Adherence; Phenylcarbamates; Piperidines; Retrospective Studies; Rivastigmine; Time Factors; Treatment Outcome; Veterans | 2010 |
Rivastigmine-induced REM sleep behavior disorder (RBD) in a 88-year-old man with Alzheimer's disease.
Topics: Aged, 80 and over; Alzheimer Disease; Anticonvulsants; Cholinesterase Inhibitors; Clonazepam; Dose-Response Relationship, Drug; Humans; Male; Phenylcarbamates; Polysomnography; REM Sleep Behavior Disorder; Rivastigmine; Taiwan; Treatment Outcome | 2010 |
Transdermal rivastigmine for Alzheimer's disease: skin deep or scratching the surface?
Topics: Administration, Cutaneous; Alzheimer Disease; Humans; Neuroprotective Agents; Phenylcarbamates; Rivastigmine | 2010 |
Tyrosine-based rivastigmine-loaded organogels in the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Chromatography, Liquid; Gels; Humans; Neuroprotective Agents; Phenylcarbamates; Rivastigmine; Tandem Mass Spectrometry; Tyrosine | 2010 |
[Cholinergic therapy of Alzheimer's disease and its effect on health and quality of life of caregivers to the patients].
Topics: Alzheimer Disease; Antipsychotic Agents; Caregivers; Cholinesterase Inhibitors; Humans; Phenylcarbamates; Quality of Life; Rivastigmine | 2010 |
Risk factors for nursing home placement in Alzheimer's disease: a longitudinal study of cognition, ADL, service utilization, and cholinesterase inhibitor treatment.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Donepezil; Female; Galantamine; Humans; Indans; Kaplan-Meier Estimate; Male; Middle Aged; Nursing Homes; Phenylcarbamates; Piperidines; Proportional Hazards Models; Prospective Studies; Risk Factors; Rivastigmine; Severity of Illness Index; Sex Factors; Sweden | 2011 |
How do we treat people with dementia in Croatia.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Croatia; Cross-Cultural Comparison; Cross-Sectional Studies; Donepezil; Drug Approval; Drug Costs; Humans; Indans; Memantine; National Health Programs; Nootropic Agents; Phenylcarbamates; Piperidines; Reimbursement Mechanisms; Rivastigmine | 2010 |
Predictors of adherence among Alzheimer's disease patients receiving oral therapy.
Topics: Administration, Oral; Aged; Aged, 80 and over; Alzheimer Disease; Donepezil; Dopamine Agents; Female; Galantamine; Humans; Indans; Insurance Claim Review; Logistic Models; Male; Medication Adherence; Memantine; Neuroprotective Agents; Nootropic Agents; Phenylcarbamates; Piperidines; Predictive Value of Tests; Retrospective Studies; Rivastigmine; Treatment Outcome | 2010 |
[Variability and trends in dementia drug consumption in Castile-La Mancha (Spain). Estimated prevalence of Alzheimer's disease].
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Dopamine Agents; Galantamine; Ginkgo biloba; Humans; Indans; Memantine; Neuroprotective Agents; Nootropic Agents; Observer Variation; Phenylcarbamates; Piperidines; Plant Extracts; Rivastigmine; Spain; Substance-Related Disorders | 2010 |
Discontinuation of cholinesterase inhibitor treatment and determinants thereof in the Netherlands: A retrospective cohort study.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cohort Studies; Dose-Response Relationship, Drug; Female; Galantamine; Humans; Medication Adherence; Netherlands; Phenylcarbamates; Retrospective Studies; Rivastigmine | 2010 |
Use of antipsychotic drugs in patients with Alzheimer's disease treated with rivastigmine versus donepezil: a retrospective, parallel-cohort, hypothesis-generating study.
Topics: Aged; Aged, 80 and over; Aging; Alzheimer Disease; Antipsychotic Agents; Cholinesterase Inhibitors; Cohort Studies; Databases, Factual; Dementia; Donepezil; Female; Humans; Indans; Male; Phenylcarbamates; Piperidines; Retrospective Studies; Rivastigmine; Time Factors | 2010 |
[Rivastigmine patch effective for 24 hours. Effective dose, good tolerance, reliable therapeutic effectiveness].
Topics: Administration, Cutaneous; Administration, Oral; Alzheimer Disease; Cholinesterase Inhibitors; Controlled Clinical Trials as Topic; Dose-Response Relationship, Drug; Humans; Phenylcarbamates; Rivastigmine; Treatment Outcome | 2010 |
New perspective for the treatment of Alzheimer diseases: liposomal rivastigmine formulations.
Topics: Alzheimer Disease; Animals; beta-Cyclodextrins; Biological Availability; Brain; Cell Line; Cholinesterase Inhibitors; Dogs; Drug Carriers; Drug Compounding; Drug Delivery Systems; Drug Stability; Humans; Liposomes; Male; Mice; Mice, Inbred BALB C; Microscopy, Electron, Transmission; Neuroprotective Agents; Particle Size; Phenylcarbamates; Rivastigmine; Taurocholic Acid | 2011 |
Cardio-vascular safety of acetyl cholinesterase inhibitors in patients suffering from Alzheimer's disease; factors that predict poor tolerability.
Topics: Alzheimer Disease; Cardiovascular Diseases; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Indans; Multivariate Analysis; Phenylcarbamates; Piperidines; Retrospective Studies; Rivastigmine | 2011 |
[Cholinergic therapy of Alzheimer's disease and its effect on health and quality of life of caregivers to the patients].
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Caregivers; Cholinesterase Inhibitors; Combined Modality Therapy; Humans; Male; Middle Aged; Phenylcarbamates; Quality of Life; Rivastigmine; Treatment Outcome | 2010 |
[Prescription differences of dementia drugs in urban and rural areas in Germany].
Topics: Aged; Alzheimer Disease; Ambulatory Care; Donepezil; Galantamine; General Practice; Germany; Humans; Indans; Medically Underserved Area; Memantine; Neuropsychiatry; Nootropic Agents; Phenylcarbamates; Piperidines; Practice Patterns, Physicians'; Rivastigmine; Rural Population; Urban Population; Workforce | 2011 |
Alzheimer's drug proves ineffective for delirium.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Critical Care; Delirium; Humans; Phenylcarbamates; Randomized Controlled Trials as Topic; Rivastigmine; Treatment Failure | 2011 |
Diagnosis of Alzheimer's disease patients with rapid cognitive decline in clinical practice: interest of the Deco questionnaire.
Topics: Age Factors; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Cohort Studies; Disease Progression; Educational Status; Female; Geriatric Assessment; Humans; Institutionalization; Logistic Models; Male; Memantine; Middle Aged; Observation; Phenylcarbamates; Qualitative Research; Risk Factors; Rivastigmine; Surveys and Questionnaires | 2011 |
BCHE and CYP2D6 genetic variation in Alzheimer's disease patients treated with cholinesterase inhibitors.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Apolipoproteins E; Butyrylcholinesterase; Cholinesterase Inhibitors; Cognition; Cytochrome P-450 CYP2D6; Donepezil; Female; Galantamine; Genetic Association Studies; Genetic Variation; Genotype; Humans; Indans; Male; Middle Aged; Phenylcarbamates; Piperidines; Rivastigmine; Treatment Outcome | 2011 |
Bradycardia due to cholinesterase inhibitors: identify adverse effects and take them into account.
Topics: Alzheimer Disease; Bradycardia; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Indans; Phenylcarbamates; Piperidines; Risk; Rivastigmine | 2011 |
Rivastigmine patches: fatal overdoses.
Topics: Alzheimer Disease; Drug Overdose; Humans; Medication Errors; Neuroprotective Agents; Phenylcarbamates; Rivastigmine; Transdermal Patch | 2011 |
Rivastigmine associated hyponatremia in an older patient with Alzheimer's disease.
Topics: Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Female; Humans; Hyponatremia; Phenylcarbamates; Rivastigmine | 2011 |
Paraoxonase 1 gene polymorphisms do not influence the response to treatment in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Apolipoproteins E; Aryldialkylphosphatase; Cholinesterase Inhibitors; DNA; Donepezil; Female; Haplotypes; Heterozygote; Humans; Indans; Male; Neuropsychological Tests; Phenylcarbamates; Piperidines; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Real-Time Polymerase Chain Reaction; Rivastigmine | 2011 |
Bioequivalence evaluation of two brands of rivastigmine of different salt forms, an acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, in healthy Beagle dogs.
Topics: Alzheimer Disease; Animals; Area Under Curve; Cholinesterase Inhibitors; Data Interpretation, Statistical; Dogs; Gas Chromatography-Mass Spectrometry; Half-Life; Male; Phenylcarbamates; Rivastigmine; Therapeutic Equivalency | 2011 |
Rivastigmine in Alzheimer's disease and Parkinson's disease dementia: an ADAS-cog factor analysis.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Databases, Factual; Humans; Neuropsychological Tests; Parkinson Disease; Phenylcarbamates; Retrospective Studies; Rivastigmine; Sensitivity and Specificity; Severity of Illness Index; Surveys and Questionnaires; Treatment Outcome | 2011 |
Cholinesterase inhibitor initiation in hospital setting.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cognitive Dysfunction; Delirium; Diagnosis, Differential; Disease Progression; Early Termination of Clinical Trials; Hospitalization; Humans; Intensive Care Units; Phenylcarbamates; Randomized Controlled Trials as Topic; Rivastigmine | 2011 |
Impact of transdermal drug delivery on treatment adherence in patients with Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Female; Humans; Male; Medication Adherence; Neuroprotective Agents; Phenylcarbamates; Rivastigmine; Transdermal Patch | 2012 |
aChE and BuChE inhibition by rivastigmin have no effect on peripheral insulin resistance in elderly patients with Alzheimer disease.
Topics: Acetylcholinesterase; Aged; Alzheimer Disease; Blood Glucose; Butyrylcholinesterase; Case-Control Studies; Cholinesterase Inhibitors; Cognition; Female; Geriatric Assessment; Humans; Insulin Resistance; Male; Mental Status Schedule; Phenylcarbamates; Rivastigmine; Treatment Outcome | 2012 |
Antioxidant enzymatic activities in Alzheimer's disease: the relationship to acetylcholinesterase inhibitors.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Catalase; Cholinesterase Inhibitors; Donepezil; Female; Galantamine; Glutathione Reductase; Humans; Indans; Male; Oxidative Stress; Phenylcarbamates; Piperidines; Rivastigmine | 2012 |
Acetylcholinesterase inhibitors and the risk of hip fracture in Alzheimer's disease patients: a case-control study.
Topics: Acetylcholinesterase; Aged; Aged, 80 and over; Alzheimer Disease; Body Mass Index; Case-Control Studies; Cholinesterase Inhibitors; Donepezil; Female; Hip Fractures; Humans; Indans; Male; Odds Ratio; Phenylcarbamates; Piperidines; Regression Analysis; Risk; Rivastigmine | 2012 |
Reduced tissue levels of noradrenaline are associated with behavioral phenotypes of the TgCRND8 mouse model of Alzheimer's disease.
Topics: Adrenergic alpha-2 Receptor Antagonists; Adrenergic Uptake Inhibitors; Aging; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Benzopyrans; Brain; Brain-Derived Neurotrophic Factor; Catecholamines; Cholinesterase Inhibitors; Desipramine; Disease Models, Animal; Imidazoles; Immobility Response, Tonic; Mice; Mice, Inbred C57BL; Mice, Transgenic; Phenylcarbamates; Recognition, Psychology; Rivastigmine | 2012 |
Do local meteorological conditions influence skin irritation caused by transdermal rivastigmine? A retroprospective, pilot study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Belgium; Cholinesterase Inhibitors; Delirium; Drug Eruptions; Female; Hospitals, University; Humans; Incidence; Male; Medical Records; Middle Aged; Nootropic Agents; Outpatient Clinics, Hospital; Phenylcarbamates; Pilot Projects; Retrospective Studies; Rivastigmine; Sweating; Transdermal Patch; Weather | 2012 |
[New anti-AD drugs--their possibilities and issues].
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Galantamine; Humans; Memantine; N-Methylaspartate; Phenylcarbamates; Rivastigmine | 2012 |
Which cholinesterase inhibitor is the safest for the heart in elderly patients with Alzheimer's disease?
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Blood Pressure; Cholinesterase Inhibitors; Donepezil; Female; Galantamine; Heart; Humans; Indans; Male; Phenylcarbamates; Piperidines; Rivastigmine | 2012 |
A rivastigmine-precipitated manic episode in a patient with Alzheimer-type dementia.
Topics: Aged; Alzheimer Disease; Bipolar Disorder; Humans; Male; Neuroprotective Agents; Phenylcarbamates; Rivastigmine | 2012 |
Concentrations of rivastigmine and NAP 226-90 and the cognitive response in Taiwanese Alzheimer's disease patients.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cognition Disorders; Female; Follow-Up Studies; Humans; Male; Phenethylamines; Phenols; Phenylcarbamates; Pilot Projects; Rivastigmine; Taiwan | 2012 |
Design and evaluation of chitosan nanoparticles as novel drug carrier for the delivery of rivastigmine to treat Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Chitosan; Cholinesterase Inhibitors; Drug Carriers; Drug Stability; Nanoparticles; Particle Size; Phenylcarbamates; Rats; Rats, Wistar; Rivastigmine; Solubility; Tissue Distribution | 2011 |
Effect of some medicinal plant extracts on the oxidative stress status in Alzheimer's disease induced in rats.
Topics: Alzheimer Disease; Animals; Antioxidants; Disease Models, Animal; Dose-Response Relationship, Drug; Male; Neuroprotective Agents; Oxidative Stress; Phenylcarbamates; Piper nigrum; Plant Extracts; Rats; Rats, Sprague-Dawley; Rivastigmine; Salvia; Superoxide Dismutase | 2012 |
Safety and tolerability of rivastigmine transdermal patch formulation in newly diagnosed patients with Alzheimer's dementia in naturalistic conditions.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Dermatitis, Contact; Female; Follow-Up Studies; Humans; Male; Middle Aged; Nausea; Neuropsychological Tests; Patient Compliance; Phenylcarbamates; Prospective Studies; Rivastigmine; Transdermal Patch; Treatment Outcome; Vomiting | 2012 |
Altered parietal-motor connections in Alzheimer's disease patients.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Efferent Pathways; Evoked Potentials, Motor; Female; Humans; Male; Motor Cortex; Neuropsychological Tests; Parietal Lobe; Phenylcarbamates; Rivastigmine; Transcranial Magnetic Stimulation | 2013 |
Rivastigmine dermal patch solves eating problems in an individual with advanced Alzheimer's disease.
Topics: Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Deglutition Disorders; Female; Humans; Phenylcarbamates; Rivastigmine; Severity of Illness Index; Transdermal Patch | 2012 |
Clinical effectiveness of rivastigmine monotherapy and combination therapy in Alzheimer's patients.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Drug Therapy, Combination; Female; Gene Frequency; Glucuronosyltransferase; Humans; Male; Memantine; Middle Aged; Pharmacogenetics; Phenylcarbamates; Rivastigmine; Treatment Outcome | 2013 |
Use of rivastigmine or galantamine and risk of adverse cardiac events: a database study from the Netherlands.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Atrioventricular Block; Cholinesterase Inhibitors; Cohort Studies; Cross-Over Studies; Databases, Factual; Female; Galantamine; Hospitalization; Humans; Incidence; Male; Netherlands; Phenylcarbamates; Poisson Distribution; Proportional Hazards Models; Risk; Rivastigmine; Syncope | 2012 |
Rivastigmine transdermal patches in the treatment of dementia in Alzheimer's disease in adults with Down syndrome-pilot study.
Topics: Alzheimer Disease; Analysis of Variance; Delayed-Action Preparations; Down Syndrome; Female; Humans; Male; Medication Adherence; Middle Aged; Neuroprotective Agents; Phenylcarbamates; Pilot Projects; Rivastigmine; Transdermal Patch | 2013 |
Potential therapeutic effect of nanobased formulation of rivastigmine on rat model of Alzheimer's disease.
Topics: Acetylcholinesterase; Aluminum Chloride; Aluminum Compounds; Alzheimer Disease; Analysis of Variance; Animals; Behavior, Animal; C-Reactive Protein; Chlorides; Disease Models, Animal; Gene Expression Profiling; Liposomes; Male; Maze Learning; Nanoparticles; Particle Size; Phenylcarbamates; Rats; Rats, Wistar; Rivastigmine | 2013 |
Trace analysis of acetylcholinesterase inhibitors with antipsychotic drugs for Alzheimer's disease by capillary electrophoresis with on column field-amplified sample injection.
Topics: Alzheimer Disease; Antipsychotic Agents; Cholinesterase Inhibitors; Donepezil; Electrophoresis, Capillary; Humans; Indans; Phenylcarbamates; Piperidines; Rivastigmine | 2013 |
Brain perfusion follow-up in Alzheimer's patients during treatment with acetylcholinesterase inhibitors.
Topics: Aged; Alzheimer Disease; Brain; Carbamates; Case-Control Studies; Cerebrovascular Circulation; Cholinesterase Inhibitors; Cognition; Donepezil; Female; Follow-Up Studies; Humans; Indans; Male; Phenylcarbamates; Piperidines; Radiopharmaceuticals; Rivastigmine; Technetium Tc 99m Exametazime; Time Factors; Tomography, Emission-Computed, Single-Photon | 2002 |
Noninvasive in vivo assessment of cholinergic cortical circuits in AD using transcranial magnetic stimulation.
Topics: Aged; Alzheimer Disease; Carbamates; Cholinergic Fibers; Cholinesterase Inhibitors; Electric Stimulation; Electromagnetic Phenomena; Evoked Potentials, Motor; Female; Humans; Linear Models; Male; Middle Aged; Motor Cortex; Multivariate Analysis; Neural Inhibition; Phenylcarbamates; Reaction Time; Rivastigmine | 2002 |
The impact of journal advertisements on prescribers of cholinesterase inhibitors.
Topics: Advertising; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Donepezil; Drug Prescriptions; Galantamine; Humans; Indans; Phenylcarbamates; Piperidines; Publishing; Random Allocation; Rivastigmine | 2002 |
Electroconvulsive therapy in a patient receiving rivastigmine.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Depressive Disorder, Major; Electroconvulsive Therapy; Female; Humans; Phenylcarbamates; Rivastigmine; Safety; Treatment Outcome | 2002 |
Alterations in brain activation during cholinergic enhancement with rivastigmine in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Attention; Brain Mapping; Carbamates; Cerebral Cortex; Cholinergic Fibers; Cholinesterase Inhibitors; Female; Frontal Lobe; Humans; Magnetic Resonance Imaging; Male; Mental Recall; Nerve Net; Neuroprotective Agents; Neuropsychological Tests; Pattern Recognition, Visual; Phenylcarbamates; Prefrontal Cortex; Rivastigmine | 2002 |
Comments on Efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Carbamates; Donepezil; Female; Humans; Indans; Male; Middle Aged; Neuroprotective Agents; Nootropic Agents; Phenylcarbamates; Piperidines; Reproducibility of Results; Research Design; Rivastigmine | 2002 |
[Ethical aspects of anti-Alzheimer drugs: experiences of caregivers].
Topics: Aged; Alzheimer Disease; Carbamates; Caregivers; Cholinesterase Inhibitors; Cognition; Decision Making; Ethics, Clinical; Female; Humans; Male; Netherlands; Phenylcarbamates; Quality of Life; Rivastigmine | 2002 |
[Early diagnosis and treatment of Alzheimer's disease. Implementation in the doctor's office].
Topics: Aged; Alzheimer Disease; Brief Psychiatric Rating Scale; Carbamates; Cholinesterase Inhibitors; Dihydroergotoxine; Donepezil; Family Practice; Female; Follow-Up Studies; Galantamine; Ginkgo biloba; Humans; Indans; Male; Memantine; Neuroprotective Agents; Nimodipine; Nootropic Agents; Phenylcarbamates; Piperidines; Piracetam; Psychiatric Status Rating Scales; Risk Factors; Rivastigmine; Time Factors; Vasodilator Agents | 2002 |
[Presentation and stability of cognitive and noncognitive symptom patterns in patients with Alzheimer's disease. Disease course over a two-year period under constant treatment conditions with rivastigmine].
Topics: Affective Disorders, Psychotic; Aged; Aged, 80 and over; Alzheimer Disease; Anxiety Disorders; Carbamates; Cholinesterase Inhibitors; Cognition; Disease Progression; Female; Hallucinations; Humans; Male; Middle Aged; Neuroprotective Agents; Neuropsychological Tests; Phenylcarbamates; Psychiatric Status Rating Scales; Rivastigmine | 2003 |
Surprising discovery with Alzheimer's medication.
Topics: Acetylcholine; Alzheimer Disease; Animals; Carbamates; Cholinesterase Inhibitors; Crystallography, X-Ray; Humans; Phenylcarbamates; Rivastigmine | 2003 |
Rivastigmine in the treatment of alcohol-induced persisting dementia.
Topics: Alcohol-Induced Disorders, Nervous System; Alzheimer Disease; Carbamates; Central Nervous System Depressants; Cholinesterase Inhibitors; Ethanol; Humans; Male; Middle Aged; Phenylcarbamates; Rivastigmine | 2003 |
Role of cholinesterase inhibitor in the management of sexual aggression in an elderly demented woman.
Topics: Aged; Aggression; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Dementia, Vascular; Female; Geriatric Assessment; Humans; Neuroprotective Agents; Phenylcarbamates; Psychomotor Agitation; Rivastigmine; Sexual Behavior; Time Factors | 2003 |
Potencies and selectivities of inhibitors of acetylcholinesterase and its molecular forms in normal and Alzheimer's disease brain.
Topics: Acetylcholinesterase; Alzheimer Disease; Benzazepines; Brain; Butyrylcholinesterase; Carbamates; Cerebral Cortex; Cholinesterase Inhibitors; Edrophonium; Humans; In Vitro Techniques; Phenylcarbamates; Physostigmine; Rivastigmine; Tacrine; Trichlorfon | 2003 |
Pharmacologic treatment expectations in the management of dementia with Lewy bodies.
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Brain; Carbamates; Cholinesterase Inhibitors; Diagnosis, Differential; Donepezil; Galantamine; Humans; Indans; Lewy Body Disease; Nootropic Agents; Phenylcarbamates; Piperidines; Randomized Controlled Trials as Topic; Rivastigmine; Treatment Outcome | 2004 |
No donepezil discontinuation effect in patients with Alzheimer's disease who were switched to rivastigmine after failing to benefit from donepezil treatment.
Topics: Aged; Alzheimer Disease; Carbamates; Donepezil; Female; Humans; Indans; Male; Neuroprotective Agents; Nootropic Agents; Phenylcarbamates; Piperidines; Rivastigmine; Treatment Failure; Treatment Outcome | 2003 |
A case history illustrating how extended release cholinesterase inhibitors could improve management of Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Indans; Phenylcarbamates; Piperidines; Rivastigmine | 2003 |
Impact of rivastigmine on costs and on time spent in caregiving for families of patients with Alzheimer's disease.
Topics: Activities of Daily Living; Alzheimer Disease; Carbamates; Caregivers; Cholinesterase Inhibitors; Cohort Studies; Cost of Illness; Cost Savings; Disease Progression; Dose-Response Relationship, Drug; Drug Administration Schedule; Health Expenditures; Humans; Institutionalization; Mental Status Schedule; New York City; Phenylcarbamates; Prospective Studies; Psychometrics; Rivastigmine | 2003 |
Long-lasting acetylcholinesterase splice variations in anticholinesterase-treated Alzheimer's disease patients.
Topics: Acetylcholinesterase; Aged; Alternative Splicing; Alzheimer Disease; Blotting, Western; Carbamates; Centrifugation, Density Gradient; Cerebrospinal Fluid; Cerebrospinal Fluid Proteins; Cholinesterase Inhibitors; Cognition Disorders; Female; Humans; Isoenzymes; Male; Middle Aged; Neuroprotective Agents; Neuropsychological Tests; Parietal Lobe; Phenylcarbamates; Rivastigmine; Tacrine; Time | 2004 |
Motor cortex hyperexcitability to transcranial magnetic stimulation in Alzheimer's disease.
Topics: Afferent Pathways; Aged; Alzheimer Disease; Carbamates; Cerebral Cortex; Cholinergic Fibers; Cholinesterase Inhibitors; Evoked Potentials, Motor; Female; gamma-Aminobutyric Acid; Humans; Male; Middle Aged; Motor Cortex; Muscle, Skeletal; N-Methylaspartate; Nerve Net; Neural Inhibition; Phenylcarbamates; Reaction Time; Rivastigmine; Sensory Thresholds; Signal Processing, Computer-Assisted; Transcranial Magnetic Stimulation | 2004 |
Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Female; Humans; Male; Middle Aged; Models, Statistical; Multicenter Studies as Topic; Phenylcarbamates; Randomized Controlled Trials as Topic; Retrospective Studies; Rivastigmine; Treatment Outcome | 2004 |
Risk of antipsychotic drug use in patients with Alzheimer's disease treated with rivastigmine.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Carbamates; Cholinesterase Inhibitors; Databases, Factual; Drug Utilization; Female; Humans; Male; Phenylcarbamates; Risk Assessment; Rivastigmine; Sex Characteristics | 2004 |
[Acetylcholinesterase inhibitors].
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Galantamine; Humans; Phenylcarbamates; Rivastigmine | 2003 |
Comparative effects of huperzine A, donepezil and rivastigmine on cortical acetylcholine level and acetylcholinesterase activity in rats.
Topics: Acetylcholine; Acetylcholinesterase; Alkaloids; Alzheimer Disease; Animals; Brain Chemistry; Carbamates; Cerebral Cortex; Cholinesterase Inhibitors; Donepezil; Dose-Response Relationship, Drug; Fasciculation; Indans; Male; Neurons; Phenylcarbamates; Piperidines; Rats; Rats, Sprague-Dawley; Rivastigmine; Sesquiterpenes; Up-Regulation | 2004 |
Understanding the latest advances in pharmacologic interventions for Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Antioxidants; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; Donepezil; Drug Therapy, Combination; Galantamine; Humans; Indans; Memantine; Nootropic Agents; Phenylcarbamates; Piperidines; Receptors, N-Methyl-D-Aspartate; Rivastigmine; Treatment Outcome | 2004 |
Differential qualitative responses to rivastigmine in APOE epsilon 4 carriers and noncarriers.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Apolipoprotein E4; Apolipoproteins E; Double-Blind Method; Female; Genetic Carrier Screening; Humans; Male; Multicenter Studies as Topic; Phenylcarbamates; Randomized Controlled Trials as Topic; Retrospective Studies; Rivastigmine | 2004 |
Rivastigmine as a modulator of the neuronal glutamate transporter rEAAC1 mRNA expression.
Topics: Administration, Oral; Alzheimer Disease; Amino Acid Transport System X-AG; Animals; Cholinesterase Inhibitors; Dentate Gyrus; Gene Expression; Glutamate Plasma Membrane Transport Proteins; Hippocampus; In Situ Hybridization; Male; Neocortex; Neurons; Neuroprotective Agents; Phenylcarbamates; Rats; Rivastigmine; RNA, Messenger; Symporters | 2005 |
Switching from donepezil or rivastigmine to galantamine in clinical practice.
Topics: Alzheimer Disease; Donepezil; Galantamine; Humans; Indans; Neuroprotective Agents; Nootropic Agents; Phenylcarbamates; Piperidines; Retrospective Studies; Rivastigmine | 2004 |
Impact of APOE in mild cognitive impairment.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alleles; Alzheimer Disease; Apolipoprotein E4; Apolipoproteins E; Atrophy; Cognition Disorders; Female; Genetic Predisposition to Disease; Genotype; Hippocampus; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neuropsychological Tests; Nootropic Agents; Phenylcarbamates; Randomized Controlled Trials as Topic; Rivastigmine | 2004 |
Impact of rivastigmine use on the risk of nursing home placement in a US sample.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cohort Studies; Databases, Factual; Donepezil; Drug Utilization Review; Female; Humans; Indans; Insurance; Male; Nursing Homes; Phenylcarbamates; Piperidines; Proportional Hazards Models; Retrospective Studies; Risk Assessment; Rivastigmine; Time Factors; United States | 2004 |
Medial temporal lobe atrophy and APOE genotype do not predict cognitive improvement upon treatment with rivastigmine in Alzheimer's disease patients.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Apolipoprotein E4; Apolipoproteins E; Atrophy; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Genetics; Genotype; Humans; Magnetic Resonance Imaging; Male; Mental Status Schedule; Netherlands; Neuroprotective Agents; Phenylcarbamates; Prognosis; Psychometrics; Rivastigmine; Temporal Lobe; Treatment Outcome | 2005 |
Symptomatic effect of donepezil, rivastigmine, galantamine and memantine on cognitive deficits in the APP23 model.
Topics: Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Cholinesterase Inhibitors; Cognition; Disease Models, Animal; Donepezil; Dose-Response Relationship, Drug; Galantamine; Humans; Indans; Male; Memantine; Mice; Mice, Mutant Strains; Phenylcarbamates; Piperidines; Rivastigmine; Sensitivity and Specificity | 2005 |
NICE proposes to withdraw Alzheimer's drugs from NHS.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cost-Benefit Analysis; Donepezil; Drug Costs; England; Formularies as Topic; Humans; Indans; Memantine; Phenylcarbamates; Piperidines; Practice Guidelines as Topic; Rivastigmine; State Medicine; Wales | 2005 |
Drug persistency patterns for patients treated with rivastigmine or donepezil in usual care settings.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cohort Studies; Donepezil; Drug Administration Schedule; Female; Humans; Indans; Male; Patient Dropouts; Phenylcarbamates; Piperidines; Retrospective Studies; Rivastigmine | 2005 |
Drugs for Alzheimer's disease and related dementias.
Topics: Alzheimer Disease; Antipsychotic Agents; Cholinesterase Inhibitors; Dementia; Dibenzothiazepines; Humans; Phenylcarbamates; Practice Guidelines as Topic; Quetiapine Fumarate; Rivastigmine; Withholding Treatment | 2005 |
One-year treatment of Alzheimer's disease with acetylcholinesterase inhibitors: improvement on ADAS-cog and TMT A, no change or worsening on other tests.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Donepezil; Female; Humans; Indans; Male; Middle Aged; Phenylcarbamates; Piperidines; Psychomotor Performance; Rivastigmine | 2005 |
Neurophysiological predictors of long term response to AChE inhibitors in AD patients.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cognition; Drug Administration Schedule; Electromagnetic Phenomena; Follow-Up Studies; Humans; Motor Cortex; Neural Inhibition; Neurons, Afferent; Neuropsychological Tests; Phenylcarbamates; Prospective Studies; Rivastigmine; Severity of Illness Index; Time | 2005 |
Drug persistency of two cholinesterase inhibitors: rivastigmine versus donepezil in elderly patients with Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Female; Humans; Indans; Male; Phenylcarbamates; Piperidines; Rivastigmine; Time Factors | 2005 |
UK government guidance on Alzheimer's drugs postponed.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Cost-Benefit Analysis; Donepezil; Excitatory Amino Acid Antagonists; Federal Government; Galantamine; Government Regulation; Humans; Indans; Memantine; Nootropic Agents; Phenylcarbamates; Piperidines; Rivastigmine; United Kingdom | 2005 |
Rivastigmine is a potent inhibitor of acetyl- and butyrylcholinesterase in Alzheimer's plaques and tangles.
Topics: Acetylcholinesterase; Aged; Aged, 80 and over; Alzheimer Disease; Brain; Butyrylcholinesterase; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Female; Humans; Immunohistochemistry; In Vitro Techniques; Male; Neurofibrillary Tangles; Phenylcarbamates; Plaque, Amyloid; Rivastigmine | 2005 |
Behavioral and neuropsychiatric outcomes in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Brain; Diagnostic and Statistical Manual of Mental Disorders; Galantamine; Humans; Mental Disorders; Phenylcarbamates; Prevalence; Rivastigmine | 2005 |
Discontinuation of rivastigmine in routine clinical practice.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Disease Progression; Drug Administration Schedule; Epidemiologic Methods; Female; Humans; Male; Middle Aged; Neuroprotective Agents; Neuropsychological Tests; Patient Dropouts; Phenylcarbamates; Psychiatric Status Rating Scales; Rivastigmine; Treatment Failure | 2005 |
Response to rivastigmine or donepezil in Alzheimer's patients with symptoms suggestive of concomitant Lewy body pathology.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Double-Blind Method; Female; Humans; Indans; Lewy Body Disease; Male; Phenylcarbamates; Piperidines; Randomized Controlled Trials as Topic; Retrospective Studies; Rivastigmine; Treatment Outcome | 2006 |
Antipsychotic drug use among nursing home residents taking rivastigmine.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Antipsychotic Agents; Chi-Square Distribution; Cholinesterase Inhibitors; Drug Utilization Review; Female; Geriatric Assessment; Grief; Humans; Male; Mental Disorders; Nursing Homes; Phenylcarbamates; Proportional Hazards Models; Retrospective Studies; Risk Assessment; Risk Factors; Rivastigmine; Sleep Wake Disorders; Stress, Psychological; Surveys and Questionnaires; Treatment Outcome; United States | 2006 |
QEEG monitoring of Alzheimer's disease treatment: a preliminary report of three case studies.
Topics: Aged; Alzheimer Disease; Diagnosis, Computer-Assisted; Electroencephalography; Female; Humans; Male; Middle Aged; Neuroprotective Agents; Nootropic Agents; Phenylcarbamates; Prognosis; Rivastigmine; Severity of Illness Index; Single-Blind Method; Treatment Outcome | 2006 |
Appeals system and its outcomes in national health insurance in Taiwan.
Topics: Adult; Aged; Aged, 80 and over; Alzheimer Disease; Donepezil; Female; Humans; Indans; Male; Middle Aged; National Health Programs; Negotiating; Nootropic Agents; Phenylcarbamates; Piperidines; Rivastigmine; Taiwan | 2006 |
Antipsychotic drug use among nursing home residents taking rivastigmine.
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Cholinesterase Inhibitors; Drug Therapy, Combination; Drug Utilization; Humans; Mental Disorders; Nursing Homes; Patient Selection; Phenylcarbamates; Research Design; Rivastigmine; Severity of Illness Index | 2006 |
[Advances in Alzheimer's disease treatment].
Topics: Alzheimer Disease; Animals; Cholinesterase Inhibitors; Clinical Trials, Phase III as Topic; Donepezil; Excitatory Amino Acid Antagonists; Galantamine; Humans; Indans; Memantine; Multicenter Studies as Topic; Neuroprotective Agents; Nootropic Agents; Phenylcarbamates; Piperidines; Placebos; Randomized Controlled Trials as Topic; Rivastigmine | 2006 |
Treatment effects of rivastigmine on cognition, performance of daily living activities and behaviour in Alzheimer's disease in an outpatient geriatric setting.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Ambulatory Care; Cholinesterase Inhibitors; Cognition Disorders; Cohort Studies; Female; Humans; Male; Memory Disorders; Middle Aged; Phenylcarbamates; Retrospective Studies; Rivastigmine; Treatment Outcome | 2006 |
[Cholinesterase inhibitor therapy in long term care settings].
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Follow-Up Studies; Galantamine; Humans; Indans; Long-Term Care; Neuroprotective Agents; Nootropic Agents; Patient Selection; Phenylcarbamates; Piperidines; Retrospective Studies; Rivastigmine; Time Factors | 2006 |
Position statement of the American Association for Geriatric Psychiatry regarding principles of care for patients with dementia resulting from Alzheimer disease.
Topics: Aged; Alkaloids; Alzheimer Disease; Brain; Caregivers; Cholinesterase Inhibitors; Cognition Disorders; Dementia; Diagnostic and Statistical Manual of Mental Disorders; Galantamine; Geriatric Psychiatry; Health Services for the Aged; Humans; Phenylcarbamates; Professional-Family Relations; Rivastigmine; Sesquiterpenes; Tacrine; United States | 2006 |
Patterns of cholinesterase-inhibitor use in the nursing home setting: a retrospective analysis.
Topics: Adult; Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Dose-Response Relationship, Drug; Drug Utilization; Female; Galantamine; Homes for the Aged; Humans; Indans; Male; Middle Aged; Nursing Homes; Phenylcarbamates; Piperidines; Polypharmacy; Retrospective Studies; Rivastigmine | 2006 |
[Pharmacological approaches to the therapy of Alzheimer's disease].
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Amino Acids; Apolipoprotein E4; Apolipoproteins E; Cholinesterase Inhibitors; Female; Follow-Up Studies; Genotype; Humans; Male; Middle Aged; Neuroprotective Agents; Nootropic Agents; Phenylcarbamates; Psychiatric Status Rating Scales; Rivastigmine; Time Factors; Treatment Outcome | 2006 |
Unsubstantiated superiority claims for rivastigmine tartrate.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Humans; Phenylcarbamates; Rivastigmine; Treatment Outcome | 2006 |
Strategies to improve tolerability of rivastigmine: a case series.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Female; Gastrointestinal Diseases; Humans; Male; Middle Aged; Phenylcarbamates; Rivastigmine | 2007 |
Evaluation of the slopes of cognitive impairment and disability in Alzheimer's disease (AD) patients treated with acetylcholinesterase inhibitors (AChEl).
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Cholinesterase Inhibitors; Cognition Disorders; Diagnostic and Statistical Manual of Mental Disorders; Disability Evaluation; Donepezil; Female; Follow-Up Studies; Galantamine; Humans; Indans; Male; Mental Disorders; Neuropsychological Tests; Phenylcarbamates; Piperidines; Rivastigmine; Severity of Illness Index | 2007 |
The kinetics of inhibition of human acetylcholinesterase and butyrylcholinesterase by two series of novel carbamates.
Topics: Acetylcholinesterase; Alzheimer Disease; Butyrylcholinesterase; Carbamates; Humans; Indans; Inhibition, Psychological; Inhibitory Concentration 50; Kinetics; Monoamine Oxidase Inhibitors; Phenylcarbamates; Rivastigmine; Selegiline | 2007 |
Cholinesterase inhibitor treatment and urinary incontinence in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Female; Humans; Indans; Male; Middle Aged; Phenylcarbamates; Piperidines; Rivastigmine; Urinary Incontinence | 2007 |
EXACT: rivastigmine improves the high prevalence of attention deficits and mood and behaviour symptoms in Alzheimer's disease.
Topics: Adult; Affect; Aged; Aged, 80 and over; Alzheimer Disease; Attention; Behavior; Canada; Caregivers; Cholinesterase Inhibitors; Cohort Studies; Female; Follow-Up Studies; Humans; Male; Mental Status Schedule; Middle Aged; Phenylcarbamates; Rivastigmine; Severity of Illness Index; Treatment Outcome | 2007 |
Impairment of nonverbal recognition in Alzheimer disease: a PET O-15 study.
Topics: Adaptation, Physiological; Aged; Alzheimer Disease; Brain Mapping; Cerebrovascular Circulation; Cholinesterase Inhibitors; Donepezil; Female; Frontal Lobe; Hippocampus; Humans; Indans; Magnetic Resonance Imaging; Male; Memory Disorders; Middle Aged; Neuropsychological Tests; Nootropic Agents; Oxygen Radioisotopes; Pattern Recognition, Visual; Phenylcarbamates; Piperidines; Positron-Emission Tomography; Radiopharmaceuticals; Rivastigmine; Temporal Lobe | 2007 |
Acetylcholinesterase inhibitors in assisted living: patterns of use and association with retention.
Topics: Activities of Daily Living; Aged, 80 and over; Alzheimer Disease; Assisted Living Facilities; Cholinesterase Inhibitors; Dementia; Donepezil; Drug Administration Schedule; Female; Galantamine; Health Surveys; Homes for the Aged; Humans; Indans; Male; Mental Status Schedule; Neuropsychological Tests; Phenylcarbamates; Piperidines; Retention, Psychology; Rivastigmine; Survival Analysis; Treatment Outcome | 2008 |
Comparing treatment effects in a clinical sample of patients with probable Alzheimer's disease treated with two different cholinesterase inhibitors.
Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Donepezil; Female; Humans; Indans; Male; Phenylcarbamates; Piperidines; Retrospective Studies; Rivastigmine | 2007 |
Patient and caregiver outcomes after 6 +/- 1.5-months of rivastigmine therapy for mild-to-moderate Alzheimer's disease: the Belgian FExT study.
Topics: Activities of Daily Living; Adult; Aged; Aged, 80 and over; Alzheimer Disease; Caregivers; Female; Humans; Male; Middle Aged; Neuroprotective Agents; Phenylcarbamates; Prospective Studies; Rivastigmine | 2007 |
NICE judgement leaves behind a nasty taste.
Topics: Alzheimer Disease; Cholinesterase Inhibitors; Disease Progression; Donepezil; Formularies as Topic; Galantamine; Humans; Indans; Insurance, Health, Reimbursement; Insurance, Pharmaceutical Services; Jurisprudence; Phenylcarbamates; Piperidines; Rivastigmine; State Medicine; Time Factors; United Kingdom | 2007 |
Rivastigmine-induced dystonia.
Topics: Acute Disease; Alzheimer Disease; Antipsychotic Agents; Benztropine; Cholinesterase Inhibitors; Comorbidity; Cyclothymic Disorder; Drug Interactions; Dystonia; Extrapyramidal Tracts; Female; Humans; Middle Aged; Phenylcarbamates; Rivastigmine; Syndrome | 2007 |
Risperidone, olanzapine and quetiapine in the treatment of behavioral and psychological symptoms in patients with Alzheimer's disease: preliminary findings from a naturalistic, retrospective study.
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Antipsychotic Agents; Behavior; Benzodiazepines; Cognition; Data Interpretation, Statistical; Dibenzothiazepines; Donepezil; Endpoint Determination; Female; Galantamine; Humans; Indans; Long-Term Care; Male; Neuropsychological Tests; Nootropic Agents; Olanzapine; Phenylcarbamates; Piperidines; Psychiatric Status Rating Scales; Quetiapine Fumarate; Retrospective Studies; Risperidone; Rivastigmine; Treatment Outcome | 2007 |
Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Blood-Brain Barrier; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Drug Delivery Systems; Enbucrilate; Male; Nanoparticles; Phenylcarbamates; Polysorbates; Rats; Rats, Wistar; Rivastigmine; Surface-Active Agents; Up-Regulation | 2008 |
Neurovascular coupling in Alzheimer patients: effect of acetylcholine-esterase inhibitors.
Topics: Aged; Alzheimer Disease; Brain; Cerebrovascular Circulation; Cholinesterase Inhibitors; Electroencephalography; Evoked Potentials, Visual; Female; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Phenylcarbamates; Psychiatric Status Rating Scales; Rivastigmine; Time Factors; Treatment Outcome | 2009 |
Estimated pre-morbid IQ effects on cognitive and functional outcomes in Alzheimer disease: a longitudinal study in a treated cohort.
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Cognition; Donepezil; Female; Follow-Up Studies; Humans; Indans; Intelligence; Intelligence Tests; Learning; Longitudinal Studies; Male; Neuroprotective Agents; Nootropic Agents; Patient Compliance; Phenylcarbamates; Piperidines; Prognosis; Reading; Rivastigmine; Self Care; Speech | 2008 |
Rivastigmine effects on EEG spectra and three-dimensional LORETA functional imaging in Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Cerebral Cortex; Cholinesterase Inhibitors; Cognition Disorders; Electroencephalography; Female; Humans; Image Processing, Computer-Assisted; Male; Middle Aged; Neuroprotective Agents; Phenylcarbamates; Psychomotor Performance; Rivastigmine | 2008 |
Steady-state pharmacokinetics of rivastigmine in patients with mild to moderate Alzheimer's disease not affected by co-administration of memantine: an open-label, crossover, single-centre study.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Area Under Curve; Benzylamines; Cholinesterase Inhibitors; Cross-Over Studies; Excitatory Amino Acid Antagonists; Female; Humans; Male; Memantine; Middle Aged; Phenethylamines; Phenols; Phenylcarbamates; Rivastigmine | 2008 |
Complete atrioventricular block associated with rivastigmine therapy.
Topics: Aged; Alzheimer Disease; Atrioventricular Block; Cholinesterase Inhibitors; Female; Humans; Pacemaker, Artificial; Phenylcarbamates; Rivastigmine; Syncope | 2008 |
Alzheimer's disease: new pharmacological perspectives.
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Dihydropyridines; Donepezil; Humans; Indans; Muscarinic Agonists; Oximes; Phenylcarbamates; Piperidines; Pyridines; Rivastigmine; Tacrine; Thiadiazoles | 1996 |
[Alzheimer disease. Pseudo-irreversible AChE inhibition with rivastigmine].
Topics: Acetylcholinesterase; Alzheimer Disease; Brain; Carbamates; Cholinesterase Inhibitors; Humans; Neuroprotective Agents; Phenylcarbamates; Rivastigmine | 1998 |
[Drug therapy strategies in Alzheimer's disease].
Topics: Aggression; Alzheimer Disease; Anti-Anxiety Agents; Antidepressive Agents; Antipsychotic Agents; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; Cognition Disorders; Depression; Donepezil; Humans; Indans; Mental Disorders; Neuroprotective Agents; Nootropic Agents; Phenylcarbamates; Piperidines; Rivastigmine; Sleep Wake Disorders; Tacrine | 1998 |
[New perspectives for Alzheimer patients: acetylcholine inhibition with Rivastigmine. Congress of the European Neurologic Society. Nice, 6 July 199].
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Humans; Phenylcarbamates; Rivastigmine | 1998 |
[Alzheimer's disease. Foreword].
Topics: Age Factors; Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Donepezil; Humans; Indans; Neuroprotective Agents; Nootropic Agents; Phenylcarbamates; Piperidines; Rivastigmine; Tacrine | 1998 |
[Cholinesterase inhibitors in Alzheimer disease: preliminary recommendations for treatment].
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Drug Approval; Europe; Female; Humans; Male; Phenylcarbamates; Rivastigmine; United States | 1998 |
Commentary: Another piece of the Alzheimer's jigsaw.
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Humans; Phenylcarbamates; Rivastigmine | 1999 |
Science commentary: rational drug design for Alzheimer's disease.
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Humans; Phenylcarbamates; Rivastigmine | 1999 |
Effectiveness of rivastigmine in Alzheimer's disease. Improvements in functional ability remain unestablished.
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Humans; Phenylcarbamates; Rivastigmine; Treatment Outcome | 1999 |
Effectiveness of rivastigmine in Alzheimer's disease. Patients' view on quality of life should be assessed.
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Humans; Phenylcarbamates; Quality of Life; Rivastigmine | 1999 |
Effectiveness of rivastigmine in Alzheimer's disease. Guidelines do not ignore clinically relevant end points.
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Humans; Phenylcarbamates; Practice Guidelines as Topic; Rivastigmine | 1999 |
[Alzheimer disease: efficacy and tolerance of rivastagmine].
Topics: Aged; Alzheimer Disease; Carbamates; Double-Blind Method; Humans; Multicenter Studies as Topic; Neuroprotective Agents; Phenylcarbamates; Randomized Controlled Trials as Topic; Rivastigmine | 1999 |
Preferential cerebrospinal fluid acetylcholinesterase inhibition by rivastigmine in humans.
Topics: Acetylcholinesterase; Adolescent; Adult; Alzheimer Disease; Butyrylcholinesterase; Carbamates; Cholinesterase Inhibitors; Feasibility Studies; Humans; Male; Phenylcarbamates; Rivastigmine | 1999 |
New drugs for Alzheimer's disease.
Topics: Alzheimer Disease; Carbamates; Donepezil; Humans; Indans; Nootropic Agents; Phenylcarbamates; Piperidines; Practice Guidelines as Topic; Rivastigmine; Tacrine | 1999 |
Rivastigmine: a review.
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Humans; Phenylcarbamates; Rivastigmine; Treatment Outcome | 1999 |
Effectiveness of rivastigmine in Alzheimer's disease. Participation in trials should be based on clinical uncertainty, not enforcement.
Topics: Alzheimer Disease; Carbamates; Clinical Trials as Topic; Humans; Neuroprotective Agents; Patient Selection; Phenylcarbamates; Rivastigmine | 2000 |
Inhibitory effect of orally administered donepezil hydrochloride (E2020), a novel treatment for Alzheimer's disease, on cholinesterase activity in rats.
Topics: Administration, Oral; Alzheimer Disease; Animals; Benzazepines; Brain; Carbamates; Cholinesterase Inhibitors; Donepezil; Dose-Response Relationship, Drug; Indans; Learning; Male; Memory; Phenylcarbamates; Piperidines; Rats; Rats, Wistar; Rivastigmine; Tacrine | 2000 |
Lack of adverse pharmacodynamic drug interactions with rivastigmine and twenty-two classes of medications.
Topics: Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Comorbidity; Cytochrome P-450 Enzyme System; Data Interpretation, Statistical; Drug Interactions; Female; Humans; Male; Phenylcarbamates; Polypharmacy; Prospective Studies; Randomized Controlled Trials as Topic; Rivastigmine | 2000 |
New insights into genetics and pathophysiology of Alzheimer's disease: what are the clinical and therapeutic implications?
Topics: Acetylcholinesterase; Alzheimer Disease; Brain; Butyrylcholinesterase; Carbamates; Cholinesterase Inhibitors; Humans; Mental Disorders; Parasympathetic Nervous System; Phenylcarbamates; Rivastigmine | 2000 |
FDA approves new cholinesterase inhibitor for Alzheimer's disease.
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Humans; Phenylcarbamates; Rivastigmine; United States; United States Food and Drug Administration | 2000 |
Relation between cholinesterase inhibitor and Pisa syndrome.
Topics: Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Donepezil; Dopamine Antagonists; Dystonia; Female; Humans; Indans; Memory Disorders; Middle Aged; Neuroprotective Agents; Nootropic Agents; Phenylcarbamates; Piperidines; Posture; Psychomotor Agitation; Risperidone; Rivastigmine; Syndrome | 2000 |
Third drug to treat Alzheimer's approved.
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Drug Approval; Humans; Phenylcarbamates; Rivastigmine | 2000 |
Spontaneous rupture of oesophagus (Boerhaave's syndrome) related to rivastigmine.
Topics: Aged; Alzheimer Disease; Carbamates; Dose-Response Relationship, Drug; Esophageal Diseases; Female; Follow-Up Studies; Humans; Neuroprotective Agents; Phenylcarbamates; Rivastigmine; Rupture, Spontaneous; Syndrome | 2000 |
Rivastigmine (Exelon) for Alzheimer's disease.
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; Dose-Response Relationship, Drug; Fees, Pharmaceutical; Humans; Neuroprotective Agents; Phenylcarbamates; Rivastigmine | 2000 |
The new cholinesterase inhibitors for Alzheimer's disease, Part 1: their similarities are different.
Topics: Aged; Alzheimer Disease; Butyrylcholinesterase; Carbamates; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Indans; Phenylcarbamates; Piperidines; Receptors, Nicotinic; Rivastigmine; Tacrine | 2000 |
Alzheimer's disease: translating neurochemical insights into clinical benefits.
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Cognition Disorders; Humans; Magnetic Resonance Imaging; Phenylcarbamates; Rivastigmine; Treatment Outcome; Trichlorfon | 2000 |
The new cholinesterase inhibitors for Alzheimer's disease, Part 2: illustrating their mechanisms of action.
Topics: Alzheimer Disease; Butyrylcholinesterase; Carbamates; Cholinesterase Inhibitors; Donepezil; Galantamine; Humans; Indans; Phenylcarbamates; Piperidines; Receptors, Nicotinic; Rivastigmine | 2000 |
A comparison of sleep profiles in patients with dementia with lewy bodies and Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Female; Humans; Lewy Body Disease; Male; Middle Aged; Phenylcarbamates; Polysomnography; Rivastigmine; Sleep Wake Disorders; Treatment Outcome | 2000 |
Cholinesterase inhibitors: expanding applications.
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Humans; Lewy Body Disease; Phenylcarbamates; Rivastigmine | 2000 |
Rivastigmine for Alzheimer's disease: Canadian interpretation of intermediate outcome measures and cost implications.
Topics: Aged; Alzheimer Disease; Canada; Carbamates; Caregivers; Cognition; Cost of Illness; Delivery of Health Care; Humans; Phenylcarbamates; Placebos; Rivastigmine; Treatment Outcome | 2000 |
Potential savings in the cost of caring for Alzheimer's disease. Treatment with rivastigmine.
Topics: Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Cost Savings; Humans; Neuroprotective Agents; Phenylcarbamates; Rivastigmine | 2000 |
Comparison of inhibitory activities of donepezil and other cholinesterase inhibitors on acetylcholinesterase and butyrylcholinesterase in vitro.
Topics: Acetylcholinesterase; Alzheimer Disease; Aminoquinolines; Animals; Benzazepines; Brain; Butyrylcholinesterase; Carbamates; Cholinesterase Inhibitors; Donepezil; In Vitro Techniques; Indans; Inhibitory Concentration 50; Male; Phenylcarbamates; Physostigmine; Piperidines; Rats; Rivastigmine; Tacrine; Time Factors | 2000 |
Pharmacokinetic profiles of current therapies for Alzheimer's disease: implications for switching to galantamine.
Topics: Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Donepezil; Drug Interactions; Galantamine; Humans; Indans; Phenylcarbamates; Piperidines; Rivastigmine; Sleep | 2001 |
Effects of ENA713 and CHF2819, two anti-Alzheimer's disease drugs, on rat amino acid levels.
Topics: Alzheimer Disease; Animals; Arginine; Aspartic Acid; Carbamates; Cholinesterase Inhibitors; Citrulline; Cyclic N-Oxides; Dose-Response Relationship, Drug; Excitatory Amino Acids; Extracellular Space; Glutamic Acid; Hippocampus; Male; Microdialysis; Neurons; Phenylcarbamates; Rats; Rats, Wistar; Rivastigmine; Synaptic Transmission; Taurine | 2001 |
Medications for the treatment of Alzheimer's disease.
Topics: Alzheimer Disease; Antioxidants; Carbamates; Cholinesterase Inhibitors; Donepezil; Estrogen Replacement Therapy; Humans; Indans; Phenylcarbamates; Piperidines; Rivastigmine; Tacrine | 2001 |
Rivastigmine in the treatment of Alzheimer's disease.
Topics: Activities of Daily Living; Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Humans; Long-Term Care; Neuropsychological Tests; Phenylcarbamates; Rivastigmine; Treatment Outcome | 2001 |
Featured CME topic: dementia. Medication update.
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Contraindications; Donepezil; Drug Interactions; Ergoloid Mesylates; Galantamine; Ginkgo biloba; Humans; Indans; Nootropic Agents; Phenylcarbamates; Phytotherapy; Piperidines; Plants, Medicinal; Rivastigmine | 2001 |
Adverse reactions to rivastigmine in three cases of dementia.
Topics: Aged; Aged, 80 and over; Akathisia, Drug-Induced; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Dementia; Female; Humans; Irritable Mood; Male; Phenylcarbamates; Rivastigmine; Treatment Failure | 2001 |
Cerebrospinal fluid acetylcholinesterase activity after long-term treatment with donepezil and rivastigmina.
Topics: Acetylcholinesterase; Aged; Alzheimer Disease; Butyrylcholinesterase; Carbamates; Cholinesterase Inhibitors; Donepezil; Drug Administration Schedule; Female; Humans; Indans; Male; Middle Aged; Phenylcarbamates; Piperidines; Protein Isoforms; Rivastigmine; Time Factors | 2001 |
Maintaining functional and behavioral abilities in Alzheimer disease.
Topics: Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Clinical Trials as Topic; Donepezil; Galantamine; Humans; Indans; Neuropsychological Tests; Nootropic Agents; Phenylcarbamates; Piperidines; Rivastigmine; Tacrine; Treatment Outcome | 2001 |
Erythematous maculopapular eruption due to rivastigmine therapy.
Topics: Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Female; Humans; Parapsoriasis; Phenylcarbamates; Rivastigmine | 2001 |
Rivastagmine-induced agitation following transient recollection of autobiographical memory.
Topics: Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Female; Humans; Phenylcarbamates; Psychomotor Agitation; Rivastigmine | 2001 |
[Rivastigmine for Alzheimer disease; evaluation of preliminary results and of structured assessment of efficacy].
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Female; Humans; Male; Middle Aged; Neuroprotective Agents; Patient Dropouts; Phenylcarbamates; Psychiatric Status Rating Scales; Retrospective Studies; Rivastigmine; Treatment Outcome | 2002 |
[Alzheimer dementia. Comparison of the effectiveness of cholinesterase inhibitors and gingko].
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Confidence Intervals; Donepezil; Galantamine; Ginkgo biloba; Humans; Indans; Neuroprotective Agents; Nootropic Agents; Parasympathomimetics; Phenylcarbamates; Phytotherapy; Piperidines; Placebos; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Rivastigmine | 2001 |
Synthesis and cholinesterase activity of phenylcarbamates related to Rivastigmine, a therapeutic agent for Alzheimer's disease.
Topics: Acetylcholinesterase; Administration, Oral; Alzheimer Disease; Animals; Brain; Carbamates; Cholinesterase Inhibitors; Drug Evaluation, Preclinical; Inhibitory Concentration 50; Mice; Phenylcarbamates; Rats; Rivastigmine; Structure-Activity Relationship | 2002 |
[Rivastigmine for Alzheimer disease; evaluation of preliminary results and of structured assessment of efficacy].
Topics: Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Humans; Neuroprotective Agents; Phenylcarbamates; Psychiatric Status Rating Scales; Quality of Life; Rivastigmine; Treatment Outcome | 2002 |
Switching cholinesterase inhibitor therapy in Alzheimer's disease--donepezil to rivastigmine, is it worth it?
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Donepezil; Female; Humans; Indans; Male; Middle Aged; Nootropic Agents; Phenylcarbamates; Piperidines; Retrospective Studies; Rivastigmine; Treatment Outcome; United Kingdom | 2002 |
Rivastigmin and impaired motor function.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Carbamates; Catatonia; Dyskinesia, Drug-Induced; Female; Humans; Neuroprotective Agents; Phenylcarbamates; Rivastigmine | 2002 |
[Cognitive rehabilitation in Alzheimer's disease patients: multidisciplinary team report].
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Alzheimer Disease; Carbamates; Caregivers; Cholinesterase Inhibitors; Cognition Disorders; Combined Modality Therapy; Female; Humans; Male; Middle Aged; Neuropsychological Tests; Patient Care Team; Phenylcarbamates; Rivastigmine | 2002 |
Prolonged QT interval with rivastigmine.
Topics: Aged; Alzheimer Disease; Carbamates; Cholinesterase Inhibitors; Humans; Long QT Syndrome; Male; Neuroprotective Agents; Phenylcarbamates; Rivastigmine | 2002 |
Evaluation of cholinergic treatment in demented patients by P300 evoked related potentials.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Analysis of Variance; Carbamates; Cholinesterase Inhibitors; Cognition; Donepezil; Evaluation Studies as Topic; Event-Related Potentials, P300; Female; Humans; Indans; Male; Middle Aged; Neuropsychological Tests; Phenylcarbamates; Piperidines; Reaction Time; Rivastigmine; Sensitivity and Specificity; Severity of Illness Index; Tacrine | 2001 |